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SUMMARY
Albendazole is a broad spectrum anthelmintic and is widely used in 
the treatment of helminth infections. Investigations have been 
undertaken to explore the possible use of this drug in the treatment 
of filariasis, although due to its poor aqueous solubility, 
albendazole is poorly absorbed in the gastrointestinal tract 
following oral administration.
In this project the possible role of using a triglyceride oil 
formulation to overcome the low bioavailability of albendazole 
associated with oral administration was investigated. These studies 
were undertaken in three related areas:
In analytical studies, sensitive, selective and reproducible HPLC 
methods were developed for the simultaneous determination of 
albendazole and its two major metabolites in bio-fluids and oil in 
order to provide suitable assay methods in the biological and 
formulation studies.
In formulation studies, the stability and solubility of albendazole 
were studied in the potential formulation vehicles. Degradation of 
albendazole in vitro via a simple thermal mechanism followed the 
same pathways as its metabolic pathways, namely oxidation and 
hydrolysis. Albendazole was formulated in a mixture of Miglyol:Tween 
80 (60:40%, w/w) and the bioavailablity of this formulation was
evaluated in animals.
Biological studies primarily involve in vivo studies in rats and some 
work was carried out in monkeys and humans. The levels of albendazole 
and its metabolites were highly variable in all species studied. 
There was no significant difference in bioavailability of albendazole 
when administered as "oily" formulation compared to PEG 400 
formulation in rat and monkey. However enhanced absorption was 
observed in animals when compared to that of a healthy volunteer who 
received albendazole in tablet form in a comparable dose. The C^x 
and AUC were 6-7 and 10-14 times higher in animals.
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ABBREVIATIONS
The following abbreviations have been used throughout this thesis.
ABZ  albendazole
ABZSO... albendazole sulphoxide 
ABZSO2 * * albendazole sulphone 
ACN  acetonitrile
AUC  area under concentration-time curve
°C.....degrees Celsius








HC1  hydrochloric acid



















RSD  relative standard deviation
SD..... standard deviation
SDS  sodium dodecyl sulphate
SPE  solid phase extraction
ti/2 .... half-life
Tmax* • • • ti10® to reach maximum concentration 
v/v volume to volume
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"Filariasis" is comprised of several tropical diseases caused by 
species of nematode worms. The most important filarial diseases are 
associated with Wuchereria bancrofti, Brugia malayi, Brugia timuri, 
Onchocerca volvulus and Loa loa, and are transmitted by bloodsucking 
insects. The adult worm develops at specific tissue sites and the 
female discharges millions of microfilariae which appear either in 
circulating blood or migrating freely in the subcutaneous tissues or 
dermis.
W. bancrofti, O. volvulus and possibly Z>. loa are the species for 
which man is the only definitely established host. However, strains 
of B. malayi can also be transmitted to primates and carnivores, 
which act as reservoirs for the infection (Mak, 1987). Fig. 1.1 shows 
the global distribution of "filariasis" associated with these 
parasites.
1.1.1 Onchocerciasis
Onchocerciasis or "river blindness" is caused by 0. volvulus, the 
only species that develops to maturity and produces microfilariae in 
the skin of man. This filarial infection is transmitted by blackflies 
of the genus Simulium which breed in fast-flowing rivers.
Onchocerciasis is probably the most serious of the filarial diseases. 
Of the estimated 85.5 million people who are at risk of this disease, 
about 17.5 million are infected with 0. volvulus, the majority of 
them living in West and Central Africa and the remainder in Yemen and 
in Central and South America (WHO, 1987). Approximately 340,000 
people are blind and 1 million people suffer from severe visual
impairment as a result of onchocerciasis worldwide.
The adult worms develop in the subcutaneous and even connective 
tissues in various parts of the body where they become encapsulated 
in fibrous nodules. The female worms can live for up to 15 years and 
can release thousands of the microfilariae per day. The migrating 
microfilariae can induce severe damage in the skin, subcutaneous 
tissues and especially the eyes. The microfilariae were also found in 
various body fluids, e.g. blood, urine, tears, cerebrospinal fluid 
and sputum (WHO, 1976).
1.1.2 Lymphatic filariasis
Human lymphatic filariasis is caused mainly by W. bancrofti, B. 
malayi and B. timuri present in the lymphatic system. W. bancrofti is 
the most widespread, affecting tropical and subtropical Africa, the 
Far-East and North-Eastern South America; B. malayi occurs in 
Southern and Eastern Asia and B. Timuri is confined to a small focus 
in Indonesia (WHO, 1984). It is transmitted by various species of 
mosquitoes. W. bancrofti, the predominant infection, is transmitted 
by mosquitoes mainly of the genera Culex, Anopheles and Aedes; B. 
malayi by Anopheles spp. and Mansonia spp., and B. timuri by 
Anopheles barbirostris (Mak, 1987).
The World Health Organization (1992) estimated that 751 million 
people are living in endemic areas, and 78.6 million are infected of 
which more than 92% (72.8 million) have W. bancrofti and less than 8 % 
(5.8 million) have B. malayi and B. timuri.
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The clinical manifestations of the infection are variable, differing 
from one endemic area to another; the spectrum of manifestation is, 
ranging from asymptomatic to chronic lymphangitis and elephantiasis. 
The adult worms in the lymphatic system produce granulomatous tissue 
reactions which are responsible for obstruction, thus interfering 
with drainage of lymph from the tissues. This effect may be seen in 
the extremities, the breast, the scrotum or the labia. The released 
microfilariae enter the blood stream and circulate to various parts 
of the body (WHO, 1984).
1.1.3 Loiasis
Loa loa is responsible for chronic infections in up to 13 million 
people living in the rainforest areas of West and Central Africa 
(Sasa, 1976) . This disease is transmitted by tabanid flies of the 
genus Chrysops. The adult worms live in the connective tissues just 
beneath the skin, migrate to the subcutaneous tissues and 
occasionally across the conjuctiva causing ocular deunage but not 
affecting vision. The movement of the worm in the subcutaneous 
tissues forms large swellings known as "Calabar swellings" which 
cause pain and severe pruritus (Argyll-Robertson, 1895).
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The Filarioses 
W. bancrofti, & malayi, 
L lua  and O.volvulus
Fig. 1.1 Global distribution of filarial diseases, 
(from James and Gilles, 1985a)
1.2 LIFE CYCLE OF FILARIAL PARASITES
The life cycle of the parasites is very similar in all species (Fig.
1.2). Upon biting an infected person, the insect vectors, which also 
serve as the intermediate host, may ingest microfilariae (first stage 
larvae, L^ ) with their blood meal. The microfilariae enter the body 
cavity of the insects and migrate to the thoracic muscle where larval 
development occurs (L^  and L3 ). The infective third stage larvae (L3 ) 
escape and enter the blood stream of the host during the next blood 
meal. The larvae develop into adult worms at selected tissues in the 
infected man. The male and female worms mate and the female releases
microfilariae (L^ ) into the surrounding tissues. These microfilariae
rapidly become distributed in the blood or skin. The density of 
microfilariae in blood fluctuates over 24 hours; in lymphatic 
filariasis the density is greatest at night whereas in loiasis the 
greatest density is reported during the day (Hawking et al., 1966; 
James and Gilles, 1985b).
Infective —  
larvoe
Adult worms
pre -  l_i — \ — Microfilariae
Insect (intermediate host)
■Man (definitive host)
Fig. 1.2 Life cycle of the filarial parasite
(from James and Gilles, 1985b)
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1.3 CHEMOTHERAPY OF FILARIASIS
Onchocerciasis, lymphatic filariasis and loiasis are major public 
health problems in many countries in tropical and subtropical regions 
of the world. At present there is no safe and effective 
chemotherapeutic agent to treat these filarial infections.
Diethylcarbamazine (DEC) has been used relatively safely against 
lymphatic filarasis and is effective against microfilariae. However 
it does have side-effects. It may be macrofilaricidal when large 
doses are administered over a long period of time. For 
onchocerciasis, DEC also kills microfilariae effectively but usually 
causes intense reactions. Suramin has been in use for about 40 years 
against the adult worms in onchocerciasis, but it causes severe, 
occasionally fatal, toxic effects (WHO, 1984).
The World Health Organization (WHO), through the Steering Committee 
of the Filarisis Scientific Working Group of the Tropical Disease 
Research Programme (TDR) has promoted a global collaborative effort 
in the search for a new drug that is safe, effective and that can be 
used, preferably in a single dose, for all filarial infections. TDR 
and the Onchocerciasis Control Programme (OCP) in West Africa have 
been working together in attempts to improve the use of existing 
antifilarial drugs in Africa (WHO, 1976). Drugs currently available 
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Fig 1.3 Drugs for the treatment of filariasis.
1.3.1 Diethylcarbamazine (DEC)
DEC is a derivative of piperazine (Fig. 1.3), active against
microfilariae and adult worms of a variety of filarial species. 
Several groups have reported that DEC is effective against
microfilariae of 0. volvulus. The skin microfilariae counts are 
reduced (>90%) within the first week, but DEC is unable to sustain 
the low levels of microfilaria in the skin, as the level gradually
increases by the end of 6-12 months, even at high doses of 30
mg/kg/day. (Dominguez-Vazquez et al., 1983; Greene et al., 1985; 
Albeiz et al., 1988). In patients suffering from onchocerciasis the
use of DEC is usually accompanied by an intense reaction known as the
Mazzotti reaction which is believed to be attributable by the death 
of the microfilariae. The severity of this reaction depends on the 
number of microfilaria killed, which in turn depends on the intensity 
of the infection and the dose of DEC (Francis et al., 1985). Awadzi 
and Gilles (1992) have recently described a recommended dosage 
regimen for DEC which aims to improve the use of the drug.
DEC has also been shown to be active against both adults and 
microfilariae of L. loa (Hawking, 1979). It has been demonstrated 
that prophylaxis against L. loa can be achieved by continuous 
administration of DEC at 5 mg/kg/day (Sasa, 1976) . Recently, Nutman 
et al. (1988) has shown that a weekly dose of 300 mg DEC provided 
prophylaxis against L. loa infection with no serious side-effects, 
despite administration of DEC for 2 years.
In lymphatic filariasis, DEC is an effective macro- and
microfilaricidal agents (Goodwin, 1984), and it has been the drug of 
choice for over 35 years (WHO, 1984) . In the treatment of this
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infection, a standard 12-day course of DEC rapidly cleared
microfilariae in the blood within the first week, but the levels of 
microfilaria gradually rose to 6 .0 % (average) of the pretreatment 
values 6 months after treatment (Ottesen et el., 1990). The 
recurrence of microfilaremia is common for this treatment. In
another study, a modified DEC dose regime of a single monthly dose 
of 6 mg/kg over 1 2  months was given to patients infected with W. 
bancrofti, the levels of microfilaria were reduced by 90% and the
infection rates among mosquitoes dropped to zero (Nathan et al.,
1987). Although DEC exhibits low toxicity and is safe for large-scale 
treatment of lymphatic filariasis (Lin et al., 1992), the dosage 
regimen of the drug is rather inconvenient; multiple doses from 1 - 2  
weeks to one year.
1.3.2 Suramin
Suramin (Fig. 1.3) was first introduced in 1921 for the treatment of 
human trypanosomiasis and was first used as an antifilarial drug in 
1947. Suramin is mainly used in the treatment of onchocerciasis; it 
is active against adult worms of O. volvulus but lacks 
microfilaricidal activity (Hawking, 1978).
When given orally suramin is absorbed only to a limited extent from 
the intestine and causes a local irritation when given by 
subcutaneous or intramuscular injections (Hawking, 1978). In clinical 
practice, suramin is administered intraveneously at weekly intervals 
for 6 weeks, with a total dose of 60 mg/kg. A higher dose may produce 
dangerous side-effects and occasionally may result in death due to 
its intrinsic toxicity (WHO,1987). The female worms are more 
susceptible to the lethal action of suramin than the males, but even
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the females take 4-5 weeks to die. To achieve a parasitological cure, 
a minimum concentration of 0 . 1  mg/ml of suramin in plasma needs to be 
maintained for 2 weeks (Hawking, 1978). The microfilariae gradually 
die after the adult worms have been killed. Side-effects resembling 
the Mazzotti reaction accompanies the death of the parasites.
1.3.3 Ivermectin
Ivermectin (Fig. 1.3) belongs to a family of macrocyclic lactones,
the avermectins. It is an 80:20 mixture of avermectin B^a and
avermectin produced by actinimycete Streptomyces avermitilis
(Campbell et al., 1983). Ivermectin is active against a wide variety 
of nematodes and arthropods (Campbell et al., 1985; Jackson, 1989). 
In humans, it is known to be effective against microfilariae of 0. 
volvulus (Aziz et al., 1982a, b) and W. bancrofti (Kumaraswami et 
al., 1988). There are several reviews of the use of ivermectin in 
the treatment of filariasis, particularly in onchocerciasis (Hay and 
Burr, 1989; Campbell, 1991, 1993; Goa et al., 1991; Mak et al., 1991; 
Vande Waa, 1991; Hillyer and Rajan, 1992).
In onchocerciasis, ivermectin is not effective against adult O. 
volvulus, as indicated by the appearance of microfilariae in the skin 
a few months post-treatment (Campbell, 1991) . It has been suggested 
that ivermectin paralyses microfilariae within the uterus of the 
female worms so that they are not released normally, but instead 
degenerate and are resorbed in utero (Awadzi et al., 1985; Schulz- 
Key, 1988, 1990). In chimpanzees, ivermectin has shown a partial in 
vivo effect against the third infective larval stage (L3 ) of 0.
volvulus but has no effect on the fourth larval stage (L4 ) of the
parasite (Taylor et al., 1988). However, ivermectin appears to reduce
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the uptake of O. volvulus microfilariae by the vectors (blackflies) 
as a results of its microfilaricidal activity, and therefore reduces 
the transmission of the infection (Cupp et al., 1986, 1989; Taylor et 
al., 1990).
Ivermectin has been shown to be efficacious against microfilariae of 
W. bancrofti (Kumaraswami et al., 1988). Dose-finding studies in 
Senegal (Diallo et al., 1987), French Polynesia (Cartel et al., 1991) 
and Haiti (Richards et al., 1991) showed that a single dose of 
1 0 0 - 2 0 0  |lg/kg ivermectin reduced the microfilaria counts more 
effectively than a dose of 50 pg/kg. However, studies in India 
(Kumaraswami et al., 1988; Vijayasekaran et al., 1990; Ottesen et 
al., 1990) indicated that lower doses of 10-25 |lg/kg ivermectin have 
a comparable efficacy to 1 0 0 - 2 0 0  ilg/kg dose in reducing the 
microfilariae and were associated with significantly fewer side- 
effects.
Ivermectin has shown no effect against all stages of B. malayi 
infection in the leaf monkeys, Presbytis cristata (Mak et al, 1988) . 
Only recently, the efficacy and safety of ivermectin in patients 
infected with B. malayi was reported (Shenoy et al., 1992). The 
clearance of the microfilaria was not complete; the effect was 
maximal at the end of the first month and gradually rose to 20-50% of 
the pretreatment levels at 6 months. The patients were treated again 
after 6 months and the levels were 10-35% of the pretreatment levels 
6 months later. The side-effects were mild to moderate and not 
related to the dose or the density of microfilariae. This study shows 
that ivermectin may be useful in Brugian filariasis but the dosage 
regime have to be evaluated.
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A low frequency adverse reaction associated with ivermectin has been 
reported in many studies (Aziz et al., 1982a, b; Awadzi et al., 1985; 
Diallo et al., 1986). The intense Mazzotti reactions are normally 
associated with the treatment of DEC which is believed to be caused 
by the death of microfilariae. Ivermectin however, causes paralysis 
of the microfilariae before they die and, therefore, a less intense 
response is associated with ivermectin (Ette et al., 1990). The 
frequency and severity of adverse reactions of ivermectin therapy are 
directly related to the intensity of the infection (de Sole et al., 
1989; Rothova et al., 1989).
Comparison studies of ivermectin and DEC in the treatment of 
onchocerciasis (Green et al., 1985; Awadzi et al., 1985; Diallo et 
al., 1986) and lymphatic filariasis (Ottesen et al., 1990; 
Vijayasekaran et al., 1990) demonstrated that ivermectin is at least 
as effective es DEC and produced similar side-effects. The only 
advantage ivermectin has over DEC is that it is given less 
frequently and as a single dose. At present, ivermectin is the drug 
of choice for the treatment of onchocerciasis (British National 
Formulary, 1992) and it is safe and effective drug for mass 
treatment.
1.3.4 Benzimidazole Carbamates
In experimental studies, mebendazole and flubendazole (Fig. 1.3), 
broad spectrum anthelmintics of the class benzimidazole carbamate 
have been demonstrated to have macrofilaricidal activity (Van den 
Bossche et al., 1982). Earlier studies in patients infected with O. 
volvulus, W. bancrofti and D. perstans treated with mebendazole did 
not show improvement in microfilarial counts (Van den Bossche et al.,
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1982) . However, recent studies of mebendazole in the treatment of 
human onchocerciasis (Rivas-Alcalei et al., 1981a, b; Awadzi et al., 
1982) showed that mebendazole reduced the microfilaria counts both in 
the skin and the eye; this is thought to be an effect of 
embyrogenesis in the adult female worms. The low microfilaria counts 
were maintained for at least 12 months (Rivas-Alcal£ et al., 1981b) 
after treatment with 2 g/day mebendazole for 28 days and fewer side- 
effects were produced by mebendazole compared to those associated 
with DEC therapy. The Mazzotti reaction was not observed because of 
the decrease in the microfilariae release due to the disruption of 
embryogenesis.
Mebendazole has also been shown to have some activity in decreasing 
the microfilaria counts in loiasis and may also kill the adult worms 
when given in high doses (Van Hoegaerden et al., 1987). It has also 
macrofilaricidal activity in patients suffering from £. malayi and W. 
bancrofti but it has to be given in large doses over a long period of 
time; 500 mg 3 times daily for 21 days (WHO, 1984) . However, due to 
its potential teratogenicity and its erratic oral absorption, 
mebendazole can be toxic when given in high doses and therefore it is 
not recommended for the treatment of lymphatic filariasis (WHO, 
1984) .
Because of its low bioavailability, the use of mebendazole in the 
treatment of filarial infections was limited (Tropical Disease 
Research, 1984). Mebendazole-citrate, a derivative of mebendazole 
prepared by Janssen Pharmaceutica (Goodwin, 1984) has a better 
bioavailability and was found to be more potent against mebendazole 
(Awadzi et al., 1990).
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Flubendazole, like mebendazole is very poorly absorbed from the 
gastrointestinal tract, and was only active when given by parenteral 
administration in the treatment of onchocerciasis (Dominguez-Vcizquez 
et al., 1983). The microfilaria counts were progressively reduced and 
approximately 2 % of the pretreatment levels were present at 1 2  months 
following 750 mg flubendazole intramuscularly for 5 weeks. No 
systemic side-effects attributable to the death of microfilariae were 
recorded. However, the intramuscular injection caused a severe 
reaction at the site of injection. Although flubendazole was more 
effective and safer than DEC, the drug has to be reformulated before 
undergoing further investigation (Tropical Disease Research, 1984).
Recently, another benzimidazole carbamate, albendazole (Fig. 1.3) has 
been studied as an antifilarial drug in the treatment of human 
onchocerciasis (Awadzi et al., 1990; Cline et al., 1992). Albendazole 
has a wider spectrum of anthelmintic activity, including activity 
against both the larvae and adult of a variety of nematodes and
cestodes (Theodorides et al., 1976; Cook, 1990) and it has a much
better absorption than mebendazole following oral administration 
(Morris et al., 1983). Studies in patients suffering from
onchocerciasis in Ghana (Awadzi et al., 1990) and in Venezuela (Cline 
et al., 1992) indicated that albendazole was neither a
microfilaricidal nor a macrofilaricidal agent at all the dose regimes 
given ( 800 mg daily for 3 days, 1200 mg daily for 3 days or 800 mg 
daily for 7 days in Ghana; 400 mg daily for 10 days in Venezuela) . 
However, the skin microfilarial counts were suppressed for over one 
year suggesting that albendazole was active against O. volvulus 
presumably because of to its embryotoxic effect.
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Albendazole has been shown to be more potent than mebendazole against 
O. volvulus (Awadzi et al., 1991) and a change in formulation of this 
promising antifilarial drug may improve its aqueous solubility and 
therefore its bioavailability.
Albendazole has also been shown to have antifilarial activity against 
B. malayi in leaf monkeys, Presbytis spp. and £. pahangi in jirds 
(WHO/ 1992). Albendazole showed a marked adulticidal activity with a 
gradual elimination of microfilariae from the blood when given 
subcutaneously/ but there was no effect either on microfilariae or 
adults of B. pahangi in Mastomys natalensis (Reddy et al., 1983). In 
the treatment of lymphatic filariasis, a recent study comparing 
albendazole (400 mg daily for 21 days) and DEC showed that 
albendazole has macrofilaricidal effect with less effect on the 
microfilariae (WHO/ 1992).
1.3.5 Other antifilarial drugs
There is a small number of new potential antifilarial drugs that have 
been discovered during screening in the experimental studies, 
including CGP 6140 (amocarzine) and CGP 20376 (benzothiazole) (Mak et 
al., 1991; Vande Waa, 1991).
CGP 6140 has been studied in patients with onchocerciasis (Soula et 
al., 1989; Lecaillon et al., 1990; Poltera et al., 1991). The skin 
microfilarial counts were reduced within one week and remained low 
(14-18% of pretreatment levels) for at least 6 months following 3 
mg/kg CGP 6140 twice a day after food for 3 days (Poltera et al., 
1991). CGP 6140 has been found ineffective against B. malayi in leaf 
monkeys, Presbytis cristata at oral doses of 25 and 50 mg/kg daily
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for 5 days (Mak et al., 1991). However, there was some adulticidal 
activity at higher doses.
CGP 20376 has shown to have both macro- and microfilaricidal activity 
against B. malayi and B. pahangi in Mastomys natalensis (Zahner et 
al., 1988) and in Presbytis cristata (Mak et al., 1990). However, due 
to its hepatotoxicity, CGP 20376 was not recommended for the 
treatment of lymphatic filariasis until better formulation is 
developed (Mak et al., 1991).
There are two other compounds; CGI 18041 (a benzothiazole) and UMF 
078 (a benzimidazole) that are still under development (WHO, 1992). 
CGI 18041 has been shown to have antifilarial activity in rodents and 
active against B. malayi and W. kalimantan in leaf monkeys, and UMF 
078 is active against B. pahangi in dogs (WHO, 1992) .
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1.4 HISTORY OF BENZIMIDAZOLE CARBAMATES
The discovery of thiabendazole in 1961 (Brown et al., 1961) has 
brought about the development of other benzimidazoles, the only class 
of broad-spectrum anhelmintics (Van den Bossche et al., 1982).
Benzimidazole is a ring system where a benzene ring is fused to the
4,5-positions of imidazole and the systemic numbering of the 
benzimidazole is as shown;
Some modifications to the ring have been made during development and 
modifications at positions at 2- and 5- of benzimidazole ring 
produced the most active compounds (Townsend and Wise, 1990). This
2 ,5-substituted benzimidazole anthelmintics may be classified into 
two main types: (1 ) - the 2 -thiazolyls, (2 ) - the 2 -carbamates.
Type (1) are well absorbed from the gastrointestinal tract whereas 
type (2 ) are poorly and erratically absorbed.
Thiabendazole is an example of the 2-thiazolyls. Although 
thiabendazole is an effective drug for the treatment of 
helminthiasis, its use in human has been limited due to its toxicity 
(Cook, 1990).
The 2-carbamates are widely used in veterinary and human medicine 
(Campbell, 1990; Martindale, 1988). There are three 2-carbamates 
currently in use in human clinical practice; mebendazole,
4 3
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flubendazole and albendazole (Martindale, 1988) . The use of these 
benzimidazole carbamates have been largely restricted to the 
treatment of intestinal helminth infections. Since these drugs are 
very effective and safe, investigations have been undertaken to 
explore the possible use of these drugs in the treatment of systemic 
infections such as filariasis (section 1.3.4). In this thesis, 
research has been focussed only on albendazole.
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1.5 PHARMACOLOGY OF ALBENDAZOLE
1.5.1 Introduction
Albendazole (ABZ) is methyl N-[5-(propylthio)-lH-benzimidazol-2- 
yl]carbamate, molecular weight of 265.3 with melting point of 214- 
215°C; it is insoluble in water and only slightly soluble in most 
organic solvents (Theodorides et al., 1976). The partition 
coefficient of albendazole between octanol and water is 40.0 and the 
pKa value is 9.4 (Jung H., personal communication).
Several studies have demonstrated the efficacy of albendazole in the 
management of systemic infections such as hydatid disease (Saimot et 
al., 1983; Morris et al., 1985; Guermoche et al., 1988) in man and 
have shown the drug to have advantages over mebendazole (Todorov et 
al., 1992a, b) . Albendazole has also been reported to be effective 
in the treatment of cysticercosis (Jung et al., 1992; Del Brutto et 
al., 1992; Vazquez and Sotelo, 1992).
1.5.2 Pharmacokinetics
There is little data available on the pharmacokinetics of albendazole 
in man because it is largely undetectable in human plasma due to its 
low gastrointestinal absorption and rapid metabolism (Penicaut et 
al., 1983; Marriner et al., 1986). However, when an albendazole 
tablet (400 mg) was given orally, the maximum concentrations of the
j[^ y  nhco2ch3 
H
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active metabolite albendazole sulphoxide were in the range of 0.04 to
0.55 |lg/ml between 0.5 and 4 hours after dosing (Marriner et al.,
1986; Lange et al., 1988). The mean plasma elimination half-life was
8.5 hours (Penicaut et al., 1983; Marriner et al., 1986; Lange et 
al., 1988).
Marriner et al. (1986) reported an inconsistent increase in
albendazole sulphoxide concentration when albendazole was 
administered with oil and milk. A significant increase of albendazole 
sulphoxide concentration was observed in patients with echinococcosis 
when albendaozle was given with a fatty breakfast (425% relative to 
fasting patients (Lange et al., 1988)).
1.5.3 Metabolism
Albendazole undergoes extensive metabolism. The main 
biotransformation observed in man (Penicaut et al., 1983), cattle, 
sheep, rats and mice (Gyurik et al., 1981) was similar; the
hydrolysis of the carbamate moiety and oxidation of the sulphur atom, 
the alkyl side-chain and the aromatic ring (Fig. 1.4).
In all species, the major metabolites found in the urine and plasma 
are the sulphoxide and sulphone metabolites and the proportion varies 
considerably among species (Lienne et al., 1989; Delatour et al., 
1991; Lanusse et al., 1992). The parent compound however was found in 
trace amount in the urine (Gyurik et al., 1981) and is normally 
undetectable in plasma of human (Penicaut et al., 1983; Marriner et 
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Fig 1.4 Metabolic pathway of albendazole.
1. Methyl N-[5-(propylthio)-lH-benzimidazol-2-yl]carbamate






6 . Methyl N-[6-hydroxy-5-(propylsulphonyl)-lH-benzimidazol- 
2 -yl]carbamate
7. Methyl N-{5-[ (2-hydroxypropyl)sulphonyl]-lif-benzimidazol- 
2 -yl)carbamate
8. Methyl N-{5-[(3-hydroxypropyl)sulphonyl]-lH-benzimidazol- 
2 -yl]carbamate
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In in vitro studies, albendazole was converted to sulphoxide by 
liver microsomes (Fargetton et al., 1986; Souhaili-El Amri et al., 
1987; Rolin et al., 1989) an effect mediated by cytochrome P-450 
and/or FAD-containing monooxygenase depending on the system used; rat 
(Fargetton et al., 1986), sheep (Galtier et al., 1986), pig 
(Souhaili-El Amri et al., 1987) or human (Rolin et al., 1989) liver 
microsomes. Albendazole sulphonation however has been exclusively 
attributable to cytochrome P-450c in perfused rat liver and it has 
also been shown that albendazole induced its own metabolism 
(Souhaili-El Amri et al., 1988).
1.5.4 Mode of action
The biochemical mode of action of benzimidazoles has not been fully 
explained. Although benzimidazoles cause many effects such as 
inhibition of the fumarate reductase system and glucose uptake (Van 
den Bossche et al., 1982), studies have indicated that the primary 
mode of action of benzimidazole is binding to tubulin and inhibiting 
tubulin polymerization to microtubules (Lacey, 1988, 1990).
Benzimidazoles have been shown to inhibit [^H]-colchicine binding to 
parasite tubulin (Barrowman et al., 1984). Mebendazole was 400 times 
and febendazole was 250 times more potent as inhibitor to the tubulin 
of embryonic Ascaris suum than of mammalian tubulin (Friedman and 
Platzer, 1978). A recent study supports the finding that 
benzimidazole specifically binds nematode tubulin with high affinity 
(Lubega and Prichard, 1991).
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1.6 IMPROVED BIOAVAILABILITY OF POORLY ABSORBED DRUGS USING LIPID- 
BASED DOSAGE FORM
Several reports have indicated that bioavailability of poorly 
absorbed drugs such as griseofulvin (Carrigan and Bates, 1973; Bates 
and Sequeira, 1975; Bloedow and Hayton, 1976), probucol (Palin and 
Wilson, 1984) and phenytoin (Shinkuma et al., 1985) were improved 
following administration of these drugs incorporated with a lipid.
Drug absorption from a lipid vehicle is considered to proceed mainly 
via diffusion into aqueous luminal fluid, followed by absorption 
through the mucosal membrane (Kakemi et al., 1972). Partitioning of 
the drug and transport from one phase to the other are therefore of 
importance. A critical factor which governs the degree of absorption 
of drugs in oil-water emulsions, when the drug partition coefficients 
are greater than unity, is the amount of drug in the aqueous phase 
rather their overall concentration (Kakemi et al., 1972).
The oral absorption of a variety of drugs has been shown to be 
altered in the presence of lipids and emulsions (Armstrong and James, 
1980). Various physiological mechanisms have been proposed to explain 
this effect including inhibition of gastric emptying (Bates and 
Sequeira 1975; Shinkuma et al., 1985), increased bile flow leading to 
drug solubilization (Bates and Sequeira, 1975), increased membrane 
permeability (Muranushi et al., 1980), facilitated lymphatic 
absorption (Palin et al., 1982) and hydrolysis by lipase (Borgstrom 
and Erlanson, 1973).
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1.6.1 Mechanism of Lipid Absorption
1.6.1.1 Inhibition of Gastric Emptying
Gastric emptying time is a very important factor affecting the 
absorption of drugs. The increased bioavailability of griseofulvin in 
rats when administered in suspensions and emulsions of corn-oil could 
be due to the long gastric transit caused by the fatty acids 
liberated during digestion of corn-oil (Carrigan and Bates, 1973; 
Bates and Sequeira, 1975). Inhibition of gastric emptying and 
motility of the upper small intestine were reported by Shinkuma et 
al. (1985) when phenytoin was given in sesame-oil and oleic acids. 
Corn-oil and sesame oil consist of long-chain triglycerides which 
are metabolised quite slowly (Alvarez and Stella, 1992). The 
saturated, low-chain and medium-chain triglycerides however, did not 
cause gastric retention although digested in vivo in the small 
intestine as observed by Yamahira et al. (1979). Rapid metabolism 
(Alvarez and Stella, 1992) and rapid dispersion (Yamahira et al.,
1979) of medium-chain triglycerides contributed to the uniformity of 
gastric emptying rates of the lipids.
1.6 .1.2 Stimulation of Bile Flow
It is known that triglycerides and fatty materials stimulate flow of 
bile into the small intestine, which may be a contributory factor in 
partitioning and absorption of poorly water-soluble drugs (Bates and 
Sequeira, 1975; Miyazaki et al., 1980). During intestinal digestion 
of dietary fat, oil was found dispersed in a micellar bile salt 
solution in the lumen of the small intestine (Hofmann and Borgstrom, 
1964). Therefore, increase in drug absorption by bile salts probably 
involves micellar solubilization and/or by lowering the surface 
tension of the gastrointestinal fluid (Miyazaki et al., 1979). The
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partition of fatty acids from emulsified oil phase to micellar phase 
was found to be strongly dependent on the chain length of the
triglycerides and the pH of the dispersion (Borgstrom, 1967). At low 
pH values, the long-chain fatty acids were distributed in favour of 
the emulsified oil phase, but between pH 6 and 8 a marked increase in 
favour of the micellar phase occurs. As the chain-length decreased, 
the distribution of the fatty acids to the micellar phase was 
increased. Medium- and short-chain fatty acids are probably present 
mainly in the form of soaps in a weakly acid solutions. This can be 
the important determinant for their mechanism of transport and
absorption; either via the portal or lymphatic pathways. Absorption 
of medium-chain triglyceride was however not affected by the 
presence of bile salts.
Bile salts micelles readily incorporate with biliary cholesterol and 
phospolipids to form mixed micelles which will remove the hydrophobic 
products of lipolysis from oil-water interface and subsequently 
transport the fatty acids and monoglycerides through the aqueous
phase to the enterocyte membrane where they are absorbed (Poelma et 
al., 1990).
1.6.1.3 Increase Membrane Permeability
Enhanced absorption of drug coadministered with oil has been proposed 
to increase mucosal permeability (Muranushi et al., 1980). Palin et 
al. (1982) suggested that formation of mixed bile salt micelles
containing unsaturated fatty acids was responsible for this increase 
in mucosal membrane permeability. According to Sallee and Dietschy 
(1973) the rate of tissue uptake of fatty acids can be described 
using apparent permeability coefficient, *P and in general increases
26
with increase in the chain length. However, several reports 
demonstrated that membrane absorption is more effective for medium- 
chain than long-chain fatty acids (Greenberger et al., 1966; Palin et 
al., 1986; Yoshitomi et al., 1987; Ichihashi et al., 1992).
1.6.1.4 Increase in Lymphatic Absorption
The absorption pathway of a drug in the gastrointestinal tract can be 
altered by the products of triglycerides digestion (Palin et al., 
1982, 1984; Ichihashi et al., 1992). The class of lipid vehicle can 
affect the rate and extent of lymphatic transport of a lipophilic 
drug (Muranishi et al., 1980; Charman and Stella, 1986); short- and 
medium-chain fatty acids are transported unesterified into the 
systemic circulation via the portal vein whereas long-chain fatty 
acids are considered to form chylomicrons and are transported by the 
lymphatic system as summarised in Fig. 1.5 (Myers and Stella, 1992). 
Lymphatic absorption varies in the GI tract being lowest in the 
stomach and large intestine and greatest in the small intestine 
(Noguchi et al., 1977).
DDT and Probucol in arachis oil, Miglyol 812 and liquid paraffin were 
studied by Palin et al. (1982, 1984). Both drugs were absorbed via a 
lymphatic pathway in all formulations with the greatest absorption 
from arachis oil. Long unsaturated and saturated fatty acids 
liberated from arachis oil digestion, incorporated with mixed bile 
salt micelles and the formation of chylomicrons within the 
enterocytes, facilitated the transport of DDT and probucol by the 
lymphatic system. It was suggested that lymphatic drug transport from 
the small intestine is dependent upon concurrent chylomicron 
synthesis by the epithelial cells (Sieber, 1976; Charman et al.,
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Fig 1.5 Pathways for drugs absorption into venous and lymphatic 
system (from Myers and Stella, 1992).
1986).
The effect of lymph flow is unclear. According to DeMarco and Levine 
(1969)* when coadministered with lipids the amount of drug 
transported to lymph increases as the lymph flow increases. However* 
the distribution of mepitiostane (Ichihashi et al., 1992) and DDT 
(Charman and Stella* 1986) in the chylomicrons and the 
transportation in the lymphatic system were not affected by the 
lymph flow.
1.6.1.5 Hydrolysis by Lipase
Hydrolysis of oil by lipase is an important factor in drug release 
from the vehicle* and may influence the absorption of poorly water- 
soluble drugs from lipid-containing dosage forms in man (Palin*
1982) . The products of triglyceride hydrolysis, the corresponding 
monoglycerides and fatty acids which are more hydrophilic than the 
parent triglycerides (Wiseman* 1964), will combine with bile salt 
forming mixed micelles and provide aid in solubilizing the drug in 
the aqueous environment of the intestinal lumen (Poelma et al.* 
1990). It has been demonstrated that the short- and medium-chain 
triglyceride are hydrolysed more rapidly by lipase than the long- 
chain triglycerides (Greenberger et al., 1966; Playoust and 
Isselbacher, 1964).
Digestion of dietary fat in mammals occurs in the stomach but is 
initiated by the lingual and gastric lipase (Borgstrom et al., 1957; 
Hamosh and Scow* 1973; Hamosh et al., 1975). Studies on digestion of 
milk showed that fat was partially hydrolyzed by lingual lipase 
(originates from the back of the tongue) at pH 5.4, resulting in
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fatty acid and diacylglycerol existing as an oil phase in aqueous 
phase (Patton et al., 1982). Fatty acid has been shown to increase 
the colipase binding and subsequent hydrolysis by lipase (Borgstrom,
1980). The product of lingual lipase therefore makes the fat droplets 
better substrates for pancreatic lipase for more efficient digestion 
in the small intestine (Patton et al., 1982).
Bile salt may have direct effects on the pancreatic lipolysis. One 
function of bile in the intestine is to protect the hydrophobic 
surface of the substrates from the pancreatic lipase (Brockerhoff, 
1971; Borgstrom and Erlanson, 1973) by building up a negatively 
charged detergent monolayer on the substrate surface and by 
electrostatic repulsion preventing the lipase from reaching the 
substrate. The maximum inhibition by bile salt is when the critical 
micelle concentration is reached (Borgstrom and Erlanson, 1973). The 
inhibition may also be seen as competition between lipase and bile 
salts for the interface or reduction of interfacial tension to hinder 
lipase adsorption to the interface (Nano and Savary, 1976).
It has been shown that colipase, a protein co-factor of lipase, 
overcomes the inhibition of lipase caused by bile salt (Borgstrom and 
Erlanson, 1973; Brockerhoff, 1971; Vandermeers, 1974; Borgstrom, 
1975) by interacting with the lipase to form a less-charged and more 
hydrophobic complex than the layer built by the bile salt on the 
substrate. The colipase-lipase complex penetrates the bile salt layer 
to reach the substrate allowing lipolysis to occur.
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1.6.2 Self-Emulsifying System
Appropriate mixtures of oil and surfactant are known as self- 
emulsifying systems due to its capability to emulsify under gentle 
agitation (Groves and de Galindez, 1976). When given orally, the 
digestive movement of the gastrointestinal tract will emulsify this 
oily solution. The system rapidly produces a fine dispersion with 
droplet size of approximately 0.1-10 |im (Pouton, 1985b; Stout et al., 
1988; Wakerly, 1989; Challis, 1991). Formation of these small oil 
droplets results in a much larger interfacial area and therefore the 
rate of transfer in the gastrointestinal tract by diffusion from the 
oily phase to the aqueous phase (luminal fluid) is increased
(Lostritto et al., 1987).
The absorption profile of a lipophilic drug in a self-emulsifying 
system depends greatly on the choice of oil and surfactant. It was 
proposed that surfactant may modify drug absorption by an number of 
mechanisms (Attwood and Florence, 1983), for example, non-ionic 
surfactant such as Tween 80 has been reported to modify
gastrointestinal absorption by partitioning drug into micelles and 
changing the mucosal barrier (Dermer, 1967). Compounds that possess 
surfactant properties such as lauric acid may solubilize lipophilic
constituents of membrane e.g. cholesterol (Palin et al., 1986). The
absorption and digestibility of an oil and/or the products may also 
affect the absorption of a drug when administered in oily solution by 
a number of mechanisms which have been discussed in section 1 .6 .1 .
A great deal of work has been done using oil e.g. Miglyol 812 and 
non-ionic surfactant e.g. Tween 80, Tween 85 and Tagat TO (Groves and 
de Galindez, 1976; Palin et al., 1982, 1986; Palin and Wilson, 1984;
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Pouton, 1984, 1985a, b; Pouton et al.,1988; Reymond et al., 1988;
Woolfrey et al., 1989; Challis, 1991; Ichihashi et al., 1992; Charman 
et al., 1992). It was suggested that the mechanism of self- 
emulsification involves formation of specific liquid crystalline 
(LCa) phase at the o/w interface (Wakerly, 1989) which aid the 
penetration of water into the emulsifying mixture by creating aqueous 
channels, thereby increasing the surface pressure close to the 
interface which results in interfacial instability.
Palin et al. (1986) demonstrated that Miglyol 812 did not promote the 
absorption of cefoxitin by increased lymphatic absorption of the drug 
nor by a reduction of gastrointestinal motility, but by protecting 
the molecule from degrading in the acid environment of the stomach. 
It was proposed that the improvement of the plasma profile following 
the oral administration of the self-emulsifying system is a function 
of solubilisation and dispersion of drug in the gastrointestinal 
tract (Charman et al., 1992).
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1.7 AIM OF STUDY
The aim of this study was primarily to investigate the possible role 
of formulation using triglyceride oil in overcoming the low 
bioavailability of albendazole associated with the oral 
administration for the treatment of filarial infections. This study 
involved three phases:
(1) Analytical studies
Published analytical methods were available for albendazole and its 
metabolites. However no suitable assay method was available for 
simultaneous analysis of albendazole with its two major metabolites/ 
the sulphoxide and sulphone. The published methods were tedious often 
involving more than one chromatographic system. Similarly there were 
no published methods for chemical degradates. Development of 
selective/ sensitive and reproducible HPLC methods for albendazole 
and its two metabolites was therefore required.
(2) Pharmaceutical aspects
\
This phase of the study involved formulation of albendazole in an 
oily system suitable for in vivo administration. Additionally/ since 
there is no information available on the chemical stability of 
albendazole/ a study was necessary to establish any degradation 
products.
(3) In vitro and in vivo biological studies
These studies were aimed at the assessment of drug absorption and 
bioavailability/ metabolism and pharmacokinetic profiling. In vivo 
animal studies involved dosing rats with the various albendazole 
formulations and following the plasma/serum profiles. Following the
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rat studies, the formulations were selected for bioavailability 
evaluation in a higher animal (monkey) . Additionally, the site of 
albendazole metabolism, either pre-■ or post-gastrointestinal tract 





2.1 REAGENTS AND SOLVENTS
Albendazole (ABZ) and mebendazole (MBZ) were obtained from Sigma 
Chemical Co. (Poole). The micronised standards of ABZ and its 
sulphoxide (ABZSO) and sulphone (ABZSO2 ) metabolites were supplied by 
Lancaster Synthesis (Morecambe).
Methanol (MeOH), acetonitrile (ACN), hexane and ethanol (EtOH) of 
HPLC grade were purchased from Fisons (Loughborough). Analytical 
grade dimethylsulphoxide (DMSO), potassium dihydrogen phosphate, 
sodium hydroxide, glacial acetic acid and hydrochloric acid (HC1) 
were also obtained from Fisons (Loughborough). Ammonium acetate used 
was a GPR grade obtained from BDH Chemicals Ltd. (Poole).
HPLC grade MeOH and ACN, and analytical grade potassium 
dihydrogensulphate used at USM were obtained from E. Merck 
(Darmstadt, Germany). Analytical grade ammonium acetate (Ajax 
Chemical Ltd., Auburn, NSW, Australia), HC1 Analar (BDH Chemicals 
Ltd., Poole) and glacial acetic acid, 91.8% (Riedel-de-Haen, Seelze, 
Germany) were also used.
Polyethylene glycol (PEG) 400 and gluconic acid (50% aqueous 
solution) were purchased from Aldrich Chemical Co. Ltd. (Gillingham) . 
Tween 80 and 85 were obtained from Sigma Chemical Co. (Poole) and 
used as received.
Miglyol 812 is a medium-chain saturated triglyceride oil produced by 
esterification of glycerol with fatty acid fraction obtained by 
distillation of hydrolysed coconut oil and it was supplied by Dynamit 




Three HPLC systems were used;
(1) Spectra Physics HPLC system (St. Albans) consisting of a SP8100 
liquid chromatograph, SP8440 UV/VIS detector and SP4200 computing 
integrator.
(2) An LC pump model 330 (SSI, State College, PA, USA), a Pye-Unicam 
variable wavelength UV/VIS detector and a Hewlett-Packard HP3390A 
integrator.
(3) Waters-Millipore 2-solvent delivery system model 510, a Waters- 
Millipore automated gradient controller (Petaling Jaya, Malaysia), a 
Gilson UV detector model 116 (Petaling Jaya, Malaysia) and a Hewlett- 
Packard HP3392A integrator (Petaling Jaya, MAlaysia).
A Perkin-Elmer Lambda3 UV/VIS spectrophotometer (Beaconsfield) or a 
Milton Roy Spectronic 601 spectrophotometer (Stone) was used for 
measuring the UV absorbance in the solubility studies.
Gilson Pipetman adjustable pipettes (200 , 1000 and 5000 Jll) with 
disposable polypropylene tips were obtained from Anachem House 
(Luton). The calibration of these pipettes was checked to ensure 
accurate and reproducibile sample delivery.
An Analytichem International Vac Elut SPS 24 (Jones Chromatography, 
Mid Glamorgan) or Supelco SPE Vacuum manifold was used for the solid 
phase extraction (SPE) of plasma/serum samples.
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An Eppendorf Centrifuge 5414 (Hamburg, Germany) or Hettich Universal 
Centrifuge (A.R. Horwell Ltd., London) was used for centrifugation of 
blood samples to give either serum or plasma.
A Segma interchangeable precision syringe (Italy) and a syringe pump 
model 341A (Sage Intruments, Cambridge) were used for solvent 
delivery in the solubility studies.
Samples from the stability studies of albendazole in solvents were 
heated in a heating block obtained from Grant, model BT3 (Cambridge).
A student microscope (M5) obtained from Vickers (York) was used to 
examine samples from solubility studies.
2.3 OTHER MATERIALS
Nucleosil C^g columns, 250 x 4.6 mm , 5 Jim particle size were
obtained from Fisons Scientific Apparatus (Loughborough) or packed by 
Capital HPLC Specialists (West Lothian, Scotland). These columns were 
employed in the reversed-phase HPLC method. The normal-phase Hypersil 
C^g silica column, 100 x 4.6 mm, 5 |lm particle size was obtained from 
Shandon Scientific (Cheshire).
Bonded octadecyl C^g packing material (200mg), 40 Jim particle size
(J.T. Baker, Hayes) was packed in a Bakerbond SPE glass column fitted 
with PTFE frit (J.T. Baker, Hayes) or in a disposable syringe packed 
with glass wool and used as SPE cartridges.
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Disposable syringes (1, 5, 10/ 20 ml) and needles used in the animal 
and human studies were obtained from various companies. Blood was 
collected in lithium heparin tubes or heparinised vacutainers (FBG 
Trident Ltd. Bristol).
2.4 PREPARATION OF STANDARD SOLUTIONS FOR HPLC
A stock solution containing either 500 Jig/ml ABZ, ABZSO or ABZSO2  was 
prepared in MeOH for reversed-phase HPLC. The "working standard 
solutions" were prepared as a mixture of the three compounds by 
diluting the stock solutions to give final concentrations of 1 / 1 0  
or 100 Jlg/ml of ABZ/ ABZSO and ABZSO2 . The internal standard/ MBZ 
stock solution was prepared in MeOH (50 pg/ml)• The solution was then 
diluted to give a concentration of 1 0  Jlg/ml and used as the working 
internal standard solution.
For normal-phase HPLC/ stock solutions containing either 500 |lg/ml 
ABZ or ABZSO/ or 100 jig/ml ABZSO2 were prepared in hexane:EtOH 
(90:10%/ v/v). These stock solutions were diluted to give a final 
concentration of 10 Jlg/ml ABZ, ABZSO and ABZSO2 (prepared as a 
mixture) and used as the "working standard solution". The stock 
solution of the internal standard, MBZ was also prepared in 
hexane :EtOH (100 |lg/ral) and diluted to give a "working internal 
standard solution" of 1 0  |lg/ml.
2.5 PREPARATION OF BUFFERS
2.5.1 Buffer for HPLC
0.05M ammonium acetate solution was prepared and the pH was adjusted 
to 4.7 with glacial acetic acid. The buffer was filtered through a 
cellulose nitrate membrane filter, 0.45 Jim pore size (Whatman Ltd.,
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Kent) prior to mixing with organic modifier (ACN) and the mixture was 
then degassed by sparging with helium.
2.5.2 Buffer for Extraction
0.01M and 0.017M potassium dihydrogenphosphate solutions were 
prepared and the solutions were buffered at pH 5.7 and 7.4,
respectively with 0.8M sodium hydroxide.
The pH of these buffers were adjusted using a Kent EIL 7020 pH meter 
(Kent Industrial Measurement Ltd., Chertsey) which was calibrated
with 0.05M potassium hydrogen phthalate buffer (pH 4.0).
2.5.3 Buffer for solubility studies
0.1M and 0.01M HC1 solutions were prepared with the same ionic 
strength of 0.154M by addition of 0.054M and 0.144M of sodium
chloride, respectively. These solutions were used in the solubility






There have been many reports on the determination of ABZ and its 
major metabolites/ ABZSO and ABZSO2 in various body fluids. One of 
the first reports for detecting benzimidazole anthelmintics including 
ABZ in plasma and gastrointestinal fluids using HPLC was developed by 
Bogan and Marriner (1980). However, this method required a large 
volume of plasma/gastrointestinal fluid (4 ml) and repeated 
extraction with large volumes of diethyl ether. The two metabolites 
were eluted at similar retention times but could be assayed using 
this method. The levels of detection for the individual metabolites 
were not reported. The same authors (Marriner et al., 1981) later 
developed an improved HPLC method to monitor ABZ, ABZSO and ABZSO2  
simultaneously using a different solvent system. However this method 
was not sensitive enough for ABZSO as the limit of detection for 
ABZSO was 300 ng/ml whereas 50 ng/ml for ABZSO2 .
A normal-phase HPLC method was described by Alvinerie and Galtier 
(1984) for the simultaneous analysis of ABZ, ABZSO and ABZSO2 • The 
separation was performed on a silica column with hexane-ethanol 
(445:55 v/v) as the eluent and detection at 225 nm. The average 
recoveries were 78-84%. However the method was too sensitive to 
interferences from the endogenous compounds extracted from plasma. 
There are certain practical considerations that need to be taken into 
account which limit the use of normal-phase HPLC for routine 
analysis. For example , the need to control the water content of 
mobile phase to obtain reproducible results.
Meulemans et al. (1984) reported a reversed-phase HPLC method for the 
determination of ABZ and ABZSO in various human organs and fluids
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used to investigate ABZ concentration in patients with hydatid 
disease. Although the method was sensitive with limit of detection of 
10 ng/ml for both ABZ and ABZSO/ it was not convenient as separate 
procedures was required for each compound because isocratic 
separation was difficult to achieve on a column. The analysis of ABZ 
was therefore performed on jiBondapak C^g column and jlPorasil C-^ g 
column for ABZSO.
Recently, simultaneous HPLC methods for ABZ and ABZSO were developed. 
Hurtado et al. (1989) developed a sensitive method to detect ABZ and 
ABZSO in plasma with limit of sensitivity of 20 ng/ml and 15 ng/ml, 
respectively. Hoaksey et al. (1991) also developed a method for ABZ 
and ABZSO in plasma but the limit of detection of the compounds were 
not reported. However these methods were not suitable for the present 
study as ABZSO2  was not included.
Due to its rapid metabolism and poor absorption, ABZ was largely 
undetectable in man. Consequently, HPLC methods were developed to 
determine only the major and active metabolite, ABZSO (Guermoche et 
al., 1986; Lange et al., 1988) or together with ABZSO2 (Prichard et 
al., 1985; Guan et al., 1990; Zeugin et al., 1990).
Zeugin et al. (1990) developed a procedure for ABZ, ABZSO and ABZSO2  
in human plasma using HPLC with UV detection at 290 nm to monitor the 
drugs in the treatment of human echinococcosis. However only ABZSO 
was determined quantitatively whereas ABZ and ABZSO2  were determined 
qualitatively since ABZSO2 has no activity against the parasite and 
ABZ normally is not detectable in man. Although this method is 
sufficiently sensitive, it is inconvenient due to the long retention
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time of ABZ (-33 min.) and a lengthy liquid-liquid extraction
procedure.
The detection of ABZ and metabolites in the HPLC methods described 
above were monitored by UV detection. ABZ can be detected as low as 
10 ng/ml at 254 nm (Meulemans et al., 1984) and the limit of 
detection of 2 ng/ml was reported for ABZSO and ABZSO2 measured at 
292 nm (Prichard et al., 1985). Separate HPLC methods with
fluorescence detection for ABZ/ ABZSO and ABZSO2 were described by 
GISnzer et al. (1988) . The limits of detection were 2 ng/ml for ABZ 
and ABZS0 2 # and 10 ng/ml for ABZSO. Although fluorescence methods 
gain sensitivity compared with UV detection (in the case of ABZ), 
because each compound requires its own excitation and emission
wavelength for maximum sensitivity/ the method is suitable for the 
determination of one compound only in one chromatographic analysis. 
In general/ the use of fluorescence detection is limited due to the 
limited number of strongly fluorescing compounds, although this 
problem can be overcome by conversion of non-fluorescent compounds 
into fluorescent products.
A summary of HPLC methods for the determination of ABZ, ABZSO and 
ABZSO2 is given in Table 1.1.
ABZ was also investigated in animal tissues (Prieto et al., 1988;
Barker et al., 1990; Long et al., 1990), meat (Marti et al., 1990)
and milk (Long et al., 1989) using HPLC. Other analytical techniques 
have been used to determine ABZ and its metabolites. The metabolic 
studies of ABZ (Gyurik et al, 1981) were assessed using radiolabelled 
compounds in cattle, sheep, rats and mice. The products were assayed
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by scintillation counting and identified by MS and NMR. Methods for 
detection of ABZ and other benzimidazoles by gas chromatography (GC) 
and verification of results by GC-MS have also been described (Marti 
et al., 1990; Markus and Sherman, 1992). However an additional 
derivatization procedure was needed as the benzimidazoles are basic 
and show low volatility. Quantitative analysis of the derivatives was 
not possible by GC because the derivatives decomposed during the 
process of injection and chromatography due to the high temperatures 
used.
The HPLC methods described in this chapter were developed for the 
detection of ABZ and its two major metabolites simultaneously in 
plasma/serum and oil.
3.1.1 Sample preparation
Liquid-liquid extraction is the most commonly reported sample 
preparation procedure in the determination of ABZ and its metabolites 
in body fluids, but these methods are frequently tedious, time- 
consuming (Zeugin et al., 1990) and require large volume of solvent 
(Bogan and Marriner, 1980; Prieto et al., 1988). The blank extracts 
of body fluids were generally not clean (Meulemans et al., 1984). 
These problems may be reduced by solid phase extraction (SPE) 
procedures. This procedure involves a partitioning of compounds 
between a solid and liquid phase rather than between two immiscible 
solvents as in liquid-liquid extraction.
SPE generally consists of a column or cartridge packed with a small 
quantity of sorbent, similar to those used in reversed-phase HPLC 
columns. The particle size of SPE sorbent is however, much larger
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(40-50 Jim) than the corresponding HPLC materials. This is to allow 
flow-rates to be obtained without applying high vacuum. To separate a 
compound from the impurities, the first step involves conditioning 
the sorbent by wetting surface silanols and bonded functional groups 
with an organic solvent such as methanol or acetonitrile and followed 
by water or buffer to prepare the sorbent for the sample. Once the
conditioning step has commenced, the top of the sorbent should not be
allowed to dry out because excessive drying can alter retention 
characteristics of the sorbent and may result in variable recoveries. 
The sample is then introduced to the cartridge and the components 
either become adsorbed onto the sorbent or pass through unretained. 
Impurities may be removed from the cartridge by washing the cartridge 
with suitable aqueous buffers and solvents of varying strength. 
Finally the compounds of interest are eluted with solvent such as
methanol, acetonitrile or a mixture of organic solvent with water or
buffer.
An SPE procedure for ABZ and ABZSO was described by Hurtado et al. 
(1989) using C^g Sep Pak cartridges. Methanol (3 ml) was used to 
elute the compounds producing cleaner extracts for chromatographic 
analysis with recoveries of >95%.
The advantages of using SPE procedures are selectivity and rapid 
extraction, small volumes of solvent give complete recovery and clean 
extracts of body fluids (Allan et al., 1980; Hurtado et al., 1989). 
The disadvantage of this procedure is potential lack of 
reproducibility due to slight variation in batches of sorbent.
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Table 3.1 Summaxy of HPLC methods for analysis of ABZ, ABZSO and ABZSO2  in plasma or serum. (LLE: liquid-liquid 
extraction; SPE: solid phase extraction)
References Column Mobile phase Flow-rate Detector and limit Sample treatment
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3.2.1 Simultaneous Determination of Albendazole, Albendazole 
Sulphoxide and Albendazole Sulphone in Biological Fluids.
3.2.1.1 Reversed-phase HPLC
(a) A Spectra Physics Liquid Chromatograph equipped with a pump with 
a tertiary gradient generator and automatic injector, a variable 
wavelength UV detector and a computing integrator were used. The 
samples were separated using a Nucleosil ODS C^q column (250 mm x 4.6 
mm, 5 pm particle size). The mobile phase consisted of acetonitrile 
and 0.05M ammonium acetate buffer (pH 4.7) based on the work of 
Guermoche et al. (1986) . The flow-rate was kept constant at 1 ml/min 
and detection was carried out at 292 nm with sensitivity of 0.01 
AUFS.
Initially, isocratic separations of ABZ, ABZSO, ABZSO2  and internal 
standard, mebendazole (MBZ) were evaluated with different 
compositions of acetonitrile ranging from 2 2  to 60% v/v acetonitrile. 
Because of their wide k 1 range (l<k*<20), a gradient elution was 
developed using the same mobile phase.
Gradient elution analysis commenced with solvent reservoir A (30:70% 
v/v acetonitrile-acetate buffer) supplying 1 0 0 % of the mobile phase. 
A linear gradient began at 7 min which brought solvent reservoir B 
(40:60% v/v acetonitrile-acetate buffer) mobile phase to 100% at 11 
min and was maintained up to 19 min. The mobile phase was then 
returned to 100% A at 21 min. This condition was held for 5 min for 
equilibration to occur before the next analysis was begun. These 
conditions were used to determine ABZ, ABZSO and ABZSO2  in most of 
the rat studies described in Chapter 5.
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A - 30% acetonitrile
B - 60% acetonitrile
100% B
100% A 100% A
0 7 11 19 21 26 min
(b) The gradient elution analysis was modified when the HPLC method 
was used in Universiti Sains Malaysia (USM), Penang, Malaysia. The 
instrument used for this analysis was a two-solvent delivery system 
and an automated gradient controller (Waters-Millipore). The 
absorbance was recorded at 292 nm with sensitivity of 0.01 AUFS using 
a variable UV detector (Gilson).
The analysis started with 100% mobile phase from reservoir A 
(25:75%v/v acetonitrile-acetate buffer). A linear gradient began at 4 
min until at 9 min solvent reservoir B (60:40% v/v 
acetonitrile:acetate buffer) was supplying 1 0 0 % mobile phase and 
this was maintained until 14 min. The mobile phase was brought to 
100% A at 17 min and 3 min was allowed for equilibration time.
A - 25% acetonitrile
B - 60% acetonitrile
100% B
100% A 100% A
0 4 9 14 17 20 min
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3.2.1.2 Calibration Curves for Standard Solutions
Standard solutions containing all three compounds ABZ, ABZSO and 
ABZSO2 at concentrations of 10, 20, 50, 100, 200, 400, 800 and 1600 
ng/ml were prepared in mobile phase for HPLC. These solutions, 
(injection volume of 50 |il) were used to measure the linearity and 
sensitivity of the detector within the range of the concentrations 
used.
3.2.1.3 Preparation of Plasma Samples
Sample preparation was carried out based on an SPE procedure reported 
in the literature (Hurtado et al., 1989) with some modifications.
50 }H internal standard solution (MBZ, 500 ng/ml), and appropriate 
volumes of standard solutions were evaporated in test-tubes. Plasma 
(1 ml) was added to the test-tube followed by 1 ml of 0.01M phosphate 
buffer (pH 7.4) and vortex-mixed for 30 sec. The SPE column was 
conditioned by flushing with 5 ml MeOH and 5 ml 0.017M phosphate 
buffer (pH 5.5), followed by the plasma sample. The column was washed 
with 20 ml phosphate buffer (pH 7.4) and 1 ml water-MeOH (80:20% v/v) 
and the compounds eluted with 3 ml acidic MeOH (0.033M HC1 in MeOH) 
into tapered test-tubes, and evaporated to dryness under a gentle 
stream of nitrogen gas in a water-bath at 40°C. The residues were 
redissolved in 500 til of mobile phase and aliquots of 50 t*l were 
injected into HPLC (in duplicate).
3.2.1.4 Calibration Curves for Plasma Samples
Spiked plasma samples containing ABZ, ABZSO and ABZSO2  at 
concentrations of 50-1600 ng/ml and a fixed concentration of internal 
standard, MBZ (50 til of 10 t*9r/ml) were extracted using SPE procedure
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described previously (3.2.1.3) and analysed by HPLC (3.2.1.1(a)).
The peak area ratio of ABZ, ABZSO or ABZSO2  internal standard were 
calculated and plotted against the corresponding concentrations of
ABZ, ABZSO and ABZSO2 . All unknown plasma samples were treated the
same way and concentrations were determined from the calibration 
curves. The calibration curves were prepared on four different days.
3.2.1.5 Recoveries from Plasma
The recoveries of ABZ, ABZSO and BAZS02 were determined by comparison 
of peak areas of spiked plasma samples (3.2.1.4) with the peak areas 
of the standard solution of the corresponding concentrations 
(3.2.1.2). The recovery of the internal standard, MBZ was determined 
similarly at a fixed concentration (500 ng/ml) to assure good and 
consistent recovery.
3.2.1.6 Within Day and Day to Day Reproducibility
The within day variations were determined by analysing a range of
concentrations (50-1600 ng/ml) of ABZ, ABZSO and ABZSO2 spiked in
plasma. Three replicates of each concentration were extracted and 
analysed by HPLC on the same day.
Three concentrations of ABZ, ABZSO and ABZSO2 (low, medium and high) 
were used to measure the day to day variations. The spiked plasma 
samples were analysed as described previously on six different 
days.
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3.2.1.7 Limits of Detection
The limit of detection of the method used was assessed with spiked 
plasma samples at concentrations of 50, 40, 20 and 10 ng/ml of ABZ, 
ABZSO and ABZS0 2 * The "concentrations" were determined from the 
calibration curves.
3.2.2 Simultaneous Determination of Albendazole, Albendazole 
Sulphoxide and Albendazole Sulphone in Oil
3.2.2.1 Normal-phase HPLC
The normal-phase HPLC method was developed for the analysis of ABZ, 
ABZSO and ABZSO2 in Miglyol (oil) as part of the solubility studies. 
A preliminary separation of ABZ and Miglyol was carried out using a 
TLC method. A good separation was obtained using a mobile phase 
system of hexane-ethanol (90:10% v/v). This mobile phase system was 
subsequently used in the normal-phase HPLC method.
The HPLC system consisted of a SSI LC pump (model 330), a Pye-Unicam 
variable wavelength UV/Vis detector and a Hewlett-Packard integrator 
(HP3390A) . Analysis was performed on a normal-phase Hypersil C^g 
silica column (100 mm x 4.6 mm, 5 pm particle size) with hexane- 
ethanol (90:10% v/v) as mobile phase at a flow-rate of 1 ml/min. The 
detection was measured at 292 nm with sensitivity of 0.01 AUFS.
3.2.2.2 Calibration Curves for Standard Solutions
Standard solutions of ABZ, ABZSO and ABZSO2  were prepared in mobile 
phase. The concentration range was 20-5000 ng/ml and aliquots of 20 
pi were injected into the HPLC (3.2.2.1).
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3.2.2.3 Calibration Curves for Oil Samples
Standard calibration curves of ABZ , ABZSO and ABZSO2 were generated 
by adding known concentrations of the three compounds (50-5000 ng/ml) 
to a fixed concentration of internal standard, MBZ (2000 ng/ml) in 
Miglyol and diluted with mobile phase. The peak area ratio of each 
compound to internal standard was calculated and plotted against the 
corresponding concentration. The peak area ratio of the unknown 
samples were treated similarly and the concentrations were determined 
from the calibration curves using linear regression method. The 
calibration curves were prepared on four separate days.
3.2.2.4 Within Day and Day to Day Reproducibility
The within day variation was studied by injecting solutions of 100 to 
5000 ng/ml of ABZ, ABZSO and ABZSO2  in oil. Three replicates of each 
concentrations were analysed on the same day.
The day to day variation was determined on solutions of 200, 500 and 
5000 ng/ml of ABZ, ABZSO and ABZSO2 of the three compounds. The 
analysis was carried out for several days.
3.2.3 Determination of Albendazole in DMSO and 95% EtOH by UV 
Spectrophotometry.
The UV absorbance of ABZ in DMSO and 95%EtOH was measured in a 10 mm 
quartz cell using a Perkin-Elmer Lambda3 UV/VIS spectrophotometer at 
the required maximum absorbances of 298 and 296 nm in DMSO and 95% 
EtOH, respectively. The determination of ABZ in these solvents was 
part of the solubility studies.
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Stock solutions of ABZ in DMSO and 95%EtOH of 100 Jlg/ml were prepared 
and diluted to give ABZ concentrations of 1-30 jlg/ml in DMSO and 1-40 
jlg/ml in 95%EtOH. Calibration curves for ABZ in these solvents were 
generated by measuring the absorbances and the data were analysed by 
linear regression analysis. The unknown samples of ABZ in DMSO and 
95%EtOH obtained from the solubility studies (4.2.2.1) were diluted 
with the respective solvent and absorbance measured. The 
concentration of these samples was determined from the calibration 
curves. Three replicate calibration curves were prepared for each 
solvent.
3.2.4 Analysis of data
Least-square regression statistical analysis was used for calibration 
data of ABZ, ABZSO and ABZSO2 to determine the slope, intercept and 
correlation coefficient (r). The equation obtained was used to 
determine the concentrations of the unknown samples.
The Bartlett test (Appendix 1) and analysis of variance (ANOVA) were 
used appropriately for comparison of data.
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3.3 RESULTS
3.3.1 Analysis of Albendazole, Albendazole Sulphoxide and Albendazole 
Sulphone in Plasma
Isocratic analysis of ABZ, ABZSO and ABZSO2  simultaneously was not 
possible due to the long retention time of ABZ (>50 min) at low 
concentrations of acetonitrile. At 40% and 50% acetonitrile there was 
no baseline resolution between ABZSO and ABZS0 2 * Rs*8 1.03 and 0.90, 
respectively. At 60% acetonitrile ABZSO and ABZSO2 were eluted 
together. Capacity factor, k' for all the compounds were calculated 
for a range of acetonitrile concentrations as shown in Table 3.1.
Table 3.1 Capacity factors and retention times for ABZ, ABZSO and 










2 2 11.7 16.6 3.41 5.30
25 8 . 0 1 1 1 . 1 2 . 0 2 3.20
30 50.3 6.38 8.77 18.0 1.42 2.31
35 26.7 4.97 6.37 9.12 0 . 8 8 1.40
40 15.7 4.29 5.07 4.93 0.62 0.91
50 8.50 3.55 3.95 2 . 2 0 0.34 0.49
60 5.81 3.28 3.28 1.19 0.24 0.24
A gradient elution system was developed for the separation of ABZ, 
ABZSO and ABZSO2  by trial and error based on the isocratic analysis. 
The retention times of ABZ, ABZSO and ABZSO2  and internal standard 
MBZ were 19.24, 5.54, 8.06 and 16.61 minutes, respectively, with an 
analysis time of 26 minutes. The mean k* for the four compounds are 
given in Table 3.2 and all the peaks were symmetrical (Table 3.2). A 
representative chromatograms of a standard solution is shown in Fig. 
3.2(a).
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Table 3.2 Retention data of gradient analysis for ABZ, ABZSO, ABZSO2  






ABZSO 1.06 1.56 1.07
ABZS02 2 . 0 0 1.77 1.13
MBZ 5.22 0.77 1.13
ABZ 6.26 1 . 6 8 1.07
Linear calibration curves for standard solutions were obtained in the 
range of 0-1600 ng/ml (r - 0.999). The mean slopes were 2.08xl0”3 
(4.20% RSD) for ABZ, 2.81xl0*“3 (1.56% RSD) for ABZSO and 3.03xl0-3 
(2.95% RSD) for ABZS02.
Similarly the calibration curves for plasma extracts were linear over 
the range 0-1600 ng/ml for the three compounds (r « 0.997-0.999). 
Table 3.3 shows the linear regression data for the calibration curves 
with mean slopes (±SD) of 2.12xl0”3±3.30xl0“3 (X2 “ 1.67), 2.80x10“ 
3±6.40xl0"5 (X2 - 4.41) and 2.91xl0"3±l.OOxlO”5 (X2 - 5.02) for ABZ, 
ABZSO and ABZS02, respectively. The replicate slopes for each 
compound were not significantly different (X^tab ~ at p “ 0.05)
and the intercepts for all the curves were not significantly 
different from zero (P<0.05). Fig. 3.2 shows typical calibration 
curves for ABZ and the 2 metabolites.
Extraction of plasma samples produced clean extracts as shown in Fig. 
3.3(b)-(d). The mean analytical recovery (±SD) was 95.5%±3.28 for 
ABZ, 94.1%±2.70 for ABZSO and 95.7%±2.00 for ABZS02. Table 3.4 shows 
the recoveries of the three compounds at different concentrations. 
The recovery of MBZ was 99.2±3.87 with RSD of 3.90%.
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The within day and day to day variations were between 0.67 and 8.82% 
as shown in Tables 3.5 and 3.6. The results from the day to day 
variation were not significantly different when compared using the 
analysis of variance (P<0.01). The detection limits of the method, 
taking a signal-to-noise ratio of two as the criterion were found to 
be 10 ng/ml (1 ng on-column) for ABZSO and 20 ng/ml (2 ng on-column) 
for ABZ and ABZSO2 .
Table 3.3 Linear regression data for ABZ, ABZSO and ABZSO2 







1 2 . 1 0 2.04 0.013 0.014 0.999
2 2.08 6.42 0.032 0.045 0.998
3 2.14 3.02 -0.003 0 . 0 2 1 0.999
4 2.15 4.88 -0 . 0 1 1 0.034 0.999
Mean 2 .1 2 * 4.09 0.008 0.028
ABZSO
1 2.75 5.54 -0.043 0.039 0.999
2 2.85 6.74 -0.054 0.047 0.999
3 2.85 4.12 -0 . 0 2 1 0.029 0.999
4 2.73 4.29 -0.031 0.030 0.999
Mean 2.80* 5.17 -0.037 0.036
abzso2
1 2.90 7.31 -0.031 0.051 0.998
2 3.09 0 . 1 0 -0.058 0.071 0.997
3 2.87 3.27 -0.034 0.023 0.999
4 3.00 8.46 -0.034 0.059 0.999
Mean 2.96* 7.31 -0.046 0.051






























Fig. 3.2 Typical calibration curves for (a) ABZ, (b) ABZSO and (c) 
ABZSO2 using reversed-phase HPLC method described in 3.2.1.1(a).
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(c) (d)
Fig. 3.3 Representative chromatograms of reversed-phase HPLC of (a) 
standard solution of 800 ng/ml of ABZSO (1), ABZS02 (2), MBZ (3) and 
ABZ (4); (b) blank plasma extract; (c) spiked standards of 1600 ng/ml 
in plasma; (d) plasma extract obtained after oral administration of 5  
mg/kg ABZ in rat.
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Table 3.4 Recoveries of ABZ, ABZSO and ABZSO2 from plasma using








50 90.5 6 . 1 0 7.58
1 0 0 92.7 5.03 5.43
2 0 0 99.1 4.37 4.41
400 96.8 4.51 4.66
800 97.9 3.43 3.50
1600 95.9 1.87 1.95
ABZSO
50 90.8 5.36 5.90
1 0 0 93.2 5.86 6.27
2 0 0 95.3 5.30 5.56
400 91.5 3.45 3.77
800 97.7 3.26 3.34
1600 96.0 1.61 1 . 6 8
ABZS02
50 93.1 7.40 7.95
1 0 0 97.8 5.97 6.14
2 0 0 96.7 5.08 5.25
400 93.4 4.28 4.58
800 96.7 2.55 2.64
1600 96.5 1 . 8 8 1.94
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Table 3.5 The within day variation for ABZ, ABZSO and ABZSO2 using









50 47.4 4.18 8.82
1 0 0 97.8 5.10 5.21
2 0 0 2 0 2 . 6 5.08 2.51
800 797.2 9.75 1 . 2 2
1600 1596.4 10.70 0.67
ABZSO
50 50.0 3.98 7.98
1 0 0 102.3 6.79 6.79
2 0 0 203.3 8.79 4.32
800 801.9 13.27 1.65
1600 1596.9 1 2 . 0 0 0.75
ABZS02
50 49.6 3.67 7.40
1 0 0 98.0 5.65 5.77
2 0 0 198.0 7.12 3.60
800 797.2 8 . 6 8 1.09
1600 1598.0 14.87 0.93
Table 3 . 6 The day to day variation for 
the reversed-phase HPLC method, (n = 6 )









50 49.2(F - 4.16)* 4.02 8.17
2 0 0 200.7(F ~ 2.64)* 7.02 3.50
800 798.9(F - 4.19)* 6 . 2 2 0.78
ABZSO
50 50.8(F « 5.45)* 3.91 7.70
2 0 0 199.1(F - 5.40)* 6.27 3.15
800 797.6 (F - 2.61)* 6.23 0.78
abzso2
50 47.9 (F « 5.06)* 3.54 7.39
2 0 0 201.6 (F - 4.60)* 6.69 3.32
800 799.9(F - 2.75)* 6.27 0.78
* not significantly different at P * 0.01 (Ftaj3 - 6.07)
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3.3.2 Analysis of Albendazole/ Albendazole Sulphoxide and Albendazole 
Sulphone in Oil
A preliminary TLC analysis showed a good separation between ABZ and 
the Miglyol with Rf of 0.11 for ABZ and 0.20/ 0.45 for the Miglyol.
The normal-phase HPLC was developed for separation of Miglyol, ABZ, 
ABZSO and ABZSO2 with MBZ as the internal standard. The retention 
times for ABZ, ABZSO, ABZSO2  and MBZ were 2.15, 6 .8 6 , 4.86 and 3.05 
minutes, respectively. The mean k' values calculated from 6 samples 
were found to be 0.58 (0.71% RSD) for ABZ, 1.24 (0.44% RSD) for MBZ, 
2.58 (0.56% RSD) for ABZS02 and 4.05 (0.51% RSD) for ABZSO. The peak 
shapes were symmetrical with As *= 1.0, 1.11, 1.15 and 1.37 for ABZ, 
MBZ, ABZSO2  and ABZSO. The oil was eluted with the solvent front. 
Representative chromatograms of oil in mobile phase and standard 
solution in oil diluted in mobile phase are shown in Fig. 3.4.
The standard calibration curves were linear over the range 0 to 5000 
ng/ml for all the three compounds (r * 0.998-0.999) and the linear 
regression data are presented in Table 3.7. The mean slopes were 
1.08x10_3±1.26x10“5 (X2 - 0.64) for ABZ, 1.48x10“3±3.87x10“5 (X2 -
6.10) for ABZSO and 1.45xl0”3±2.50xl0“5 (%2 = 1.27) for ABZS02. The 
replicate slopes for each compound were not significantly different 
(X2tab = 9.46 at P *= 0.05). The intercepts for the curves passed 
through the origin within ±2 SD. Fig. 3.5 shows a typical 
calibration curve for ABZ, ABZSO and ABZSO2 .
The limits of detection were 50 ng/ml (2.5 ng on-column) for ABZ and
100 ng/ml (5 ng on-column) for ABZSO and ABZSO2 . The within day and
day to day variations were 0.32-6.66% as tabulated in Tables 3.8 and
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3.9. When compared by analysis of variance the data from the day to 
day variation were not significantly different within and between 
days (P<0.01).
Table 3.7 Linear regression data for ABZ, ABZSO and ABZSO2 







1 1.06 1 . 1 1 0.026 0.027 0.999
2 1.08 3.54 -0.054 0.086 0.998
3 1.08 3.98 0.065 0.096 0.998
4 1.09 0.40 0.015 0 . 0 1 0 0.998
Mean 1.08* 2.26 0.013 0.055
ABZSO
1 1.50 2.78 -0.058 0.067 0.999
2 1.44 1.50 -0.041 0.036 0.999
3 1.47 3.31 -0 . 0 1 0 0.074 0.999
4 1.53 2.78 -0 . 0 2 2 0.058 0.999
Mean 1.48* 2.59 -0.033 0.059
ABZS02
1 1.46 1.63 -0.050 0.039 0.999
2 1.48 3.04 -0.018 0.074 0.998
3 1.42 1.28 0.006 0.031 0.999
4 1.45 3.14 0.064 0.071 0.998
Mean 1.45* 2.27 0 . 0 0 1 0.054
* not significantly different at P = 0.05
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Fig. 3.4 Representative chromatograms of normal-phase HPLC of (a) 
Miglyol in mobile phase; (b) standard solution of 500 ng/ml of ABZ 
(1), ABZS02 (3), ABZSO (4) and MBZ (2).
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Fig. 3.5 Typical calibration curves for (a) ABZ, (b) ABZSO and (c) 
ABZSO2 using the normal-phase HPLC method described in 3.2.1.2.
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Table 3.8 The within day variation for ABZ, ABZSO and ABZSO2 using









50 47.5 2.85 6 . 0 0
1 0 0 99.4 4.37 4.40
2 0 0 197.1 7.55 3.82
500 499.8 6.83 1.37
2 0 0 0 2 0 0 2 . 0 24.2 1 . 2 0
5000 4999.8 29.0 0.58
ABZSO
1 0 0 98.9 6.57 6 . 6 8
2 0 0 198.4 8.80 4.44
500 498.6 8.40 1 . 6 8
2 0 0 0 2007.1 23.7 1.18
5000 4999.5 22.4 0.45
ABZS02
1 0 0 99.0 6.15 6 . 2 1
2 0 0 2 0 0 . 0 8.24 4.12
500 501.9 9.44 1 . 8 8
2 0 0 0 1998.1 27.8 1.39
5000 4997.2 27.0 0.54
Table 3.9 The day to day variation for ABZ, 
the normal-phase HPLC method, (n = 5)
ABZSO and ABZSO2  using




2 0 0 207.4(F * 3.39)* 13.0 6.26
500 502.3(F = 4.43)* 2 2 . 2 4.42
5000 4999.7(F 8 7.12)* 47.7 0.95
ABZSO
2 0 0 197.1(F «= 5.57)* 9.99 5.07
500 498.8(F - 3.14)* 8.35 1.67
5000 4991.5(F ■ 7.04)* 16.0 0.32
ABZS02
2 0 0 195.2 (F 3.74)* 9.84 5.04
500 497.9(F 8 6.78)* 2 0 . 0 4.02
5000 4997.6 (F * 5.54)* 18.0 0.36
* not significantly different at P It 0 • 0 M <Ftab ~ 7-34)
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3.3.3 Validation of Reversed-phase HPLC Method
The reversed-phase HPLC method was validated before it was used in 
USM, Malaysia. Some modifications were made as described previously 
(3.2.1.1(b)). The retention times of ABZ, ABZSO, ABZSO2 and internal 
standard, MBZ were 14.99, 8.11, 11.15 and 13.45 minutes,
respectively. Representative chromatograms of standard solution, a 
blank plasma extract and a spiked plasma extract are shown in Fig.
3.6 and plasma sample extracts obtained after oral administration of 
ABZ tablet (400 mg) in man in Fig. 3.7.
The calibration curves for standard solution were linear over the 
range of 0-1600 ng/ml (r - 0.999). The mean slopes were 2.20xl0“ 3  
(3.27% RSD) for ABZ, 2.86xl0“ 3 (1.34% RSD) for ABZSO and 22.82xl0”3 
(1.88% RSD) for ABZS02.
The calibration curves for plasma extracts for ABZ and the two 
metabolites were also linear over the range of 0-1600 ng/ml (r « 
0.997-0.999). Table 3.10 shows the linear regression data with mean 
slopes of 2.20xl0- 3  ±2.45xl0” 3 (X^  “ 0.65) for ABZ, 2.90xl0”3±
5.68xl0“ 3 (X^  “ 1.89) for ABZSO and 2.83xl0**3±6.60xl0”3 ■ 7.21)
for ABZS02. The replicate slopes for all the compounds were not 
significantly different (X^tab “ 9*46 at P * 0.05) and the intercepts 
were not significantly different from zero (P<0.05). Fig. 3.8 shows 
typical calibration curve of ABZ, ABZSO and ABZS02.
Plasma samples were extracted using the SPE procedure described in
3.2.1.4 with mean recoveries (±SD) of 97.6%±2.19 for ABZ, 92.3%±3.24 
for ABZSO and 96.3%±1.55 for ABZS02. The recoveries of the three 








Fig. 3.6 Representative chromatograms of reversed-phase HPLC (USM) of 
(a) standard solution of 400 ng/ml of ABZSO (1), ABZSO2 (2), ABZ (4) 
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Fig. 3.7 Representative chromatograms of extracted plasma obtained 
from human study after oral administration of 400 mg albendazole 
tablet at (a) pre-dose and (b) 2.5 hr after dosing ( 1 = ABZSO, 3 = 
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Fig. 3.8 Typical calibration curves for (a) ABZ, (b) ABZSO and (c) 
ABZSO2 using the reversed-phase HPLC method described in 3.2.1.1(b).
72
recovery of internal standard MBZ was 95.1%±0.34 with 3.78% RSD for 
extraction carried out on 6 samples.
The within day and day to day variations were in the range of 0.15 
and 8.72% as tabulated in Tables 3.12 and 3.13. The results from the 
day to day variation were not significantly different within and 
between days (PC0.01). The limit of detection taking into account a 
signal-to-noise ratio of 2, were found to be 10 ng/ml for ABZSO and 
20 ng/ml for ABZ and ABZSO2 .
Table 3.10 Linear regression data for ABZ, ABZSO and ABZSO2 







1 2.19 4.60 -0 . 0 2 0 0.032 0.999
2 2 . 2 2 4.34 -0.044 0.030 0.999
3 2 . 2 2 5.72 -0.062 0.040 0.999
4 2.17 6.19 -0.025 0.043 0.998
Mean 2 .2 0 * 1.58 -0.040 0.036
ABZSO
1 2.89 1 0 . 0 0.016 0.070 0.997
2 2.98 4.83 -0.004 0.034 0.999
3 2 . 8 6 7.24 -0.013 0.051 0.999
4 2 . 8 6 5.35 -0.085 0.037 0.998
Mean 2.90* 6 . 8 6 -0 . 0 2 2 0.048
ABZS02
1 2.93 5.45 -0.033 0.038 0.999
2 2.82 3.17 -0.027 0 . 0 2 2 0.999
3 2.79 5.11 -0.066 0.036 0.999
4 2.79 2.79 -0.076 0.066 0.997
Mean 2.83* 4.13 -0.051 0.040
* not significantly different at P = 0.05
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Table 3.11 Recoveries of ABZ, ABZSO and ABZSO2 from plasma using the









50 97.9 8.85 9.04
1 0 0 96.2 6.50 6.75
2 0 0 99.1 6.45 6.51
400 1 0 1 . 0 5.85 5.79
800 96.2 3.26 4.43
1600 95.1 1.92 2.06
ABZSO
50 89.9 8.65 9.63
1 0 0 90.5 6.91 7.6.4
2 0 0 92.9 6.45 6.62
400 90.5 5.92 6.54
800 94.7 3.62 3.82
1600 95.3 2.65 2.78
ABZS02
50 95.2 7.91 8.74
1 0 0 94.8 6.97 7.35
2 0 0 95.9 6.77 7.06
400 98.8 5.45 5.52
800 97.1 4.43 4.56
1600 94.9 2.30 2.42
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Table 3.12 The within day variation for ABZ, ABZSO and ABZSO2 using










50 47.6 4.15 8.72
1 0 0 1 0 1 . 0 6.09 6.03
2 0 0 2 0 1 . 0 1 1 . 6 5.76
800 795.3 11.5 1.45
1600 1598.0 18.1 1.13
ABZSO
50 47.7 3.58 7.50
1 0 0 97.4 4.50 4.62
2 0 0 199.5 7.52 3.77
800 797.0 1 0 . 1 1.26
1600 1599.9 12.5 0.78
ABZS02
50 48.2 3.51 7.28
1 0 0 96.5 3.98 4.12
2 0 0 199.2 6.67 3.35
800 798.4 8.99 1 . 1 2
1600 1597.6 1 0 . 8 0.63
Table 3.13 The day to day variation for ABZ, ABZSO 
the reversed-phase HPLC method (USM).
(n = 6 )
and ABZSO2  using
Concentration Mean SD RSD
(ng/ml) concent rat ion (%)
determined (ng/ml)
ABZ
50 47.8 (F - 5.80)* 4.03 8.43
2 0 0 199.8(F m 6 .0 1 )* 6.98 3.49
1600 1600.1 (F * 3.02)* 5.60 0.35
ABZSO
50 49.2 (F 4.34)* 3.98 8.09
2 0 0 200.1(F - 5.66)* 6 . 1 0 3.05
1600 1600.2(F ■ 2 .2 0 )* 4.45 0.28
ABZS02
50 48.2 (F - 4.64)* 3.96 8 . 2 2
2 0 0 199.8(F - 4.45)* 4.52 2.26
1600 1601.4 (F 0.60)* 2.43 0.15
* not significantly different at P « 0.01 <Ftab - 6.07)
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3.3.4 Calibration curves for albendazole in DMSO and 95% EtOH
The calibration curves for ABZ in DMSO and 95% EtOH were linear over 
the range 0-30 [ig/ml and 0-40 pg/ml, respectively. Table 3.14 shows 
the linear regression data for ABZ in these solvents. The replicate 
slopes for each solvents were not significantly different with mean 
slope of 0.044±0.0006 (X^  “ 1.64) for ABZ in DMSO and 0.041 in
95%EtOH (X2tab at p “ 0.05). All the intercepts passed through
the origin within ±2 SD. Fig. 3.9 shows a typical calibration curve 
for ABZ in DMSO and 95% EtOH.
Table 3.14 Linear regression data for ABZ in DMSO and 95% EtOH.
Replicate Slope SD Intercept SD r
In DMSO
1 0.044 0.0007 0.0007 0 . 0 1 0 0.999
2 0.045 0.0006 0.003 0 . 0 1 2 0.999
3 0.044 0.0006 0.006 0 . 0 1 0 0.999
Mean 0.044 0.0006 0.003 0 . 0 1 1
In 95%EtOH
1 0.041 0.0007 0 . 0 1 0 0.015 0.999
2 0.041 0.0004 0.005 0.009 0.999
3 0.041 0.005 0.008 0.041 0.999
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Fig. 3.9 Typical calibration curves for ABZ in (a) DMSO and (b) 95% 
EtOH. Inserts are the UV absorbance of ABZ in the respective solvent.
77
3.4 DISCUSSION
The separation of ABZ and its metabolites was not achieved by 
reversed-phase HPLC isocratic analysis using 0.05M ammonium acetate 
buffer pH 4.7 and acetonitrile. The capacity factor, kf values of the 
three compounds fell outside the desired range of l<k* < 2 0  when low 
acetonitrile concentration was used (22-35%). When the acetonitrile 
concentration was varied from 40 to 60% v/v, no baseline resolution 
was observed (Rs<1.5) between ABZSO and ABZSO2 • A gradient elution 
analysis was therefore developed based on these retention data with 
initial concentration of acetonitrile of 30% v/v to avoid any 
interference from plasma peaks. A good separation was achieved with 
k* value ranged between 1 and 7. The reproducibility of the retention 
times of all the compounds were good (0.77-1.77% RSD) considering it 
was a gradient analysis system and the shape of the peaks were sharp 
and symmetrical (As - 1.07-1.13). This is probably due to the
excellent masking of residual silanol groups by ammonium acetate (Lim 
et al., 1984) and therefore minimized the silanol effects of the 
column.
The advantage of employing gradient elution analysis is that the late 
eluting compounds still produce sharp peak shapes which helps to 
improve quantitation. The retention time of ABZ was considerably 
shorter (19.24 min.) using the gradient run compared to the isocratic 
analysis (~33 min.) developed by Zeugin et al. (1990).
Sample preparation using SPE was employed with modifications from 
the work reported by Hurtado et al. (1989) . 1 ml of plasma was used 
in this extraction procedure and the compounds were eluted with 
acidic methanol since ABZ is more soluble in hydrochloric acid.
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Pre-preparation of plasma prior to the SPE stage was carried out by 
diluting the plasma with buffer at pH 7.4 which may improve the 
selectivity of the extraction and reduce drug-protein binding. The 
extraction produced clean extracts as shown in Fig. 3.1(b) and there 
were no interfering peaks from the plasma. The recoveries were found 
to be comparable with those reported by Hurtado et al. (1989) 
although the initial volume of plasma used was reduced by 50%. The 
detection limits for ABZ (20 ng/ml) was comparable and were lower for 
ABZSO (10 ng/ml) and ABZSO2 (20 ng/ml) compared to those detected at 
225 nm (Alvinerie and Galtier, 1984) when the three compounds were 
analysed simultaneously. A lower ng/ml sample concentration may be 
determined by dissolving the final residue for analysis in smaller 
volume. Volume of 0.5 ml was used because the HPLC system (Spectra 
Physics auto-injector) needs a larger volume for duplicate injections 
of 50 Jll sample. The within day and day to day reproducibility of 
the assay were within the acceptable limits for the analysis of 
biological samples for pharmacokinetics studies (<10% RSD).
Some adjustments were made to the gradient elution run when a 
different HPLC system was used in USM, Malaysia. The method was 
validated in the same manner as in Bath. The recoveries of all the 
three compounds were comparable to those found in Bath and the 
precisions were within the acceptable limits. Initially, there were 
problems in getting reproducible recoveries when the extracts were 
dried using a Speedvac Concentrator (where extracts were centrifuged 
under vacuum). It was realised that these problems probably arise 
owing to the drugs sticking strongly to the test-tube wall caused by 
the centrifugal force. The amount of drugs dissolved during the 
reconstitution step were therefore not consistent. This method was
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tried as an alternative way to reduce the time taken to dry the 
extracts. However the extracts were dried by using the nitrogen gas. 
The validated method was then used to determine ABZ and the two 
metabolites in rat serum and human plasma.
As mentioned earlier, ABZ normally is not detectable in human plasma. 
A peak at a retention time of 14.94 minutes was observed in the 
extracted plasma obtained from a human volunteer who received 400 mg 
ABZ tablet which was not present in the pre-dose sample (Fig. 3.7). 
This retention time corresponded to the ABZ peak. There was no 
chromatographic interference from the any endogenous plasma compounds 
and therefore this peak could be ABZ. However this could not be 
confirmed by any other methods (eg. diode-array detector, LC-MS) 
because of limited volume of plasma sample. Nevertheless it was taken 
as ABZ peak in the determination of ABZ concentration in human plasma 
described in Chapter 5.
Although the previous HPLC methods developed to determine ABZ have 
acceptable sensitivity; the limits of detection of ABZ were low (<20 
ng/ml) and the recoveries of ABZ from plasma were generally high 
(>90%), ABZ has not previously been detected in human plasma 
(Marriner et al., 1986; Hurtado et al., 1989; Hoaksey et al., 1991). 
ABZ was only detected in some echinococcosis patients; in one study 
ABZ was detected in one out of 13 patients (Zeugin et al., 1990). 
However the patient suffered from severe cholestasis and due to this 
obstruction ABZ was not recycled and therefore present in a higher 
concentration. In another study ABZ was detected <45 ng/ml in plasma 
of a few echinococcosis patients who received 5 to 7 mg/kg ABZ for 
two 39 consecutive days (Meulemans et al., 1984). These patients
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suffered from cirrhosis and therefore probably had difficulty in 
metabolising ABZ.
Possible explanations of this finding of an ABZ peak are (i) the use 
of gradient elution analysis which produces a sharp ABZ peak, (ii) 
the SPE procedure employed which gives clean plasma extracts and 
(iii) the detection wavelength used which matches the wavelength of 
maximum absorption of ABZ.
In the preliminary analysis, Miglyol and ABZ were well separated on 
the TLC plate. The same mobile phase system was then transferred to 
the HPLC system without any problems. The order of elution of ABZ, 
ABZSO and ABZSO2 was reversed from the reversed-phase method as 
expected. Miglyol was eluted rapidly by the column and therefore did 
not interfere with the quantitation of ABZ. All the compounds were 
baseline resolved and the retention times were reproducible. The 
analysis time was <10 minutes. However this system was not as 
sensitive as the reversed-phase HPLC; the limits of detection for ABZ 
were 50 ng/ml and 100 ng/ml for ABZSO and ABZSO2 using the normal- 
phase HPLC method whereas the limits of detection of ABZ and ABZSO2  
were 20 ng/ml and 10 ng/ml for ABZSO using the reversed-phase HPLC 
method.
The maximum absorbance of ABZ in DMSO and 95% EtOH was observed at 
298 and 296 nm, respectively. The calibration curves of ABZ in these 
solvents were linear and reproducible and therefore can be used to 
determine ABZ concentration in the samples from the solubility 
studies.
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In conclusion, the gradient elution reversed-phase HPLC system is 
sensitive, precise and reproducible for the determination of ABZ and 
it two metabolites, ABZSO and ABZSO2 in plasma and this method can 
therefore be used in pharmacokinetic studies of ABZ.
Normal-phase HPLC method is simple, fast and reproducible for the 
analysis of ABZ and degradation products in the Miglyol and can be 






The formulation aspects of this work are largely concerned with the 
aspects of stability and solubility of ABZ.
4.1.1 Stability
As demonstrated by the metabolism pathways described by Gyurik et 
al. (1981) and Penicaut et al. (1983) discussed in section 1.5.3, ABZ 
can undergo oxidative and hydrolytic degradation. It was necessary 
therefore to establish whether these processes could occur in vitro 
via simple thermal mechanism and to obtain some idea of the stability 
of drug in the various solvent systems of interest.
4.1.1.1 Hydrolysis
Hydrolytic reactions are pseudo-first order reactions and involve 
nucleophilic attack of the labile carbonyl centres such as those of 
lactones and esters by water. The rate of hydrolysis increases as 
temperature increases and generally follows an Arrhenius-type 
relationship:
k = Ae”EaRT Eqn 4.1
or
Ea
log k » log A - -------  Eqn 4.2
2.303 RT
where k is the specific reaction rate, A is a constant termed as 
frequency factor, Ea is the activation energy, R is the gas constant 
and T is the temperature. Accelarated stability tests are carried out 
at higher temperatures to understand the rate and mechanism of the 
reactions as at low temperature when the rate is slow it may not be 
possible to study the process within a reasonable period of time. The 
rate constant at any temperatures may then be obtained by 
extrapolating from the plot of log k against 1/T.
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The hydrolysis of many drugs is catalysed by pH (Connors et al., 
1968). In solution of high pH, the primary attacking species are the 
hydroxide ions and the rate of reaction depends on [0H~] . At low pH 
solution, the hydrolysis rate depends on [H+  ^ as the primary 
attacking species are the hydrogen ions.
According to Dittert and Higuchi (1963), alkaline hydrolysis of 
carbamate esters is a pseudo-first order reaction and that two 
possible mechanisms are responsible for this hydrolysis; via 
hydroxide ion followed by a carbamate intermediate or via hydroxide 
ion attack followed by an isocyanate intermadiate (Fig. 4.1).
Fig. 4.1 The possible mechanisms of alkaline hydrolysis of carbamate.








R— 0— C— NRo1  >  ROH + Ro'N— COO*
I
OH
R2 ,N— C00“ + H20  ^ R2 'N—  COOH + 0H“
r2'ncooh ------- ^ co2 + r2*nh
C02 + 20H”’  > CO3 2" + H20
fast
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(2 ) via hydroxide ion attack followed by an isocyanate intermediate
O
II
R— O— C— NHR* + OH- —
O
II
R— 0— C— NR’ “ + H20 R0“ + R’N— C=-0
R'N=C=0 + H20 R'— NH— COOH
R'— NH— COOH >  C02 + R*--NH2
fast
C02  + 20H" >  C032" + H20
The second mechanism appears to be predominate in the reactions of N- 
substituted and N-monosubstituted aromatic compounds.
4.1.1.2 Oxidation
Oxidative reactions involve the removal of electrons from an atom or
a molecule. The occurrence of these reactions does not necessarily
involve molecular oxygen. However, pharmaceutical oxidations, often 
involve reactions with molecular oxygen and are termed as
autoxidation. In an other type of autoxidation, the process is
initiated by free radicals that are formed by actions of light, heat 
or trace metals.
Pharmaceutical compounds that are susceptible to oxidation such as 
antibiotics, vitamins and steroids are listed individually by Connors
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et al. (1986) and the oxidation process may involve very complex 
pathways.
4.1.1.3 Degradation of Drugs in Suspensions
In the degradation of a drug in suspension, the amount of drug in 
the solution remains constant despite its degradation with time due 
to replenishment from the solid drug reservoir. The degradation 
process is therefore expected to follow apparent zero-order kinetics:
-dc/dt * kQ Eqn 4.3
where kQ is the apparent zero-order rate constant.
4.1.2 Solubility
Solubility of a drug is an important factor in its formulation since 
in whatever dosage form a drug is administered, the drug has to
dissolve aqueous fluids of the gastrointestinal tract before
absorption across the membrane can proceed.
Poorly water-soluble drugs such as griseofulvin (Carrigan and Bates, 
1973) and cefoxitin (Schrogie et al.,1978) frequently have problems 
of low bioavailability primarily caused by the slow dissolution rate 
of the drug in the gastrointestinal tract. The dissolution rate of a 
drug is described by the Noyes-Whitney equation:
dm/dt “ ksA(S - Ct) Eqn 4.4
where dm/dt is the dissolution rate, ks is the dissolution rate
constant, A is the surface area of the dissolving solid, S is the
solubility and Ct is the concentration of the drug in the medium at 
time t.
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According to this equation, the solubility of a drug is one of the 
main factors that determine its dissolution rate. Solubility is also 
influence by temperature and pH of the solution as described in
4.2.2.1 and 4.2.2.2, respectively. The dissolution rate of a drug may
be increased by reducing the particle size e.g. micronised form.
It was suggested that to avoid any potential problems associated with 
dissolution in gastrointestinal absorption, a drug should have an 
aqueous solubility greater than 10 mg/ml with the lower limit of 1 
mg/ml (dissolution rate of 0.1 mg/cm2/min) . This indicates the need 
for a more soluble salt in these cases (Kaplan, 1972).
One approach to remove the dissolution step in the gastrointestinal 
tract is to incorporate drug into lipid (Palin et al., 1986; 
Serajuddin et al., 1988). Oil droplets will be formed in 
gastrointestinal aqueous fluids and the drug in its molecular state 
will partition from the oil droplets into the aqueous phase. The drug 
is thus available for absorption in molecular form.
4.1.2.1 Effect of Temperature
The solubility of a drug in a liquid depends on temperature. The 
effect can be described by a form of the Van't Hoff equation (4.5) 
which defines the relationship between absolute temperature and 
solubility, S.
dlogeS AH
-------  =   Eqn 4.5
dT RT2
where AH is the standard heat of solution and R is the gas constant.
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Integration of Eqn 4.5 gives
AH
logeS = - ---  + constant Eqn 4. 6
RT
According to Eqn 4.6, when the standard heat of solution is 
exothermic, solubility decreases with increases in temperature. On 
the other hand, when the standard heat of solution is endothermic, as 
temperature increases, the solubility increases.
4.1.2.2 Effect of pH
Many important drugs belong to the class of weak electrolytes; weak 
acids and bases. The solubility of these drugs is strongly influenced 
by the pH of the solution. For simple drug dissociation systems 
comprising a weak acid and its ionised conjugate base or a weak base 
and its protonated conjugate acid, pH solubility effects can be 
predicted from equations 4.7 and 4.8.
Weak acid-ionised base form:
where S is the saturation solubility and SQ is the solubility of the 
undissociated form.
For amphoteric drugs which possess both acidic and basic groups, the 
dissociation process comprises of a cation (at low pH), a zwitterion 
and an anion (at high pH) . The equations for predicting the pH 
solubility for amphoteric drugs are given by equations 4.9 and 4.10. 
At pH values below the isoelectric point:
pH - pKa - log Eqn 4.7
Weak base-protonated acid form:
pH - pKa - log Eqn 4. 8
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( Sz
pH - pKal = log Eqn 6.9
S - S
At pH values above the isoelectric point:
pH - pKa2 = log Eqn 4.10
S
where S is the saturation solubility and Sz is the lowest solubility 
of the zwitterion.
4.1.2.3 Solvent and Solute Polarity
Solubility of a drug in a solvent depends on the polarity of the 
solvent and the solute, often simplicitically expressed as "like 
dissolves like". Polarity represents the ability of a solvent to 
interact with solute molecules and can be scaled using the
electrostatic properties; dielectric constant and dipole moment.
Dielectric constant indicates the ability of a solvent to separate 
the oppositely charged ions whereas dipole moment largely determines 
the orientation of a solvent around the solute molecules in the 
absence of specific solute-solvent interactions. In general the
greater the dielectric constant and dipole moment values, the more 
polar the solvent.
Table 4.0 shows the dielectric constants and dipole moments of some 
solvents. Ionic compounds such as sodium chloride will dissolve in 
polar solvent such as water but is insoluble in solvents having low 
dielectric constant such as benzene (Martin et al., 1983). Having a 
high dielectric constant of 78, water will lower the attraction 
forces between the oppositely charged sodium and chloride ions.
90
Solubility of many drugs e.g. salicylic acid, xanthines, parabens and 
some barbiturates have been studied in a range of solvents of various 
dielectric constants (Paruta et al., 1965; Paruta, 1969; Laprade et 
al., 1976; Alexander et al., 1977).
Solubility parameter is a measurement of intermolecular forces within
the solvent that indicates the ability of a liquid to act as a
solvent. This parameter was first introduced by Hildebrand and Scott 
(1964) to explain the behaviour of solvents of little or no polarity 
and those unable to hydrogen bond. The solubility of one components 
in another is predicted by calculating the difference in the 
solubility parameters, (8  ^ - 8 2 ); the smaller the difference, the 
greater the solubility. Solubility of many drugs e.g. halobenzenes, 
benzoates, alcohols in water have been succesfully estimated using 
their solubility parameters (Yalkowsky and Valvani, 1980). This
concept has been extended by introduction of partial solubility 
parameters that have improved the measurement of the systems in which 
polar interactions and effects occur (Beerbower et al., 1984; Martin 
et al., 1984; Bustamante et al., 1989; Regosz et al., 1992).
Intermolecular forces such as hydrogen bonding, dipole-dipole 
interaction (Keesom) and induced dipole-induced dipole interaction 
(London) contribute to the interaction between the solvent and solute 
molecules.
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Water 78.25(20)d 1.84 23.4




PEG 300 or 400 35.0b 9.9
Methanol 32.63(25) 1 . 6 6 14.7
95% Ethanol 27.0e
Ethanol 24.30(25) 1 . 6 8 12.7
Chloroform 21.81(20) 1.15 9.3
Benzyl alcohol 13.1 (20) 1 . 6 6 1 2 . 1
Benzene 2.28(25) 0 9.1
Liquid paraffin 7.1
a from Dack (1976) 
b from Wells (1988)
c dipole moment determined in solution unless otherwise stated 
d temperature in °C 
e calculated using: 
e95%EtOH “ 0.95 x (^ethanol1 + 0*05 x (^water1
Another important scale of polarity for solutes is its partition 
coefficient, P which can be expressed as
where CQ is the concentration of solute in oil and Cw is the 
concentration in aqueous phase. The partition coefficient measures 
the partition of a compound between aqueous phase and oil or an 
immiscible solvent. The greater the P value, the higher lipid
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solubility of the compound. Octanol is generally used to generate 
this coefficient because of its solubility parameter, 8  = 10.24 which is 
in the middle of the range of most drugs ( 8 = 8-12) . Due to its 
partial polarity, water is solubilised to some extent in the octanol 
phase, which is a feature of biological lipid membrane since the 
solubility parameter for the whole lipid membrane derived from 
erythrocyte ghost is 8  * 10.310.4 (which is similar to that of 
octanol) and dehydration of the membrane to lipid constituent only 




Stability of ABZ was studied in aqueous suspension and solvents of 
interest.
4.2.1.1 Stability of Albendazole Aqueous Suspension
When suspensions of ABZ were prepared in glycine buffer, ABZ was not 
readily wetted. Therefore, sodium dodecyl sulphate (SDS) was added to 
the suspension to aid wetting.
100 ml lots of suspensions of 0.1% ABZ in glycine buffer at pH 9.00 
and 1 0 . 0 0  were prepared with and without the addition of 0 .0 1 1 % of 
SDS and transferred into a 3-necked 250 ml flask and was boiled under 
reflux at 100°C. 5 ml of the solution was sampled at the appropriate 
sampling times using a pipette. Samples were assayed for ABZ by 
diluting with water ( 1 in 1 0 0 ) and followed by 1 in 1 0  dilution with 
mobile phase prior to HPLC analysis as described in Chapter 3 
(3.2.1.1(a)). The zero time sample was obtained by pipetting 5 ml of 
the suspension before it was boiled, and was diluted in the same 
manner as the other samples before HPLC analysis.
In all the studies, the suspended drug dissolved after a period of 
time. After completing the experiment at pH 10.00 with SDS, crystals 
were noted in the cooled solution remaining in the flask. The 
crystals were collected by filtration, washed with distilled water 
and dried. Sample was dissolved in mobile phase and injected into 
HPLC. The sample was identified by NMR and MS (see Appendix 2) . 
Sample was also analysed by TLC using solvent system of 
chloroform/ethyl ether/acetic acid (6:1:1) as reported by Gyurik et
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al. <1981).
4.2.1.2 Stability of Albendazole Sulphoxide Aqueous Suspension
A suspension of 0.1% ABZSO with 0.011% SDS was prepared in glycine 
buffer at pH 10.00. 100 ml of suspension was boiled under reflux at 
100°C as previously. 5 ml aliquots were sample at zero time and at 
the appropriate sampling times and samples were diluted 1 in 1 0 0 0  (as 
described for ABZ samples in 4.2.1.1)) before samples were assayed 
for ABZSO by HPLC (3.2.1.1(a)).
4.2.1.3 Stability of Albendazole in Solvents
(a) DMSO
1 mg/ml solution of ABZ was prepared in DMSO. 1 ml of the solution 
was pipetted using a micropipette (Gilson Pipetman) into a series of 
plastic vials with plastic caps. 5 vials were kept in the freezer 
(-18°C) as control samples. Vials in group of 5 were placed at room 
temperature (22°C), in the heating block at 37°C and 55°C for 48 
hours. The reaction was stopped by putting the vials in ice and 
stored in the freezer up to 2 weeks until time of analysis. 0 . 2  ml of 
sample was pipetted into a 1 ml volumetric flask and the volume was 
made up to the mark with mobile phase, and injected into HPLC 
(3.2.1.1 (a)).
(b) 0.1M HC1
1 ml aliquots of 10 Jig/ml prepared in 0.1M HC1 were pipetted into 
plastic vials and heated at room temperature (22°C), or placed in the 
heating block at 37°C and 55°C for 48 hours. Vials were also heated 
at 55°C for 3, 7 and 24 hours. Control samples were kept in the
freezer (-18°C). 0.1 ml samples were pipetted into a 1 ml volumetric
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flask and was made up to volume with mobile phase and analysed by
HPLC (3.2.1.1 (a)).
4.2.2 Solubility Studies
Solubility of ABZ in solvents of interest was determined using four 
different methods. Methods 1-3 are related techniques:
Method 1
100 ml of solvent was transferred into a jacketed-beaker. Excess of 
ABZ was added and stirred. Nitrogen gas was bubbled into the solvent 
to create anoxic conditions; the vessel was covered with "para-film". 
The apparatus used is shown in Fig. 4.1. The solution was sampled 
through a tube fitted with a number 3 glass sinter filter to ensure 
no particles could pass through. 0.1 ml aliquots of the clear 
supernatant obtained were removed and assayed for ABZ 
spectrophotometrically (3.2.3) and by HPLC (3.2.1.1(a) and (b)) . 
Plots of concentration against time were constructed and the 
solubility of ABZ was determined when the concentration was 
constant, indicating saturating concentration of ABZ.
n2 gas
WATER IN
i f - : - :
c
► WATER OUT
■GLASS SINTER FILTER 
.MAGNETIC BAR
/ STIRRER \
Fig. 4.2 Diagram of the apparatus used in the solubility studies of
ABZ using Method 1.
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Method 2
20-100 mg amounts of ABZ were accurately weighed and transferred into 
a mortar and ground with 10 g of solvent. The solvent was added in 
small amount whilst mixing to form a homogeneous slurry. The slurry 
was transferred into a test-tube, heated in the water-bath (70°C) 
until it turned clear and cooled. The solubility of ABZ was assessed 
by visual inspection.
Method 3
5-100 mg quantities of ABZ were accurately weighed into a series of 
test-tubes. 10 g of solvent was added to give ABZ concentration of 
0.5-10 mg/g. The test-tubes were then placed in a water-bath at 25°C 
or 37°C and shaken. The solubility of ABZ was assessed visually. The 
test-tubes were kept at room temperature for another 2  weeks with 
occasional shaking.
Method 4 (Turbidity Method)
The turbidity of the system was measured using UV/VIS 
spectrophotometer in the visible region, 450 nm.
(a) A 100 ml volumetric flask was filled up to the mark with water or 
0.1M HC1 at room temperature (~17°C) or placed in a water-bath at 
37°C. 50 |ll aliquots of "ABZ solution" (solution in DMSO) was added 
to the water or HC1 using a micropipette and mixed thoroughly. After 
each addition the absorbance of the system was measured. 2 ml was 
removed for this measurement and was returned to the flask after the 
absorbance was recorded.
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(b) 100 ml of 0.1M HC1 or water was pipetted into jacketed-beaker at 
37°C. The "ABZ solution" was added to HC1 solution or water using a 
10 ml Segma Interchangeable precision syringe placed on a syringe 
pump. The rate of delivery was calibrated using water (10
replicates); rate (1 ): 1 .1 2 ±0 . 0 1  ml/min. and rate (2 ): 0 .1 0 2 ±0 . 0 0 1
ml/min. Aliquots of 0.56 ml (30 seconds at rate (1)) or 8.5 |ll (5 
seconds at rate (2)) of "ABZ solution " was added to HC1 solution or 
water. 2 ml of the system was removed to measure the absorbance and 
was returned to the beaker before the next addition of "ABZ
solution".
(c) 2 ml of "ABZ solution" was transferred into a test-tube using the 
syringe and the test-tubes was then placed in a water-bath at 37°C. 
Cumulative volumes of 1 ml 0.1M HC1 were added and mixed thoroughly. 
Absorbance was measured after each addition of HC1 solution.
4.2.2.1 Solubility of Albendazole in Solvents
The solubilities of ABZ in various solvents; DMSO/ 95% EtOH, Miglyol, 
water, 0.1M and 0.01M HC1 and at different temperatures were
determined using Method 1 (4.2.2).
4.2.2.2 Solubility of Albendazole in Miglyol, Tween 80 & 85 and 
Polyethylene Glycol 400
The solubilities of ABZ in polyethylene glycol (PEG) 400, Miglyol, 
Tween 80 or mixtures of Miglyol and Tween 80 (60:40%, 58:42%, 61:39%, 
w/w) were determined using Method 3.
The solubility of ABZ was also determined in mixtures of Tween 80 or 
85 and Miglyol (60:40%, w/w) and in PEG 400 using Method 2.
98
4.2.2.3 Solubility of "albendazole solutions”
Studies were carried out to establish the solubility of "ABZ 
solutions" in water and simulated gastrointestinal fluid.
(a) ABZ-DMSO Solution
5 mg/g of ABZ in DMSO was added to water or 0.1M HC1 using Method 
4(a) (4.2.2). The solubility of "ABZ-DMSO solution" in 0.1M HC1 was
also determined using Method 4(b) (4.2.2). 6 replicate determinations 
were carried out. Results are shown in Tables 4.12 and 4.13.
(b) ABZ-Miglyol:Tween 80 Solution
2 mg/g of ABZ was prepared in Miglyol: Tween 80, 60:40%, w/w
(Mig:Twn) . The ABZ-Mig:Twn solution was added to 0.1M HC1 and the 
solubility was determined using Method 4(b) (4.2.2) at a rate of 
delivery of 0.102 ml/min. This experiment was repeated using Mig:Twn 
solution without ABZ (blank). 6 replicate determinations were carried 
out. Results are shown in Table 4.14
The system resulting from the addition of "ABZ Mig:Twn solution" to 
0.1M HC1 and a suspension of ABZ in water were examined under 
microscope (Vickers, York) with x40 magnification.
The density of Mig:Twn 80 solution was determined in duplicate at 
22°C using a pycnometer as described in the British Pharmacopoeia 
(1988).
The density of MigiTwn solution at 22°C was 0.994 g/ml.
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(C) ABZ-PEG 400 Solution
The solubility of ABZ-PEG 400 solution in 0.1M HC1 was determined 
using Method 4(c). 5 mg/g ABZ was prepared in PEG 400 was used. 5 
replicate determinations were carried out.
4.2.2.4 Analysis of Samples
Samples from studies in DMSO and 95%EtOH were assayed by UV 
spectrophotometry as described in Chapter 3 (3.2.3). The samples were 
diluted with the respective solvent; 1 in 250 for DMSO and 1 in 50 
for 95%EtOH. Samples from these studies were analysed for presence of 
any degradation products by HPLC (3.2.1.1(a)).
Samples dissolved in Miglyol were assayed for ABZ using the normal- 
phase HPLC method (3.2.1.1 (b)) . Samples were diluted with mobile
phase (1 in 50) prior to analysis.
The reversed-phase HPLC method (3.2.1.1(a)) was used to assay for ABZ 
in samples obtained from studies in water and HC1 (0.1M and 0.01M). 
Samples were diluted prior to injection into HPLC.
4.2.3 Triangular Phase Solubility Diagram
A solution of ABZ in Miglyol is highly desirable. The possibility of 
increasing solubility of ABZ in Miglyol by addition of Tween 80 
and/or PEG was considered. The miscibility of the 3 components 
(Miglyol, PEG 400 and Tween 80) was therefore studied since a one- 
phase system is required for potential drug-vehicle. Data for the 
construction of a triangular phase diagram were obtained by weighing 
the components into vials, mixing thoroughly and examining after the 
vials were left standing overnight.
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4.2.4 Preparation of Gluconate Salt
5 mg/g ABZ was prepared in mixture of Tween 80:gluconic acid (20:80%, 
w/w) by heating. The clear solution was evaporated on a rotary 
evaporator at 40°C and a sticky solid was formed. The solubility of 
the solid in some solvents was studied. The solid product (0.5 g) was 
dispersed in Miglyol (5-10 g), water (1-5 ml) and PEG 400 (1-5 g) in 
test-tubes, heated and cooled.
4.2.5 Statistical Analysis
The data from the solubility studies of "ABZ solutions" in water and 
0.1M HC1 (4.3.2.3) were subjected to least-square regression analysis 
to determine the slope and the intercept of the curves.
The Student*s t-test, analysis of variance (ANOVA) and Bartlett test 




4.3.1.1 Results from Stability Study of ABZ Aqueous Suspension
The results from the studies of 0.1% ABZ with and without 0.011% SDS 
in glycine buffer suspension at pH 9.00 and 10.00 heated at 100°C are 
presented in Tables 4.1 and 4.2.
Chromatograms in Figs. 4.3 and 4.4 illustrate the loss of ABZ and the 
appearance of degradation compounds; ABZSO (R^-5.70 min.), Unknown 1 
(Rt»7.54 min.) and Unknown 2 (^“12.84 min.) in systems with and
without SDS at pH 9.00. The "dissolution" of ABZ was higher in the 
presence of SDS (Fig. 4.5). ABZSO was present in both zero time
samples and in higher concentration in suspension with no SDS (Fig. 
4.6). Table 4.3 shows the rate of formation of the degradation
compounds which was calculated from the peak area ratio against time 
plot (Fig. 4.6).
Other than for the crystalline materials of ABZ, ABZSO and ABZSO2  
used as the standard solutions, no attempts were made to identify the 
degradation compounds and therefore standards are not available. For 
this reason peak area ratios are used in Figs. 4.5 and 4.6 to
compared the changes in the concentration of ABZ and its degradation
compounds.
1 0 2
Table 4.1 Results from the stability study of 0.1% ABZ suspension 






Unknown 1 Unknown 2
With SDS
0 1 . 0 0 2 0.033 0 . 0 0 0 0 . 0 0 0
24 1.077 0.029 0 . 0 0 0 0 . 0 0 0
48 0.515 0.027 0 . 0 0 0 0 . 0 0 0
1 2 0 0.330 0.052 0.059 0.146
144 0.072 0.036 0.082 0.259
Without SDS 
0 0.216 0.128 0 . 0 0 0 0 . 0 0 0
24 0.251 0 . 1 2 0 0 . 0 0 0 0 . 0 0 0
48 0.183 0.116 0.039 0.126
115 0.124 0 . 1 2 0 0.089 0.425
Table 4.2 Results from the stability study of 0.1% ABZ suspension
with and without 0 .0 1 1 % SDS at pH 10.00.
Time Peak Area Ratio
(hr) ABZ Unknown 1 Unknown 2
With SDS
0 1.585 0 . 0 0 0 0 . 0 0 0
6 1.771 0 . 0 0 0 0.285
9 1.242 0 . 0 0 0 0.470
1 2 0.836 0.052 0.604
24 0 . 0 0 0 0.125 1.510
30 0 . 0 0 0 0.150 1.484
Without SDS
0 0.197 0 . 0 0 0
6 0.294 0.131


















Fig.4.3 Chromatograms of (a) std. solution of 0.8 ng/ml each of ABZSO 
(1), ABZS02 (2), MBZ (3) and ABZ (4), and 1/1000 dilutions of 0.1% 
ABZ suspension with 0.011% SDS in glycine buffer at pH 9.00 heated 






















Fig. 4.4 Chromatograms of (a) std. solution of 0.8 pig/ml each of 
ABZSO (1), ABZS02 (2), MBZ (3) and ABZ (4), and 1/1000 dilutions of 
0.1% ABZ suspension in glycine buffer (no SDS) at pH 9.00 heated at 















Fig.4.5 Degradation profile of ABZ after heating 0.1% ABZ suspension 
at 100°C with and without 0.011% SDS in glycine buffer at pH 9.00. 



















Fig. 4.6 Peak area ratio-time profile showing the formation of the 
degradation compounds after heating 0.1% ABZ suspension at 100°C with 
(•) and without (o) 0.011% SDS in glycine buffer at pH 9.00.
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Table 4.3 Rate of formation of degradation compounds after heating 




Rate of formation 









* Remains constant at initial sample value.
The chromatograms in Figs. 4.7 and 4.8 show degradation compounds, 
Unknown 1 and 2 were formed when ABZ suspension with and without SDS 
at pH 10.00 were heated at 100°C. "Dissolution" of ABZ was again 
higher in suspension prepared with SDS and it was completely degraded 
at 24 hours (Fig. 4.9). It appears that degradation of ABZ was faster 
at pH 10.00 than pH 9.00 when ABZ suspensions with and without SDS 
were heated at 100°C (Fig. 4.6 and 4.9). Only Unknown 2 was formed in 
suspension with no SDS (Fig. 4.10) but both Unknowns 1 and 2 were 
detected in suspensions with SDS. ABZSO was not present in any of the 
system at pH 10.00. The rate of formation of the degradation 
compounds is given in Table 4.4, was calculated from the peak area 















Fig. 4.7 Chromatograms of (a) std. solution of 0.8 |ig/ml each of 
ABZSO (1), ABZS02  (2) , MBZ (3) and ABZ (4), and 1/1000 dilutions of 
0.1% ABZ suspension with 0.011% SDS in glycine buffer at pH 10.00 
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Fig. 4.8 Chromatograms of (a) std. solution of 0.8 pg/ml each of 
ABZSO (1), ABZS02, MBZ (3) and ABZ (4), and 1/1000 dilutions of 0.1% 
ABZ suspension in glycine buffer at pH 10.00 heated at 100°C for (b) 
Ohr, (c) 6hrs, (d) 12hrs and (e) 24hrs.
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Fig.4.9 Degradation profile of ABZ after heating 0.1% ABZ suspension 
at 100°C with and without 0.011% SDS in glycine buffer at pH 10.00. 
Data are shown as peak area ratio agianst time.
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Fig. 4.10 Peak area ratio-time profile showing the formation of the 
degradation compounds after heating 0.1% ABZ suspension at 100°C with 
(•) and without (o) 0.0115% SDS in glycine buffer at pH 10.00.
110
The crystals found in the degraded ABZ solution (pH 10.0) gave a peak 
at 13.2 min when injected into the HPLC which corresponds to Unknown 
2. The crystals were identified by NMR and confirmed by MS (Tables
4.5 and 4.6) to be the 5-(propylthio)-ltf-benzimidazol-2-amine (ABZ 2- 
amine) . The NMR and MS spectra are given in Appendix 2. This 
characterization was also confirmed by TLC analysis. The Rf of 
Unknown 2 (Rf * 0.10) corresponded to the Rf of the ABZ 2-amine 
compound (Rf « 0.09) as reported by Gyurik et al. (1981).
Table 4.4 Rate of formation of degradation compounds after heating 




Rate of formation 







Table 4.5 NMR data (5, multiplicity) for ABZ, ABZSO and Unknown 2.
Compound H-aromatic CH3-0 H-a H- 0 H-y N-H
ABZ 7.1-7.4,m 3.7, s 2 .8 , t 1.5,m 0 .9, t 11.6,3
ABZSO 7.3—7.7,m 3.7,s 2 .8 ,m 1.5,m 0 .9,t M *-» • VO CO
Unknown 2 7.6—7.2 ,m 2 .8 , t 1.5,m 0 .9,t 10.7,s
6.2,3
Table 4.6 Mass*-spectral data for ABZ, ABZSO and Unknown 2 .


















































4.3.1.2 Results from Stability Study of ABZSO Aqueous Suspension
Table 4.7 shows the results from the 0.1% ABZSO suspension with 
0.011% SDS at pH 10.00 when heated at 100°C. ABZSO was completely 
degraded at 9 hours and a third degradation compound/ Unknown 3 can
be seen in the chromatograms in Fig. 4.11 having a retention time of
3.29 minutes. The loss of ABZSO and the formation of Unknown 3 are
illustrated in Fig. 4.12. The rate of formation of Unknown 3 was
calculated to be 0.34±0.07.
Table 4.7 Results from the stability study of 0.1% ABZSO with .011% 





0 . 0 3.67 0 . 0 0
1.5 4.77 0.72
3.0 0 . 8 6 1.60
6 . 0 0 . 1 0 2.06
9.0 0 . 0 0 2.08
1 2 . 0 0 . 0 0 2.13
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Fig. 4.11 Chromatograms of (a) std. solution of 0.8 ng/ml each of 
ABZSO (1), ABZS02 (2), MBZ (3) and ABZ (4), and 1/1000 dilutions of 
0.1% ABZSO suspension with 0.011% SDS in glycine buffer at pH 10.00 
heated at 100°C for (b) Ohr, (c) 1.5hrs, (d) 3.0hrs and (e) 9.0hrs.
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Fig. 4.12 Peak area ratio-time profile showing the degradation of 
ABZSO and the formation of the degradation compound after heating 
0.1% ABZSO suspension at 100°C with 0.011% SDS in glycine buffer at 
pH 10.00.
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4.3.1.3 Results From Stability Studies o£ ABZ in Solvents
(a) DMSO
ABZ was found to be degrading in all the samples at all temperatures 
studied/ including control samples which were kept in the freezer 
(-18°C). Fig 4.13 shows typical chromatogram patterns for ABZ 
solutions (1 mg/ml) in DMSO at all temperatures. There were 9 peaks 
detected by HPLC. Peak 3 is the internal standard/ MBZ spiked prior 
to the analysis and peak 4 is ABZ. Peaks 1, 2, 6, 8-11 are the
degradation compounds. When compared with standard solutions/ peaks 
1/ 2, and 6 correspond to ABZSO/ ABZSO2  and ABZ 2-amino compound 
(Unknown 2), respectively. Peaks 8-11 are unknown and no attempts 
were made to identify them. Percentage total of peak area ratio of 
all the peaks are summarised in Table 4.8 and they were comparable at 
all temperatures except for peak 6 . Peak 6 makes a significant 
contribution (~4.3%) to the %total of peak area ratio compared to 
control sample and samples at 22°C and 37°C. Correspondingly ABZ 
degraded faster at 55°C in DMSO (lowest %total of peak area ratio).
Table 4.8 Percentage total of peak area ratio (against MBZ) of ABZ 
and degradation compounds in the stability study of ABZ in DMSO for 
48 hr. Results represent mean of 5 samples. (meanlSD)
Peak Control




1 0.0810.04 0.1010.04 0.2610.05 0.1010.07
2 0.0910.02 0.0910.06 0 .1 2 1 0 . 0 1 0.1310.12
4 98.4612.67 98.4411.01 97.9611.52 94.2312.28
6 0 .1 1 1 0 . 0 2 0.0910.03 0.2610.04 4.3010.34
8 0.0510.01 0.0410.01 0 .1 2 1 0 . 0 1 0.0710.04
9 0.1710.05 0.1710.04 0.1410.03 0.1510.04
1 0 0.3410.08 0.3510.09 0.4310.03 0.3710.03








12 20 24160 4 8
(a) (b)
Fig. 4.13 Typical chromatogram pattern for ABZ (4) solutions (1 
mg/ml) in DMSO. (a) sample heated at 22°C and (b) sample heated at 
55°C for 48 hours.
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(b) 0.1M HC1
Table 4.9 shows the results of ABZ stability in 0.1M HC1 at different 
temperatures studied; -18°C (control), 22°C, 37°C and 55°C for 48
hours. The mean of these 4 values was 9.79±0.45 (RSD = 4.6%) and 
comparison by analysis of variance at P = 0.05 showed there was no 
significant difference (F * 3.77, Ftab = 4.47) between them; no 
degradation products were detected by HPLC (Fig. 4.14).
Samples heated in 0.1M HC1 at 55°C were also analysed at 3, 7 and 24 
hours. Although a decreasing trend in concentration of ABZ was 
observed with time of heating (Table 4.9) these values were not 
significantly different when compared using analysis of variance at 
P-0.05. (F - 3.77, Ftafc - 4.47 ; 13 / 4 3  " 1.92, ttaj;) - 2.31). The mean 
of these 4 values at 55°C was 9.65±0.24 (RSD = 2.5).
Table 4.9 Concentration (mean±SD) of ABZ in the stability study of 





Control 1 M 00 O O 9.86±0.75a




55° 1 2 hr 9.55±1.22b
55° 48hr 9.39±0.45a,b/*
General mean: 9.77±0.34 
RSD =3.5%
a not significantly different F = 3.77 
b not significantly different F = 3.77 
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min.
Fig. 4.14 Typical chromatogram of ABZ Solution (10 Jig/ml) in 0.1M 
HC1, sample heated at 55°C for 48 hours.
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4.3.2 Solubility Studies
4.3.2.1 Results from Solubility of ABZ in Solvents
(a) DMSO
Table 4.10 shows the solubility of ABZ in DMSO (Method 1, 4.2.2). It 
is apparent that solubility of ABZ increases with temperature. The 
corresponding Van*t Hoff plot is shown in Fig. 4.15a. The standard 
enthalpy of the dissolution was estimated from the slope as 44±6 
kJ/mole; it is recognised that the data set is limited and further 
data over this temperature range would needed to be generated to 
confirm this figure.
Even though the study was carried out in anoxic conditions/ some 
degradation of ABZ still took place. The peaks of the degradation 
products were first seen in samples at 108hr when the studies were 
carried out at 23.30°C and in samples at 72hr for 25.20°C and 
30.00°C. The degradation products included ABZSO (peak 1), ABZSO2  
(peak 2) and ABZ 2-amino compound (peak 6 ) (Fig. 4.16) which were 
identified by their HPLC retention times.
(b) 95% EtOH
Solubility of ABZ in 95% EtOH is given in Table 4.10. The plot of 
loge solubility against 1/T for ABZ in 95% EtOH was linear (Fig 
4.15b) although the data set is limited. Further data over this 
temperature range would needed to be generated to confirm this plot. 
The estimated standard enthalpy for dissolution was 36±2 kJ/mole. ABZ 
was stable in 95% EtOH at different temperatures (Table 4.11) and 
HPLC analysis did not show any degradation products present (Fig. 
4.17).
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Fig. 4.15 Van't Hoff plot for solubility of ABZ in (a) DMSO, (b) 95% 
EtOH and (c) Miglyol.
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ABZ
200 4 8 12 2416
m in .
Fig. 4.16 A typical chromatogram of ABZ (4) and the degradation 
products in DMSO in the solubility study of ABZ. (144hr sample when 
study was carried out at 23.30°C).
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Table 4.11 Concentrations of 
temperatures.
ABZ in 95% EtOH at different
Sampling ABZ concentration (mg/ml)
time (hr) 23.30°C 25.20°C 29.10°C
12.0 0.86 0.96 1.19
24.0 0.80 0.82 1.06
36.0 0.89 0.85 1.09
60.0 0.80 0.95 1.05
96.0 0.85 0.89 0.95
144.0 0.85 0.90 0.93
ABZ
20 24B 12 160 4
ABZ
2016 248 120 4
(a) (b)
Fig. 4.17 Representative chromatograms from solubility study of ABZ 
in 95% EtOH. (a) 144 hr sample when study was carried out at 23.30°C 
and (b) 96 hr sample at 29.10°C.
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(c) Miglyol
Table 4.10 gives the solubility of ABZ in Miglyol at various 
temperatures and the Van't Hoff plot (Fig. 4.15c) shows a linear 
relationship; the calculated standard enthalpy for ABZ dissolution 
was 10±1 kJ/mole. ABZ was stable in Miglyol at these temperatures 
(Table 4.12) and degradation products were not observed (Fig. 4.18).
(d) Water
The solubility of ABZ in water was impossible to determine by Method 
1 (4.2.2) because the assayed concentrations of ABZ increased until 8  
and 36 hours for 23.10°C and 29.10°C, respectively and then gradually 
decreased as shown in Fig. 4.19. ABZSO was present up to 4% of ABZ 
analysed.
(e) 0.1M and 0.01M HC1
The measured concentrations of ABZ in 0.1M and 0.01M HC1 solutions 
progressively increased over 5-6 days (Fig. 4.20) and therefore, the 
solubility of ABZ in these solutions was not established by the
Method 1 (4.2.2). ABZSO was detected from 24 hours in both solutions 
and was present up to 7.0% and 8.0% of the ABZ by 48 hours in 0.1M 
and 96 hours in 0.01M HC1 solution, respectively.. The ABZ 2-amino 
compound was also found in 0.1M HC1 solution from 48 hours. The
concentrations of ABZ achieved in 0.1M HC1 solution appear to be an




Concentrations of ABZ in Miglyol at different
Sampling 
time (hr) 20.02°C
ABZ concentration (mg/ml) 
24.75°C 30.40°C 37.10°C
24.0 0.46 0.50 0.51 0.56
48.0 0.46 0.48 0.53 0.54
72.0 ND 0.47 0.41 0.55
96.0 0.46 0.49 0.52 0.63
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(b)
Fig. 4.18 Representative chromatograms from solubility study of ABZ 
in Miglyol. (a) 96 hr sample when study was carried out at 20.05°C 
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Fig. 4.19 Dissolution profile of ABZ in water at 23.10°C and 29.10°C. 



























o 26 - 
O
20 -
0 30 60 90 120 150
Tim e (hr)
(b)
Fig. 4.20 Dissolution profile of ABZ (a) in 0.1M HC1 and (b) in 
0.01M HC1, both at 30.30°C. Data are shown as concentration against 
time plot.
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4.3.2.2 Results for Solubility of ABZ in Miglyol/ Tween and PEG 400
(a) Method 3
ABZ was soluble up to 1 mg/g in PEG 400 at 37°C. The dissolution of 
ABZ in any of the drug-vehicle mixtures (Mig:Twn 80; 60:40%/ 58:42%, 
61:39%, w/w) was very slow. The concentration of ABZ dissolved in 
these mixtures was 0.5 mg/g after 2 weeks at room temperature.
(b) Method 2
When the solubility of ABZ was determined by using Method 2 (4.2.2) 
in PEG 400 and mixtures of Tween 80 or 85 and Miglyol (40:60%, w/w), 
ABZ was soluble up to 2 mg/g in the mixtures and up to 5 mg/g in PEG 
400. Results are presented in Table 4.13.
Table 4.13 Results from the solubility study of ABZ in Tween 80/85 





After heating After overnight
standing at room 
temperature
Tween 80:Miglyol (40:60%,w/w)
2 . 0 clear clear
3.0 clear drug precipitation
5.0 clear drug precipitation
1 0 . 0 cloudy cloudy
Tween 85:Miglyol (40:60%,w/w)
2 . 0 clear clear
5.0 clear drug precipitation




6 . 0 clear drug precipitation
7.5 clear drug precipitation
9.5 clear drug precipitation
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4.3.2.3 Results from Solubility Studies of "ABZ Solutions"
Tables 4.14, 4.16, 4.18 and 4.21 summarise the absorbance data as the 
mean value for each replicate run at a given ABZ concentration. 
However the data for each individual run was subjected to linear 
regression analysis, the results from which are shown in Tables 4.15,
4.17, 4.19, 4.20 and 4.22. Figs. 4.21-4.23 and 4.25 illustrate
typical concentration-absorbance plots obtained from the solubility 
of ABZ-DMSO solution when added to water and 0.1M HC1, ABZ-Mig:Twn 80 
solution when added to 0.1M HC1 and ABZ-PEG 400 solution when added 
to 0.1M HC1, respectively. A typical concentration-volume added plot 
obtained from the solubility of ABZ-Mig:Twn 80 solution when added to 
0.1M HC1 solution is shown in Fig. 4.24.
(a) ABZ-DMSO Solution
(i) When added to water
At room temperature (~17°C) a few particles were observed in the 
solution after 100 |il of ABZ-DMSO solution (5 mg/ml) had been added, 
giving a final ABZ concentration of 5.00 |ig/ml (0.1% DMSO) in the 
volumetric flask (Method 4 (a)). At a concentration of 7.49 |lg/ml ABZ 
(0.15% DMSO), a milky precipitate formed in the solution. A similar 
situation occurred at ABZ concentration of 12.47 pg/ml (0.25% DMSO) 
and 17.89 pg/ml (0.36% DMSO) when using the volumetric flask and 
jacketed-beaker (Method 4 (b)) techniques, respectively at 37°C.
Particles (ABZ) were found on the wall of the volumetric flask or 
beaker above the solution level.
The absorbances measured at 450 nm to assess turbidity when ABZ-DMSO 
solution was added to water in volumetric flask (17°C and 37°C) and 
jacketed-beaker (37°C) are presented in Table 4.14 and the linear
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regression data are shown in Table 4.15. Fig. 4.21 shows a typical 
plot of concentration against absorbance for the solubility of "ABZ- 
DMSO solution" added to water. The plot axes are reversed from normal 
to allow solubility determination by linear regression analysis of 
the data; solubility *= intercept. The replicate intercepts for a 
given method at 17°C (volumetric flask; 4.3±0.5 pg/ml, X^ “ 8.09/ 
X^tab “ 1 1  *07) and at 37°C (volumetric flask: 7.5±0.4 pg/ml, - 
6.09; jacketed-beaker: 11.7± 0.4 |ig/ml, %  ^- 0.64, X^tab “ H*07) were 
not significantly different. However comparison using Student's t- 
test the solubilities in the flask and jacketed-beaker at 37°C were 
different at P ■ 0.05 (t ** 8.42, ttab ** 2.25).
(ii) When added to 0.1M HC1
When ABZ-DMSO solution was added to 0.1M HC1 at 37°C, particles were 
observed in the solution at ABZ concentration of 0.98 and 0.87 mg/ml 
in the jacketed-beaker (Method 4(b)) and flask (method 4 (a)), 
respectively. The mean results are shown in Table 4.16 and the 
regression analysis data in Table 4.17. Fig. 4.22 shows a typical 
plot of absorbance versus concentration for the solubility of ABZ in 
0.1M HC1 from DMSO solution. The replicate intercepts were different 
between a given method; jacketed-beaker: 0.3±0.05 mg/ml, “ 11*20 
and flask: 0.32±0.09 mg/ml, 24.48, X^tab “ 11.07 at P = 0.05. The 
enhanced solubility of ABZ in 0.1M HC1 from DMSO solution at 37°C 
however were not significantly different between the two techniques 
(jacketed-beaker and flask, t ** 0.99, ttat) - 2.25 at P « 0.05).
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Table 4.14 Absorbance (mean±SD) of ABZ solution in the solubility








in volumetric flask 
17°C 37°C
5.00 0 . 1 0 0.00710.004
7.49 0.15 0.01810.004 0.00410.002
9.98 0 . 2 0 0.03610.006 0.01510.004
12.47 0.25 0.05610.007 0.03310.004
14.96 0.30 0.07410.007 0.05610.005
17.44 0.35 0.08710.008 0.08810.006
19.92 0.40 0.10110.008 0.09710.007
in jacketed-beaker 37°C
12.77 0.26 0.00610.001






Table 4.15 Linear regression data for the plots of concentration-
absorbance for ABZ-DMSO solution added to water.
Replicate Slope SD Intercept
(mg/ml)
SD
Volumetric flask at 17°C 
1 142.2 3.8 3.4 0.3
2 165.0 6.3 4.7 0.5
3 153.3 6 . 6 4.0 0.4
4 157.6 6 . 6 4.3 0.4
5 157.5 8.3 4.5 0 . 6
6 134.0 5.8 4.9 0.4




144.8 6.5 7.3 0 . 2
2 131.8 4.6 7.0 0.3
3 143.3 7.0 7.2 0.5
4 135.8 8.7 8 . 1 0 . 6
5 135.9 5.4 7.3 0.3
6 138.2 6.7 8 . 0 0.4
Mean 138.3 6.7 7.5 0.4
Jacketed-beaker at 37°C
1 235.1 44.9 11.5 1.7
2 214.6 43.6 12.3 1 . 6
3 298.3 30.7 11.5 0.9
4 350.9 47.2 1 1 . 2 1 . 2
5 298.7 29.2 1 2 . 2 0 . 8
6 290.1 26.8 1 1.7 1 . 2
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o Volumetric flask, 17°C 
•  Volumetric flask, 37°C  
■ Jacketed-beaker, 37°C
0.09 0.12 0.150.03 0.060.00
Absorbance
Fig. 4.21 A typical plot of concentration against absorbance obtained 
from the solubility of " ABZ-DMSO solution" (5 mg/ml) when added to 
water at 17°C in flask, 37°C in flask and 37°C in jacketed-beaker.
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Table 4.16 Absorbance (Mean±SD) of ABZ solution in the solubility
study of ABZ-DMSO solution added to 0.1M HC1 at 37°C. (n = 6)
ABZ DMSO Absorbance ABZ DMSO Absorbance
concn concn jacketed- concn concn volumetric
(mg/ml) (%) beaker (mg/ml) (%) flask
0 . 6 6 2 . 2 0.003 0.59 2 . 0 0.004
±0 . 0 0 1 ±0 . 0 0 1
0.82 2 . 8 0.005 0.73 2.5 0.005
±0 . 0 0 1 ±0 . 0 0 1
0.98 3.4 0.007 0.87 3.0 0.007
±0 . 0 0 2 ±0 . 0 0 1
1.13 3.9 0.009 1 . 0 1 3.5 0.008
±0 . 0 0 2 ±0 . 0 0 2
1.29 4.5 0 . 0 1 0 1.15 4.0 0 . 0 1 0
±0 . 0 0 2 ±0 . 0 0 1
1.44 5.0 0 . 0 1 1 1.29 4.5 0 . 0 1 2
±0 . 0 0 2 ±0 . 0 0 1
1.59 5.6 0.013 1.43 5.0 0.014
±0 . 0 0 2 ±0 . 0 0 1
1.74 6 . 2 0.014 1.56 5.5 0.016
±0 . 0 0 2 ±0 . 0 0 2
1.89 6.7 0.016 1.70 6 . 0 0.017
±0 . 0 0 2 ±0 . 0 0 1
2.04 7.3 0.018 1.83 6.5 0.018
±0 . 0 0 2 ±0 . 0 0 2
2.18 7.8 0.019 1.96 7.0 0 . 0 2 0
±0.003 ±0 . 0 0 1
2.09 7.5 0 . 0 2 2
±0 . 0 0 1
2 . 2 2 8 . 0 0.023











O  ° - 5  "
•  Volumetric flask 
■ Jacketed-beaker
0.0
0.000 0.005 0.010 0.015 0.020 0 .025
Absorbance
Fig. 4.22 A typical plot of concentration against absorbance obtained 
from the solubility of " ABZ-DMSO solution" (30 mg/ml) when added to 
0.1M HC1 at 37°C in the flask and jacketed-beaker.
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(b) ABZ-Mig:Twn 80 Solution (Method 4(b))
On addition of ABZ Mig:Twn solution to 0.1M HC1 (37°C) the solution 
became turbid. The mean measured absorbances are presented in Table
4.18. Linear plots of concentration against absorbance were obtained 
and regression analysis data are presented in Table 4.19. The 
replicate intercepts were significant difference (%^  = 18.38, X^tab
= 11.07 at P “ 0.05) with a mean value of -0.02±0.05, i.e. passing 
through origin. Fig. 4.23 shows a typical concentration against 
absorbance plot for the solubility of ABZ in 0.1M HC1 from MigrTwn 
solution.
Similar behaviour was observed when blank Mig:Twn solution was added 
to 100 ml 0.1M HC1 at the same temperature. The mean absorbance are 
given in Table 4.18. For comparison with the blank, the volume of 
Mig:Twn solution added was plotted against the absorbance. The 
regression analysis data are shown in Table 4.20 and Fig. 4.24 shows 
a typical plot. The mean intercepts for both systems have negative 
values; with ABZ: -1.2±2.2 and with no ABZ (blank): -4.5±5.1 and they 
were significantly different (t - 4.39, tta^ ■ 2.25 at P =* 0.05). The 
negative intercepts suggest that the intercepts for these systems 
were masked by the presence of Mig:Twn and therefore the solubility 
of ABZ-Mig:Twn solution added to 0.1M HC1 was not established.
Microscopic examination of the emulsion formed by adding ABZ Mig:Twn 
solution to 0.1M HC1 showed that some ABZ crystals were found in the 
aqueous phase. The scale-drawing of the blank Mig:Twn solution in 
HC1, ABZ in an aqueous suspension and the emulsion are shown in Fig. 
4.25. Although photomicrographs were developed, these gave poor 
images and have therefore not been included.
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Table 4.17 Linear regression data for plots of absorbance-
concentration for ABZ-DMSO solution added to 0.1M HC1 at 37°C.
Replicate Slope SD Intercept SD
(mg/ml)
Volumetric flask
1 83.1 2 . 0 0.37 0.03
2 83.6 2.7 0.29 0.04
3 84.4 1.9 0.27 0.03
4 82.4 1.9 0.36 0.03
5 81.7 1.4 0.27 0 . 0 1
6 79.0 2.3 0.27 0.04
Mean 82.4 2 . 0 0.30 0.03
Jacketed-beaker
1 109.9 3.4 0.28 0.04
2 106.9 3.5 0.32 0.04
3 97.7 2 . 8 0.50 0.03
4 99.3 4.0 0.30 0.05
5 105.2 2.7 0.24 0.03
6 106.7 4.0 0.31 0.05
Mean 103.3 3.4 0.32 0.04
Table 4.18 Absorbance (meaniSD) of ABZ solution 
study of ABZ-Mig:Twn solution added to 0.1M HC1 at
in the solubility 









0.17 0.129±0.031 8.50 0.175±0.062
0.34 0.262±0.052 17.10 0.275±0.047
0.51 0.372±0.038 25.60 0.405±0.048
0.69 0.496±0.077 34.20 0.50810.049
0 . 8 6 0.627±0.049 42.70 0.62610.044
1.03 0.749±0.050 51.20 0.73910.040
1 . 2 0 0.870±0.071 59.80 0.85810.028




Table 4.19 Linear regression data for plots of absorbance-
concentration for ABZ-Mig:Twn solution added to 0.1M HC1 at 37°C.
Replicate Slope SD Intercept
(Hg/ml)
SD
1 1.39 0.04 0 . 0 2 0.03
2 1.43 0 . 0 2 0.07 0 . 0 2
3 1.53 0 . 0 2 -0.05 0 . 0 1
4 1.40 0.04 -0.06 0.03
5 1.41 0.04 -0.07 0.03
6 1.65 0.06 -0 . 0 1 0.04
Mean 1.47 0.04 -0 . 0 2 0.03
Table 4.20 Linear regression data for plots of absorbance-added
volume for ABZ-Mig:Twn solution added to 0.1M HC1 at 37°C.




1 64.3 1 . 0 3.0 2.5
2 70.3 1 . 8 -3.2 1 . 2
3 74.7 1 . 1 -1.9 0.7
4 65.7 1.4 -0.9 0.9
5 6 8 . 0 2.4 -2.7 1 . 6
6 77.6 3.4 -1.4 1 . 8




78.6 1 . 8 -6.3 1 . 1
2 70.0 2.3 0 . 6 1.4
3 76.6 1.4 -5.8 0.9
4 81.1 1.9 -1 2 . 2 1.3
5 74.5 1 . 1 -5.1 1 . 1
6 72.6 1.5 1.7 0.9




















0.0 TT T T
0.0 0.3 0.6 0.9
Absorbance
1.2 1.5
Fig. 4.23 A typical plot of concentration against absorbance obtained 
from the solubility of "ABZ-Mig: Twn solution" (2 mg/g) when added to 













o ABZ-Mig:Twn solution 
■ Blank Mig:Twn solution
0.80 1.000.600.400.00 0.20
Absorbance
Fig. 4.24 A typical plot of concentration against volume added 
obtained from the solubility of "Mig:Twn solution" with and without 







Fig. 4.25 Diagram from the scale-drawing of (a) ABZ in aqueous 
suspension, (b) blank Mig:Twn in 0.1M HC1 and (c) "ABZ-Mig: Twn 
solution" in 0.1M HC1 (the dark spots are ABZ).
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(c) ABZ-PEG 400 Solution (Method 4(c))
When 0.1M HC1 was added to ABZ-PEG solution, some particles were seen 
in the solution but then decreased as the volume 0.1M HC1 solution 
added was increased. The absorbances measured were all very low 
(<0.02) leading to high standard error for slopes. The mean 
absorbance are shown in Table 4.21 and a typical plot of 
concentration versus absorbance is presented in Fig.4.26. Table 4.22 
gives the linear regression data with mean intercept of 0.2±0.7 and 
there was no significant difference between the replicates (%^  
1.58, X^tab “ 9.49 at P * 0.05). However these intercepts passed 
through zero within ±2 SD, no definitive solubility value could be 
established.
Table 4.21 Absorbance (mean±SD) of ABZ solution in the solubility 















Table 4.22 Linear regression data for plots of absorbance-
concentration for ABZ-PEG 400 solution added to 0.1M HC1 at 37°C.
Replicate Slope SD Intercept
(mg/ml)
SD
1 229.1 151.7 -0.30 1.2
2 129.8 33.3 -0.33 0.50
3 88.1 76.0 0.68 0.82
4 116.0 25.1 0.47 0.26














Fig. 4.26 A typical plot of concentration against absorbance obtained 
from the solubility study of "ABZ-PEG 400 solution" (5 mg/g) when 
added to 0.1M HC1 at 37°C.
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4.3.3 Triangular-Phase Diagram for Miglyol, Tween 80 and PEG 400
Fig. 4.27 shows the miscibility phase diagram for the three potential 
vehicle components; Miglyol, PEG 400 and Tween 80. Miscible regions 
were found in the lower left end of the triangle and when 10% Tween 
80 was mixed with 90% PEG 400. The mixture of 60:40% of Miglyol:Tween 
80 was selected for ABZ formulation as it formed one-phase system 
with the highest volume of the oil.
M  iglyol
Fig. 4.27 Triangular phase diagram showing the boundaries of micsible 
region and the 2-layer system of Miglyol, Tween 80 and PEG 400 at 
room temperature. (• represents miscible region and o represents the
2 -layer system).
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4.3.4 Solubility of Gluconate Salt
ABZ gluconate salt was formed as sticky solid. It was soluble in PEG 
400 (up to 0.5 g/g) , slightly soluble in water (0.1 g/ml) and 
completely insoluble in Miglyol (Table 4.23). Since drug solubility 
was not improved, further work using this approach was discontinued.
Table 4.23 Results from the solubility study of ABZ gluconate solid 
product (0.5g) in water, PEG 400 and Miglyol.
Observation
Solvent After heating After overnight
added standing at room
temperature
Hater
1 ml clear drug precipitation
2 ml clear drug precipitation
3 ml clear clear
PEG 400
i g clear clear
2 g clear clear
3 g clear clear
5 g clear clear
Miglyol
5 g not soluble
1 0  g not soluble
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4.4 DISCUSSION
In the stability studies of ABZ suspensions in the glycine buffer 
with and without SDS at pH 9.00 and 10.00/ the overall reaction can 
be represented as:
(I) (II)
^suspension ^ Asolution ^ B(products)
Dissolution Degradation
At the start of the process, the solid drug in ASUSpens£on started to 
dissolve slowly in the solution with as the temperature increased to 
become ASolution* TAe degradation of ABZ occurred simultaneously with 
dissolution process as shown by the detection of the degradation
compounds (Figs. 4.6 and 4.10)
Three degradation products were detected by HPLC; ABZSO, Unknown 1 
and Unknown 2, suggesting that the degradation of ABZ may involve 
more than one pathway. Oxidation of ABZ must have taken place in 
order to produce ABZSO. ABZ also undergoes hydrolysis as evidenced 
by the formation of Unknown 2, confirmed to be the ABZ 2-amino 
compound which is consistent with the findings of the alkaline 
hydrolysis of other carbamate esters (Dittert and Higuchi, 1963).
At pH 9.00, ABZSO was found in both systems. It was found in higher
concentration in the system without SDS, although the initial ABZ 
concentration was 4-fold lower than in the presence of SDS. This 
observation is similar to the situation with Unknowns 1 and 2, where 
their rates of formation are faster in the absence of SDS than those 
in the system with SDS (Table 4.3). However, at pH 10.00 the rate of 
formation of Unknown 2 was higher in the system with SDS than in that
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without SDS. The rate of formation of Unknown 2 was faster at pH
10.00 than at pH 9.00 in both systems, as was the degradation of ABZ 
(Figs. 4.5 and 4.9). The absence of ABZSO in both systems at pH 10.00 
may thus be explained. Unknown 1 was not found in the system with no 
SDS at pH 10.00 probably due to rapid degradation of ABZ as well as 
owing to the low initial ABZ concentration in the suspension.
The possibility that SDS micelles solubilize ABZ and therefore 
protect it from degradation was considered. However, the critical 
micelle concentration (cmc) of SDS at the experimental conditions is 
much higher than the concentration of SDS used (0.011% solution). 
From the plot of cmc of SDS in water against temperature (Flockhart, 
1957), the cmc of SDS at 25°C is 0.23%. By extrapolating the curve, 
the cmc of SDS at 100°C is 0.39%; 1.7 times higher than the value at 
25°C. The cmc of SDS is also affected by the presence of 
electrolytes, the cmc of SDS at total cation concentration of 0.058M 
(at pH 9.00) was 0.06% at 26°C (Corrin and Harkins, 1947). Therefore, 
the cmc of SDS can be estimated as 0.10% at 100°C in glycine buffer 
at pH 9.00. The cmc of SDS at 100°C in glycine buffer at pH 10.00 
(total cation concentrations = 0.082M, 0.05% at 26°C) was estimated 
in the same manner and found to be 0.09%.
Since the rate of formation of the hydrolytic degradation compound 
(Unknown 2) was higher than the formation of ABZSO, it may be assumed 
that the hydrolysis of ABZ dominates the oxidative degradation and 
the overall reaction is more likely to follow first-order kinetics. 
Therefore this assumption was tested by plotting log concentration 
against time for ABZ in aqueous suspension with and without SDS at pH
9.00 and 10.00. These plots are shown in Figs. 4.28 and 4.29. For pH
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1 0 . 0 0  the fit is reasonable, although the data are limited, this is 
not the case for pH 9.00 where the points are scattered badly around 
the line of the best fit (Fig. 4.28). This indicates that at pH 
10.00, hydrolysis dominates the overall degradation pattern of ABZ 
whilst at pH 9.00 other reactions (e.g. oxidation) occurring 
simultaneously with hydrolysis are probably a greater contribution to 
the degradation rate. This was also evidenced from the t^/2 values of 
ABZ (Table 4.24). The t^/2s calculated from the log concentration­
time plot (Fig. 4.29) for the suspensions (with and without SDS) at 
pH 10.00 were the same as that measured from the simple 
concentration-time plot (Fig. 4.31) whereas for suspensions at pH
9.00 the calculated and measured t^/23 were very different (Figs. 
4.28 and 4.30).
The hydrolysis of ABZ at pH 10.00 was 2-times faster in the system 
with SDS compared to the system without SDS. The rates of degradation 
of ABZ at pH 9.00 in the presence and absence of SDS however were not 
significantly different (X^  “ 0.89, X^tab " 3.84 at P - 0.05). An 
increase from pH 9.00 to 10.00 would gave a theoretical increase in 
degradation rates of -10-fold if specific OH” catalysis is operating. 
However the rates of ABZ degradation at pH 10.00 were increased by 
7.5-fold for system with SDS and 5.6-fold for system with no SDS 
which suggests the degradation of ABZ involved other pathways.
The stability studies of ABZ in aqueous suspensions showed that the 
degradation of ABZ was fastest at pH 10.00 at 100°C and the process 
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Fig. 4.28 Plot of log concentration against time showing the 
degradation of ABZ after heating 0.1% ABZ suspension at 100°C with 
and without SDS at pH 9.00. (The line of best fit is shown).
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Fig. 4.29 Plot of log concentration against time showing the 
degradation of ABZ after heating 0.1% ABZ suspension at 100°C with 
and without SDS at pH 10.00. (The best fit line is shown).
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Fig. 4.30 Plot of concentration against time showing the degradation 
of ABZ after heating 0.1% ABZ suspension at 100°C with and without 
SDS at pH 9.00
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Fig. 4.31 Plot of concentration against time showing the degradation 
of ABZ after heating 0.1% ABZ suspension at 100°C with and without 
SDS at pH 10.00
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Table 4.24 The rates of reaction (k) and half-lifes (ti/2 ) of 











With SDS 0.016 43 24
Without SDS 0 . 0 1 2 58 17
At pH 10.00
With SDS 0 . 1 2 0 6 6
Without SDS
:... . ....
0.067 1 0 1 0
y """ 1 1   ■— ■ ■  ^  ,.■■■ .
the t^/2 3 w©r© measured from the plots of concentration against 
time of ABZ suspension heated at 100°C with and without SDS at pH 
9.00 and 10.00 shown in Figs. 4.29 and 4.30.
Only one unidentified peak (Unknown 3) was found when ABZSO aqueous 
suspension with SDS at pH 10.00 was heated at 100°C. The rate of 
formation of the Unknown 3 was much faster than any of the other 
degradation compounds found in ABZ suspension under the same 
conditions. There was no evidence of any ABZSO2 formed. There are 2 
possible explanations; either oxidation of ABZSO did not take place 
or ABZSO2 was formed by oxidation of ABZSO but was being degraded as 
it was formed and therefore would not be seen. If ABZSO behaves 
similarly to ABZ, then ABZSO will undergo hydrolysis in alkaline 






This characterization is supported by HPLC analysis. The peak of 
Unknown 3 having earlier retention time than ABZSO indicating that 
Unknown 3 is more polar than ABZSO.
Assuming that a hydrolytic reaction dominates in the degradation of 
ABZSO, the degradation data were fitted to first-order kinetic 
relationship (Fig. 4.32). From the curve, the calculated rate of 
reaction and t^ / 2  w©re 0.8510.11 hr” 1 and 0.82 hr, respectively. The 
measured t^ / 2  from the plot of ABZSO concentration against time (Fig. 
4.33) was 0.9hr. The difference between the measured and the 
calculated tl/ 2  was 0 . 1  hr suggest that the data reasonably fit the 
first-order kinetics and therefore the overall degradation of ABZSO 
was also dominated by hydrolytic reaction at pH 10.00. The rate of 
reaction was rapid which explains the absence of ABZSO in the ABZ 
suspensions under the same conditions.
ABZSO, ABZSO2 , ABZ 2-amine compound (Unknown 2) and the other 4 
unidentified peaks were found after samples of ABZ in DMSO were kept 
in the freezer (control samples) and when the samples were heated at 
22°C, 37°C and 55°C for 48 hours. A possible explanation for ABZ
degradation observed in the control samples may be due to DMSO 
reaction with ABZ while the samples were being thawed before the HPLC 
analysis. However degradation of samples at 55°C may be due to 
thermal effects as the ABZ 2-amine compound formed in these samples 
was higher compared to the control samples and samples at 22°C and 
37°C. ABZ was also found to be degrading in DMSO during the 
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Fig. 4.32 Plot of log concentration against time showing the 
degradation of ABZSO after heating 0.1% ABZSO suspension at 100°C 
with SDS at pH 10.00. (The best fit line is shown).
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Fig. 4.33 Plot of concentration against time showing the degradation 
of ABZSO after heating 0.1% ABZSO suspension at 100°C with SDS at pH 
10.00.
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The mechanisms of reactions of DMSO are not certain. DMSO is known to 
serve as an oxidising agent in several organic and inorganic
reactions (Ranky and Nelson, 1961). Therefore DMSO could oxidise ABZ 
to ABZSO as shown in Fig. 4.34. As DMSO does not oxidise sulphoxide 
to sulphone, the formation of ABZSO2 may be due to oxidation of ABZSO 
with molecular oxygen. DMSO is very hygroscopic (absorbing over 70% 
of its own weight of water at 20°C and 65% relative humidity (Ranky 
and Nelson, 1961)) and ABZ may therefore react with water in the DMSO 
sample to form other products including ABZ 2-amino compounds. Once 
ABZSO and ABZSO2 are formed, they may also form corresponding 2-amine 
compounds in the same manner as ABZ.
ABZ when heated in 0.1M HC1 solution at 22°C, 37°C and 55°C for 48
hours was relatively stable. However during the solubility study in
0.01M and 0.1M HC1, ABZ was found to be degrading (7-8% ABZSO was
found by 48-96 hours). There were several differences in these
studies; (1) the HC1 solutions in the solubility studies were
prepared with constant ionic strength (0.154M). The degradation rate
was faster in HC1 solution with ionic strength of 0.154M because the 
rate of reaction increases as ionic strength increases (Florence and 
Attwood, 1988). (2) ABZ concentration in the stability studies was
10 p.g/ml whereas ABZ was at the saturation concentration in the 
solubility studies (>22 ng/ml). Since rate of oxidation is often 
dependent on the concentration of the oxidising molecule, oxidation 
could well proceed faster in the HC1 solutions in the solubility 
studies. (3) As the initial concentration of ABZ was much lower (in 
the thermal stress study), the products formed would also be in low 
concentration and therefore may not be detected during HPLC analysis 




















Fig 4.34 The possible mechanism for ABZ oxidation to ABZSO by DMSO.
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It is apparent that the solubilities of ABZ in DMSO, 95%EtOH and 
Miglyol increase with temperature. ABZ appears to have higher 
solubility in DMSO than 95%EtOH and Miglyol. This can be explained on 
the basis of the higher dielectric constant of DMSO (Table 4.0) and 
DMSO also has a high hydrogen bonding capacity compared to EtOH 
(Craver, 1970). As expected from its high partition coefficient 
(poctanol/water “ section 1.5.1), solubility of ABZ in Miglyol is 
higher than in water. However, the solubility of ABZ in 95%EtOH and 
Miglyol was still <1 mg/ml.
A mixture of Mig:Twn 80, 60:40%, w/w was selected from the triangular 
phase diagram study of Miglyol, Tween 80 and PEG 400 (section 4.3.3, 
Fig. 4.27) for solubility study. The solubility of ABZ in this 
mixture was higher when ABZ was ground with the mixture followed by 
heating at high temperature (Method 2) giving a final concentration 
of 2 mg/g whereas only 0.5 mg/g was obtained when ABZ was shaken in 
the mixture at 25°C and 37°C and left at room temperature for 2 weeks 
(Method 3) . This is because the dissolution of ABZ in Mig:Twn 80 was 
very slow. However the solubility of ABZ was higher in the mixture 
than in Miglyol alone, presumably due to the micellisation/liquid 
crystal formation.
The solubility of ABZ in water was not determined using Method 1 as 
concentration of ABZ was found to decrease with time at the two 
temperatures studied. ABZ could probably be undergoing degradation 
and/or some other processes were occurring simultaneously. No other 
peaks were detected by HPLC except for ABZSO which was present in a 
small amount (4% of ABZ) and it appears that the loss of ABZ was much 
faster than the formation of the sulphoxide. It was considered that
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it could be due to the possibility of polymorphic changes of ABZ 
which would result in different solubilities in water. However the 
DSC thermogram (Fig. 4.35) indicates this was unlikely.
The solubility of ABZ in water was determined by titrating ABZ 
solution prepared in DMSO into water. However the solubility values 
found at 37°C were different (P<0.05) using different techniques. 
This could be due to several reasons including the different in 
method of introducing ABZ-DMSO solution, method of mixing and the 
type of vessel used.
The solubility of ABZ in 0.1M and 0.01M HC1 was not established using 
Method 1 due to increasing ABZ concentration and degradation of ABZ. 
More ABZ dissolved in the HC1 solution due to the low pH and the 
formation of the protonated drug form. However the solubility of ABZ 
in 0.1M HC1 at 37°C was determined using Methods 4(a) and (b) by 
titrating ABZ solution prepared in DMSO into 0.1M HC1 solution. The 
solubility values found using the two different techniques were not 
statistically different (P<0.05); 0.30±0.05 mg/ml when carried out 
in volumetric flask and 0.32±0.09 mg/ml in the jacketed-beaker. These 
values were obtained after addition of 1.0-1.1% DMSO solution to 100 
ml of 0.1M HC1, thus the co-solvent influence of DMSO was negligible.
When "ABZ-Mig:Twn 80 solution" was added to 0.1M HC1 solution, the 
system became turbid almost immediately. The solubility of ABZ in 
0.1M HC1 from Mig:Twn solution was not established because the 
intercepts of the plot of concentration against absorbance passed 
through zero within ±2 SD. Therefore no definitive value could be 



















Fig. 4.35 DSC analysis of ABZ.
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solution was added to 0.1M HC1. The turbidity of the solution 
probably was caused by Miglyol self-emulsification.
Solubility determination of PEG 400 in 0.1M HC1 was carried out in 
the reverse method from the ABZ-DMSO and ABZ-Mig:Twn solution (i.e. 
0.1M HC1 solution was added to ABZ-PEG 400 solution). The solubility 
of ABZ in 0.1M HC1 when added to PEG 400 solution (at 37°C) was not 
established due to low absorbance values and due to the intercepts of 
the plots of concentration against absorbance being not definitive 
(passing through zero within ±2 SD) .
When 0.1M HC1 was added to the ABZ-PEG solution, the HC1 effect is 
to increase the solubility of ABZ. However addition of the "water" to 
the PEG solution would decrease the solubility of ABZ. At 50:50 PEG 
solution and 0.1M HC1, the overall concentration is supposed to be 
"0.05M HC1" but H+ concentration in the solution would not be 0.05M 
as 50% PEG solution interferes with HC1 ionisation. The general 
effect therefore was likely to decrease ABZ solubility as PEG 
solution is mixed with 0.1M HC1.
The solubility of "ABZ solutions" in 0.1M HC1 at 37°C was determined 
to simulate the condition present in the stomach when these solutions 
are introduced. Volumes of 0.18-0.19 ml (1.8-1.9 mg ABZ, dose of 5 mg 
ABZ/kg) and 0.35-0.39 ml (3.5-3.9 mg ABZ, dose of 10 mg ABZ/kg) ABZ- 
DMSO solutions were given to rats. Considering the fasting volume of 
aqueous fluid in rat gastric lumen is 0.15±0.01 ml (Yamahira et al., 
1979), ABZ concentration in the rat stomach was 5.45-5.59 mg/min and 
7.00-7.22 mg/ml. As these values are higher than the solubility value 
of ABZ in 0.1M HC1 obtained from DMSO solution (concentration of 30
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mg/ml) at 37°C, it is expected that ABZ would precipitate in the rat 
stomach. However when 50:50 ABZ-DMSO solution (10 mg/ml -
concentration used to dose the rat) and 0.1M HC1 were mixed in a 
test-tube, no precipitation occurred. Therefore it is likely that ABZ 
remains in solution in the rat stomach.
At a given dose of 6 mg ABZ/kg, 0.20-0.35 ml of ABZ-PEG 400 solution
(1.0-1.7 mg ABZ) was introduced to rat stomach. Although the
solubility of ABZ from PEG 400 in 0.1M HC1 was not fully determined, 
it is likely that 0.59-0.92 mg/ml ABZ in solution in the stomach.
The results from the microscopic examination of ABZ-Mig:Twn in 0.1M 
HC1 shows that solid ABZ was present in the aqueous phase, indicating 
that ABZ is at the saturation in both the oil droplets and aqueous 
phase. Therefore, there is a dual reservoir for albendazole present 
in the stomach environment.
In conclusion, ABZ undergoes oxidative and hydrolytic degradation in 
vitro when exposed to high temperature. The rate of ABZ degradation 
was faster at pH 10.00 than at pH 9.00 under the same conditions. ABZ 
was found to degrade in DMSO solution and it is believed that DMSO 
reacted with ABZ. ABZ was relatively stable in 0.1M HC1, 95%EtOH and 
Miglyol.
The solubility of ABZ was higher in DMSO compared to the other
solvents studied. Although the solubility of ABZ in Mig:Twn was
higher than in Miglyol alone, the solubility of ABZ is <10 mg/ml and
thereby indicates the need for a suspension preparation. The
solubilities of ABZ in water and 0.1M HC1 (at 37°C) were determined
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from DMSO solution whereas solubilities of ABZ in 0.1M HC1 from 
Mig:Twn and PEG 400 solutions were not established.
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CHAPTER 5 




ABZ, although poorly soluble, has the advantage of.greater absorption 
following oral administration over the other benzimidazole carbamates 
(Morris et al., 1983). In vitro studies in perfused rat stomachs 
demonstrated that plasma concentrations of ABZ found were 40% higher 
than those for MBZ (Prieto et al., 1991). Bioavailability of ABZ was 
shown to be inproved when co-administered with a fatty meal (Lange 
et al., 1988) or administered as a suspension in oil/milk (Marriner 
et al., 1986). An increase in plasma concentrations of MBZ has also 
been observed when MBZ was administered with a fatty meal (Munst et 
al., 1980), in olive oil (Dawson and Watson, 1985) or as a suspension 
in sunflower-seed oil (Lurie and Scherbakov, 1987; Lurie et al, 
1988). Recently, a similar finding was reported when oxfendazole was 
administered to sheep as an oil-based formulation (Ali and Chick, 
1992).
These studies demonstrate that co-administration with lipid enhances 
the bioavailability of benzimidazole carbamates which may be 
beneficial in the treatment of a systemic infection such as 
filariasis. In this chapter, the effect of an "oily" formulation on 
the systemic bioavailability of ABZ is investigated. Plasma 
concentrations after a single dose in a healthy volunteer and 




ABZ and ABZSO used for the following preparations were micronised 
standards. ABZ and ABZSO solutions were prepared in DMSO (10 mg/ml) 
for the rat studies. No impurities were detected in these solutions 
when analysed by HPLC (3.2.1.1. (a)). The chromatograms are shown in 
Appendix 2 (Fig. 2A.1).
ABZ in Miglyol: Tween 80 (MigrTwn), 60:40% w/w was prepared by 
grinding up ABZ, using a pestle and mortar, and adding Mig:Twn 
(60:40%, w/w) solution in small amounts whilst mixing. The mixture 
was transferred to a conical flask, heated (~70°C) until the solution 
turned clear and cooled. The final concentration of ABZ was 2 mg/g. 
ABZ in PEG 400 was prepared in a similar manner to give a final 
concentration of 5 mg/g which was used as a "control" formulation.
ABZ tablet (Zentel, SmithKline & French, France) was formulated in 
Mig:Twn and PEG 400 using the above procedure to give final 
concentrations of 2 mg/g and 5 mg/g, respectively.
5.2.2 Animals
The experimental animals used were male Wistar albino rats (Bath 
University strain) weighing between 313 and 385 g, and female Wistar 
rats weighing between 168 to 270 g, housed in ventilated rooms at a 
temperature of 24°C. They were maintained on commercial diet pellets 
and tap water, ad libitum.
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Female Wistar albino rats from the School of Pharmacy, USM breeding 
colony, weighing between 168-250g were employed. They were housed in 
a ventilated rooms at ambient temperature and maintained on a 
commercial diet pellet and tap water, ad libitum.
8 healthy Macaca Fascicularis monkeys (2 males and 6 females) 
weighing between 2.5 and 6.4 kg from a breeding colony at the 
Institute of Medical Research, Kuala Lumpur, Malaysia were used. They 
were housed in individual cages and maintained on vegetables, fruits 
and tap water, ad libitum.
5.2.3 Human Volunteer and Patients
A single male human volunteer (age 26 years and body weight, 65 kg) 
clinically healthy and not receiving any other drugs was recruited.
The "albendazole treatment for human loiasis" study (study number: 
90-1-101) was conducted by the National Institute of Health of the 
United of States of America and the Centre National Universitaire at 
Hospitaller du Benin, Africa. The study was carried out in Benin with 
Dr. Thomas Nutman as the principal investigator. Loa loa patients: 
apparently healthy men and non-pregnant women (18-70 years) with 
levels of microfilariae in the blood 1 0 0 -1 0 , 0 0 0  microfilariae/ml as 
determined by blood filtration who gave their informed consents were 
enrolled for ABZ treatment.
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5.2.4 Administration of Drugs to Animals and Humans 
(a) Animal Studies
ABZ or ABZSO were given orally in various doses and formulations 
using an oral dosing cannula for rats and a stomach tube for monkeys. 
ABZ and ABZSO administered to rats in the initial studies were 
prepared in DMSO or as otherwise stated. The animals were starved 
overnight prior to dosing.
In the initial studies, 10 male rats (352-385 g) were randomly 
divided into 2 groups. One group was treated with 5 mg/kg body weight 
of ABZ and the other group received 10 mg/kg ABZ in DMSO. The study 
was repeated with 2 other groups of 10 male rats (364-385 g and 350- 
385 g) on separate days. An inter-rat variability study was carried 
out by dosing 8 male rats (265-280 g) with 10 mg/kg ABZ in DMSO. A 
dose of 10 mg/kg of ABZSO was also given to a group of 10 male rats 
(313-335 g).
ABZ standard in Mig:Twn and tablet in PEG 400 were given to 20 female 
rats (168-250g) which were divided into 2 groups. The dose of ABZ in 
both instances was 5 mg/kg. This study was carried out at USM.
72 female rats (185-270 g) were treated with ABZ standard prepared 
either in Mig:Twn or PEG 400, both at 6 mg/kg. Additionally, 0.6 
mg/kg ABZ in Mig:Twn and PEG 400 were given to 32 female rats (190- 
2 2 0  g).
A four "solutions" study was carried out in 6 monkeys. 3 monkeys (Grp 
1) received ABZ tablet in PEG 400 (Prep.A) and the other 3 monkeys 
(Grp 2) received ABZ standard in Mig:Twn (Prep.B) on the first arm of
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the study. After an interval of 2 weeks, the second leg was carried 
out where the Grp 1 monkeys received ABZ tablet in Mig:Twn (Prep.C) 
and the Grp 2 received ABZ standard in PEG 400 (Prep.D) . 2 monkeys 
(one from each group) died before the second part of the study 
commenced and they were replaced (for the final dose only) . The 
details of the monkeys are shown in Table 5.1.











First part of the study
513 3.7 F 8 . 0 38.7 A
533 5.5 M 8 . 0 38.6 A
535 2.5 F 6 . 0 38.2 A
434 4.5 F 8 . 0 37.5 B
486 5.1 M 9.0 38.3 B
435 3.1 F 6 . 0 38.1 B
Second part of the study
252 6.4 F 8 . 0 38.4 C
533 5.5 M 7.0 38.3 C
535 2.5 F
oCO 38.2 C
434 4.5 F 7.0 37.8 D
486 5.1 M 8 . 0 38.8 D
316 5.5 F 4.0 37.2 D
F = female, M = male 
A = ABZ tablet in PEG 400 
B * ABZ standard in MigiTwn 
C = ABZ tablet in MigiTwn 
D ** ABZ standard in PEG 400
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(b) Human Studies
The single volunteer received 400 mg (approximately 6.2 mg/kg) ABZ 
tablet after fasting overnight. A dwelling cannula was inserted into 
a forearm vein until 1 2  hours after drug administration for blood 
sampling. Food and drink were allowed as normal 2 hours after dosing.
The loa loa patients were given orally 200 mg ABZ or placebo twice a 
day for 21 days in a double-blind study. Both ABZ and placebo were 
packaged identically by SmithKline Beecham (SB,USA).
5.2.5 Blood Sampling
(a) Animal Studies
Rats were anaesthetized using diethyl ether or carbon dioxide, and 
blood samples (1-5 ml) were drawn by cardiac puncture. Samples were 
collected at 0.5, 1.0 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0 and 7.0 hours 
after drug administration. Rats were bled at most 2 times. In the 
study where rats were given ABZ in Mig:Twn and PEG 400, samples were 
collected for up to 24 hours. In the variability study, samples were 
collected at 2, 4 and 6 hours after dosing. Blood was placed into 
plain eppendorf or heparinised glass tubes, and centrifuged at 1 0 , 0 0 0  
g or 2500 g for 10 minutes to obtain serum or plasma, respectively. 
The separated serum or plasma were stored in plastic vials at -20°C 
until required for analysis.
Monkeys were anaesthetized using Ketalar (ketamine hydrochloride) 
prior to blood collection. Blood samples (3 ml) were drawn predose 
and at 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, 24.0 and 48.0 hours after 
dosing by venepuncture of the femoral vein. Blood was drawn into 
heparinised vacutainers, thoroughly mixed with the anticoagulant, and
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centrifuged at 2500 g for 10 minutes. The plasma was separated and 
stored at -50°C until time of analysis.
(b) Human Studies
Serial blood samples (5 ml) were collected in the vacutainer prior to 
dosing and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 
12.0, 24.0, 32.0 and 48.0 hours after drug administration for the 
single subject study. The plasma samples were maintained at -50oc 
until analysis.
Blood samples from loa loa patients were drawn 4-6 hours after the 
patients received their dose (generally around 7.00 a.m.). Serum
samples were collected for drug measurement on days 0, 1, 3, 6 , 9, 14 
and 20 post-treatment. Samples were transferred to USM packed in 
solid carbon dioxide and examination on arrival showed the samples 
were still frozen.
5.2.6 Intestinal and Stomach Preparations
Highly variable ABZ, ABZSO and ABZSO2 concentrations were observed in 
the initial studies in rats. In vitro experiments were carried out to 
investigate whether this variability was caused by the metabolism of 
ABZ by the GI tract, degradation of ABZ by the gastric pH, damage of 
GI tract membrane by DMSO, or indeed was the results of variable 
absorption.
ABZ in DMSO was administered orally to 3 rats at a dose of 10 mg/kg. 
2 or 4 hours after dosing blood was collected by cardiac puncture, 
the rat killed and the stomach and intestine removed. Stomachs and 
intestines were flushed with 50 ml of distilled water using a syringe
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which was then filtered under gravity. The clear filtrate was 
collected and 1 ml was used for HPLC analysis.
A rat (400 g) was anaesthetized with hypnorm/medazolam and the 
abdomen was opened. The stomach was identified and both ends of the 
stomach were occluded to form a "bag" like which 0.4 ml of 10 mg/ml 
ABZ in DMSO was introduced via a cannula. The stomach was then 
placed into a small beaker of saline and placed in a water-bath at 
37°C. After 6 hours incubation, the stomach was removed from the 
water-bath. The following washings were collected:
(1) The fluid in the stomach was flushed out with 30 ml distilled 
water using a syringe.
(2) The stomach was then cut open and the contents were transferred 
into a beaker and washed with 2 0  ml distilled water.
(3) The mucosal layer of the stomach was scraped off and washed with 
2 0  ml distilled water.
All the washings from (1), (2) and (3) were filtered separately and 1 
ml of the clear filtrate was assayed by HPLC.
Stomachs and intestines were removed from untreated rats. The mucosal 
layers were scraped off and put into saline ( 2 0 ml) in test-tubes 
which were placed in a water-bath at 37°C. 0.4 ml of 10 mg/ml ABZ in 
DMSO was introduced to the solutions and mixed thoroughly. Saline 
solution without mucosa was set-up as a control. Samples (1 ml) were 
taken at 1, 2, 4, 5, and 6 hours after addition of ABZ. Each sample 
drawn from the test-tubes was replaced with saline solution ( 1 ml).
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5.2.7 Analysis of Samples
Serum and plasma samples (0.2-1.0 ml) and the washings from stomach 
and intestinal preparations were extracted using the SPE procedure 
described in section 3.2.1.3. The samples from rat studies were 
assayed by the HPLC method described in section 3.2.1.1(a) and 
samples from the rat study carried out at USM, monkey studies and 
human studies were analysed by the HPLC method described in section 
3.2.1.1(b). Spiked serum, plasma and saline solutions were extracted 
and assayed together with the samples as quality control.
ABZSO and ABZSO2 concentrations were also presented as ABZ 
equivalents in the intestinal and stomach preparation studies.
5.2.8 Pharmacokinetic Analysis
The time to reach the maximum concentration (Tmav) and the value for 
maximum concentrations (Cmax) of ABZ, ABZSO and ABZSO2 were 
determined by inspection. The area under the concentration-time curve 
(AUC) was calculated using the trapezoidal method (Gibaldi and 
Perrier, 1982).
5.2.9 Statistical Analysis
Statistical comparison was carried out using the Student’s t-test. 
t values of P>0.05 were rejected.
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5.3 RESULTS
5.3.1 Results from Preliminary Studies in Rats
Single oral dose studies of 5 and 10 mg/kg ABZ in rats were carried 
out on three separate days collecting one sample at each time point 
per day. Fig. 5.1 shows the mean concentration-time profiles of ABZ, 
ABZSO and ABZSO2 following both dosage. The individuals
concentrations are tabulated in Appendix 3 (Tables 3A.1-3A.2). ABZ 
appeared to have two distinct phases (Fig. 5.1(a)) with the first 
peak at around 2.0hr and second at 5.0hr for both dosages. The mean 
maximum concentration of 479±157 ng/ml was achieved when 5 mg/kg ABZ 
was administered and 664±291 ng/ml following a dose of 10 mg/kg at 
2.0hr after dosing. ABZSO (Fig.5.1(b)) behaved similarly to ABZ with 
mean maximum concentrations at 2.5hr (2046±392 ng/ml) and 2.0hr
(3978±132 ng/ml) after administration of 5 mg/kg and 10 mg/kg ABZ, 
respectively. The mean maximum concentration for ABZSO2 was achieved 
at 7.0hr (408±187 ng/ml) and 5.0hr (613±91 ng/ml) following 5 and 10 
mg/kg ABZ, respectively.
The pharmacokinetic parameters of ABZ, ABZSO and ABZSO2 were
calculated individually for each set of results obtained from the 
three days and the parameters are summarised in Table 5.2. The ratio 
of the AUC (5/10 mg/kg) for ABZSO (0.47) and ABZSO2 (0.68) were 
comparable with the dose ratio (0.5) . In contrast, the AUC for ABZ 
were similar for both dosage (ratio of 0.89). The ratios of AUC
ABZSO/ABZ were 4.68 and 8.75, ABZSO2 /ABZ were 0.72 and 0.93 and 
ABZSO2 /ABZSO were 0.15 and 0.11 for 5 and 10 mg/kg, respectively 
indicating dose-proportionality for the ABZSO only.
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Fig. 5.1 The concentration-time profiles of (a) ABZ, (b) AZBSO and
(c) ABZS02 following a single oral dose of 5 mg/Jcg and 10 mg/kg ABZ 
in DMSO in rats, (n = 3)
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Table 5.2 Summary of the pharmacokinetic parameters (meanlSD) after a








ABZ 2 .7±1.2 614± 82 2052± 136
ABZSO 2 .0 ± 0 .5 2364±699 9609±2759
abzso2 6 .3±0.6 463±154 1484± 357
1 0  mg/kg
ABZ 1. 7±0. 6 731± 343 2313± 780
ABZSO 4.3±2.1 3886±5003 2030313011
abzso2 5.0 ± 0 .0 613± 91 21611 275
Concentrations of ABZ, ABZSO and ABZSO2 were found to be highly 
variable. A variability study in rats at three time points after 
receiving 10 mg/kg ABZ orally showed that ABZ concentration ranged 
from 152 to 955 ng/ml at 2.0hr, 259 to 1327 ng/ml at 4.0hr and 126 to 
506 ng/ml at 6.0hr. ABZSO concentrations were 1649-4038 ng/ml at 
2.0hr, 2220-4969 ng/ml at 4.0hr and 2085-5169 ng/ml at 6.0hr.
Concentrations of ABZSO2 found at 2.0hr were 144-281 ng/ml, 320-650 
ng/ml at 4.0hr and 344-795 ng/ml at 6.0hr. The AUC^Q_gjlrj for ABZ 
varies from 1115 to 3877 ng/ml.hr, 9809-19413 ng/ml.hr for ABZSO and 
1063-2649 ng/ml.hr for ABZSO2 . The mean, standard deviation (SD) and 
relative standard deviation (RSD) of ABZ, ABZSO and ABZSO2 are shown 
in Table 5.3. These results indicate a significant inter-rat 
variation in absorption rates or in bioavailability.
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Table 5.3 The variation of ABZ, ABZSO and ABZSO2 concentrations 
following 10 mg/kg ABZ in DMSO in rats.
Sampling Serum concentration (ng/ml) AUC{0_6hr)
time (hr) mean SD RSD(%) meanD SD RSD(%)
ABZ
2 . 0 a 545 336 62
4. 0 a 664 494 82 2138 1429 67
6 .0 b 344 114 33
ABZSO
2 . 0 a 2476 1306 53
4. 0 a 3830 1259 33 14792 3726 25
6 .0 b 1214 1214 34
abzso2
2 . 0 a 2 1 1 59 28
4. 0 a 450 142 32 1710 516 30
6 .0 b 574 162 28
a : n ■ 4 
b : n « 7
Fig. 5.2 shows the concentration-time profiles of ABZ, ABZSO and 
ABZS02 in serum of rats treated with 10 mg/kg ABZSO. Each point 
represents a mean of two samples obtained from two different rats. 
The individual concentrations are given in Table 3A.3 (Appendix 3). 
The trend of the profiles for ABZ, ABZSO and ABZS02 in rats receiving 
10 mg/kg ABZSO were found to be similar to those in rats that 
received 5 or 10 mg/kg ABZ, with ABZ and ABZSO having 2 peaks. The 
pharmacokinetic parameters were obtained from the mean concentration­
time curves (Fig.5.2) and are summarised in Table 5.4. The ratio of 
AUC ABZ/ABZSO was 0.08 and for ABZS02 /ABZS0 0.14.
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Fig. 5.2 The mean concentration-time profiles of ABZ, ABZSO and 
ABZS02 following a single oral dose of 10 mg/kg ABZSO in DMSO in 
rats.
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Table 5.4 Summary of the phacmacokinetic parameter after a single







ABZ 1.5 853 2487
ABZSO 2.5 7252 32344
abzso2 6 . 0 941 4478
5.3.2 The Influence of a MigiTwn Formulation on the Systemic 
Availability of Albendazole
The mean concentration-time profiles of ABZ, ABZSO and ABZSO2 in rats 
which received 5 mg/kg standard in Mig:Twn or tablet in PEG 400 are 
shown in Fig. 5.3. Each point represents a mean of two samples and 
the individual concentrations are given in Appendix 3 (Tables 3A.4- 
3A.5). Peak concentration of ABZ when standard ABZ was given was 
attained within l.Ohr after dosing. When ABZ tablet formulation was 
given, ABZ was absorbed to a lesser extent(~48%) with an initial peak 
at l.Ohr although the maximum concentration was reached within 5.0hr 
after drug administration. The ratio of AUC^g-6 hr) (standard/tablet) 
of ABZ was 0.68.
The concentrations of ABZSO were extremely variable for both 
formulations. Maximum concentrations of ABZSO were achieved at 2.0hr 
for standard formulation and 4.0hr for tablet formulation with the 
latter having a 9% higher concentration. ABZSO was still measured at 
24.0hr whereas ABZ was undetectable after 6.0hr when ABZ was given in 
standard form. The ratio of AUC(0 -i2hr) (standard/tablet) of ABZSO 
was 0.95.
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Fig. 5.3 The mean concent rat ion-time profiles of (a) ABZ, (b) ABZSO 
and (c) ABZSO2 following a single oral dose of 5 mg/kg ABZ standard 
in Mig:Twn and tablet in PEG 400 in rats.
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ABZSO2 showed a similar pattern with peak concentrations at 1 2 .0 hr 
for both formulations. The peak concentration was higher when ABZ 
given as tablet and the ratio of AUC^Q-i2 hr) (standard/tablet) of 
ABZSO2 was 0.73. The T ^ ^  Cp,ay and AUC for ABZ, ABZSO and ABZSO2  are 
given in Table 5.5.
ABZ standard in Mig:Twn or PEG 400 was administered to rats at a dose 
of 6 mg/kg. The mean plasma concentration-time profiles of ABZ, ABZSO 
and ABZSO2 are shown in Fig.5.4 . Each point represents the mean of 
three samples and the individual concentrations are tabulated in 
Appendix 3 (Tables 3A.6-3A.7). The pharmacokinetic parameters were 
obtained from the mean concentration-time curves (Fig.5.4). The time 
to reach the peak concentration of ABZ for both formulations was 
2.0hr, although ABZ achieved a concentration approximately 1.4 times 
higher after the PEG formulation than the oily formulation. The 
AUC's of ABZ were comparable for both formulations as shown in Table 
5.6.
The time to maximum plasma concentration for ABZSO were 4. Ohr and 
5.0hr in rats receiving ABZ in Mig:Twn or PEG 400, respectively. The 
maximum concentrations were similar (Table 5.6) and the AUC ratio for 
Mig:Twn/PEG 400 ratio was 0.82.
The maximum concentrations of ABZSO2 were approximately 20% of those 
of ABZSO for both formulations. The Tmax's were 7.5hr and 6 . Ohr when 
ABZ was given in Mig:Twn and PEG 400, respectively. The ratio of 
AUC's (Mig:Twn/PEG 400) for ABZSO2 was 0.91.
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Table 5.5 Summary of the pharmacokinetic parameters after a single








Standard in Mig: Twn
ABZ 1.0 1521 2510
ABZSO 2.0 2156 14762
ABZS02 12.0 612 8538
Tablet in PEG 400
ABZ 5.0 1080 4477
ABZSO 4.0 2366 11721
ABZS02  12.0 912 5654
Table 5 . 6  Summary of the pharmacokinetic parameters after a single 








ABZ 2 . 0 544 2446
ABZSO 4.0 2467 13905
abzso2 7.5 485 3297
PEG 400
ABZ 2 . 0 794 3362
ABZSO 5.0 2363 16956
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Fig. 5.4 The mean concentration-time profiles of (a) ABZ, (b) ABZSO 
and (c) ABZS02 following a single oral dose of € mg/kg ABZ standard 
in Mig:Twn and PEG 400 in rats.
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Fig.5.5 shows the mean concentration-time curves of ABZ, ABZSO and 
ABZS02 following a single oral dose of 0.6 mg/kg ABZ standard and 
tablet in Mig:Twn. Each point represents the mean of two samples. The 
individual concentrations are given in Tables 3A.8-3A.9 (Appendix 3). 
When ABZ standard was administered, absorption of ABZ was rapid with 
the maximum concentration being attained at l.Ohr after dosing. On 
the other hand when powdered ABZ tablet was administered, absorption 
was slower (Tmax * 3.Ohr) but the maximum concentration achieved was 
higher. The ratio of the AUC was 1.11 (Table 5.7).
The Tm=lv for ABZSO was 2.Ohr for both formulations, although them d A
mavimum concentration was approximately 2 0 % lower in rats receiving 
ABZ standard compared to the rats that received ABZ tablet (Table 
5.7). The ratio of AUC(Q-6 hr) (standard/tablet) of ABZSO was 0.85.
A delayed absorption of ABZS02 was observed after administration of 
ABZ standard or tablet in Mig:Twn and the T^x was achieved at 5.Ohr 
for both formulations.
Table 5.7 Summary of the pharmacokinetic parameters after a single 
oral dose of 0.6 mg/kg ABZ standard and tablet in Mig:Twn in rats.
Compound Tmax 9max AUC(0 -t)
(hr) (ng/ml) (ng/ml.hr)
Standard
ABZ 1 . 0 109 435
ABZSO 3.0 425 1689
abzso2 5.0 178 599
Tablet
ABZ 3.0 89 392
ABZSO 3.0 565 2048
abzso2 5.0 2 0 2 568
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Fig. 5.5 The mean concentration-time profiles of (a) ABZ, (b) ABZSO 
and (c) ABZS02 following a single oral dose of 0.6 mg/kg ABZ standard 
and tablet in Mig:Twn in rats.
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The plasma concentration-time profiles of ABZ, ABZSO and ABZSO2  
following oral doses of 6 mg/kg ABZ in four different formulations in 
monkeys are shown in Fig. 5.6, Fig. 5.7 and Fig. 5.8, respectively. 
The individual plasma levels are tabulated in Appendix 3 (Tables 
3A.10-3A.13). Monkey 513 was omitted since there were no samples 
after 5.Ohr due to difficulty in blood sampling. The absorption of 
ABZ in monkeys receiving Prep.A was faster compared to that from the 
other three preparations when maximum concentration of ABZ was 
reached within 2.0-5.Ohr (Fig. 5.6). Interestingly, the maximum 
concentration of ABZ was achieved at 24.Ohr in monkeys receiving 
Prep.B except for one monkey (434) which displayed the C^x at 4.0 
hr. The absorption rate of ABZ was variable for all the formulations 
demonstrated by shown in Table 5.8. ABZ appeared to have a
second absorption phase in 6 out of the 12 monkeys. C ^ x ’s for ABZ 
achieved were higher in monkeys receiving preparations made in PEG 
400 compared to those receiving Mig:Twn preparations. There were no 
significant differences in AUC(0-24hr) °f ABZ f°r anY °f the 
formulations (F - 0.47, Ftab - 5.89 at P * 0.05) as shown in Table 
5.9.
The plasma concentration-time profiles of ABZSO in monkeys (Fig. 5.7) 
shows a similar pattern to ABZ. The time to reach peak concentration 
of ABZSO in monkeys receiving Prep.A was 4.0-5.Ohr which was faster 
than that in monkeys which received Prep.B (24.Ohr), Prep.C (4.0- 
12.Ohr) or Prep.D (8 .Ohr). The plasma concentrations of ABZSO were
2.5 to 20 fold the plasma concentrations of the parent ABZ. 
Consequently, the metabolite AUC^g-24hr) w®r© substantially higher 
than the AUC(Q_2 4hr) found for ABZ. The mean Tm^v, C^x and 
AUC(0-24hr) ^or ^ZSO are tabulated in Table 5.8. There were no
185
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Fig. 5.6 The plasma concentration-time profiles of ABZ following a 
single oral dose of 6 mg/kg ABZ as (a) Prep.A-tablet in PEG 400, (b) 
Prep.B-standard in Mig: Twn, (c) Prep.C-tablet in Mig: Twn and (d) 
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Fig. 5.7 The plasma concentration-time profiles of ABZSO following a 
single oral dose of 6 mg/kg ABZ as (a) Prep.A-tablet in PEG 400, (b)
Prep.B-standard in Mig:Twn, (c) Prep.C-tablet in Mig:Twn and (d) 
Prep.D-standard in PEG 400 in monkeys.
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Fig. 5.8 The plasma concentration-time profiles of ABZS02 following 
a single oral dose of 6 mg/kg A B Z as (a) Prep.A-tablet in PEG 400, 
(b) Prep.B-standard in Mig:Twn, (c) Prep.C-tablet in Mig:Twn and (d) 
Prep.D-standard in PEG 400 in monkeys.
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Table 5.8 Summary of the pharmacokinetics parameters (mean+SD) after 
oral dose of 6  mg/kg ABZ as Prep.A (tablet in PEG 400), Prep.B (std. 









ABZ 3.5±2.1 0.6210.34 5.5514.19
ABZSO 4.5±0.7 3.7811.21 42.6111.3
abzso2 6.512.1 0.8910.43 12.614.36
Prep.B
ABZ 17.311.5 0.4810.22 5.0311.55
ABZSO 17.3111.5 3.5311.02 56.7143.4
abzso2 24.010.0 0.7410.44 7.0114.00
Prep.C
ABZ 5.712.1 0.4310.22 3.3211.17
ABZSO 8.014.0 1.6610.88 21.4111.7
abzso2 8 .0 1 0 . 0 0.5910.27 9.0413.58
Prep.D
ABZ 6.714.7 0.6310.20 6.6815.50
ABZSO 8 .0 1 0 . 0 2.0710.56 30.218.87
abzso2 14.718.3 0.5910.06 8.4811.70
* n- 2
Table 5.9 The ratios of AUC{Q_2 4hr) from the monkey studies. (A - 
tablet in PEG 400/ B - standard in MigiTwn, C - tablet in Mig:Twn and 
D - standard in PEG 400) .
ABZ ABZSO abzso2
aucd






0.75 1 . 8 8 0.83
aucd
AUCC
--- 0.60 0.50 0.72
AUCa
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5.3.3 Results from Human Studies
The plasma concentration profiles of ABZ, ABZSO and ABZSO2 after a 
single oral dose of 400 mg (approximately 6.2 mg/kg) ABZ tablet in a 
single volunteer are illustrated in Fig.5.9 and the concentrations 
are quoted in Table 3A.14 (Appendix 3). Some ABZ was absorbed at 
l.Ohr but the maximum concentration was achieved at 3.0hr. The peak 
concentration for ABZSO was 2-fold greater than the peak 
concentration for ABZ, whereas the peak concentration for ABZSO2 was 
80% that of ABZ. The Tmax, C^x and AUC for ABZ and its metabolites 
are shown in Table 5.10.
Samples of 5 patients from loa loa study were analysed. These samples 
were picked at random and it was not known whether they had received 
placebo or ABZ. ABZ and metabolites were not detected in any of the 
serum samples of 2 out of the 5 patients which indicated that they 
had probably received the placebo. The concentration-time profiles of 
ABZ, ABZSO and ABZSO2 for the 3 patients are shown in Fig. 5.10 and 
the concentration given in Table 3A.15 (Appendix 3). ABZSO2 anc* ABZ 
concentrations were low and ABZSO were variable in all 3 patients.
Table 5.10 Summary of the pharmacokinetic parameters following a 







ABZ 3.0 74 354
ABZSO 2.5 151 2729
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Fig. 5.9 The plasma concentration-time profiles of ABZ, ABZSO and 
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5.3.4 Results from the Stomach and Intestinal Preparations
ABZ (10 mg/kg in DMSO directly into the stomach) was metabolised into 
ABZSO and ABZSO2 in the stomach and/or intestine of rats (Table 
5.11). The concentration of ABZSO found in the stomach at 2.0hr was 
1.24 times and 0.09-1.22 times at 4.0hr the concentration of 
remaining ABZ. ABZSO found in the intestine was higher, 1.51 times 
that of ABZ at 2.0hr and 1.71-2.13 times at 4.0hr. The concentrations 
of ABZSO2  found in the stomach were 3-6% of the ABZ concentration and 
in the intestine were 14-34%. Total drug concentrations in plasma, 
stomach and intestine wash were 7.02 Jig/ml at 2.0hr, 4.72 and 4.82 
|lg/ml at 4.0hr (ABZ equivalent).
After 6 .Ohr incubation of ABZ in the rat stomach, ABZ and ABZSO were 
found in the stomach wash and contents, and the mucosal layer. The 
conversion of ABZ to ABZSO was highest in the mucosal layer with a 
ratio of ABZ to ABZSO of 1.28 compared to 2.67 in the stomach wash 
and 8.30 in the stomach contents. The concentrations of ABZ and ABZSO 
are presented in Table 5.12.
Fig. 5.11 shows the concentration-time profiles for ABZ and ABZSO 
after ABZ in DMSO (0.4 ml of 10 mg/ml) was incubated with mucosal 
scrapings taken from the stomach and intestine. The decrease in ABZ 
concentration was observed in samples with mucosa. After 6.0 hr 
incubation, 4.15% and 4.58% ABZSO (ABZ equivalent) were present in 
the control samples, 21.70% (at 5.Ohr) and 16.18% in the stomach 
samples and, 82.69% and 24.41% in the intestine samples. 
Concentration levels are presented in Table 3A.16.
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Table 5.11 ABZ, ABZSO and ABZSO2 levels in stomach and intestinal
wash following oral dose of 10 mg/kg ABZ in rats.
Sampling Amount in 50 ml sample (Hg)
time ABZSO ABZSO2 ABZ
(hr) a b a b
Stomach
2.0(1) 58.2 54.7 1.61 1.44 44.1
4.0(3) 46.8 44.1 2.25 2.01 36.3
4.0(4) 46.4 43.8 3.24 2.89 46.7
Intestine
2.0(1) 9.98 9.41 0.99 0.88 6.22
4.0(3) 10.6 9.96 1.63 1.45 4.67
4.0(4) 6.78 6.39 1.43 1.28 3.74
a: actual concentrations 
b: ABZ equivalent
Table 5.12 ABZ and ABZSO levels following incubation of ABZ in 
stomach for 6.Ohr at 37°C.
Samples
a





Stomach washing 840 792 2118
Stomach contents 2752 2595 21536
Mucosal layer 4023 3794 4856
Q
a: actual concentrations 
b: ABZ equivalent
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ABZ kinetics have been described in this chapter.The absorption of 
ABZ and metabolites were highly variable and the variation in 
concentrations between rats were large. This variability may be 
caused by variation in the individual rates of absorption as well as 
differences iri the rates of metabolism. The concentration profiles of 
ABZ and its metabolites show secondary absorption suggesting a 
possibility of enterohepatic cycling. Prieto et al. (1988, 1991) 
suggested the main absorption route of ABZ is by gastric absorption 
with a secondary step of intestinal absorption for ABZ and/or 
metabolites excreted in the bile.
The ratios of C^x and AUC for ABZSO and ABZSO2 after 5 and 10 mg/kg 
ABZ were comparable with the dose ratio of 0.5, indicating that 
concentrations of ABZSO and ABZSO2 increase proportionally to dose. 
In contrast, the ratios for ABZ were close to unity suggesting that 
there may be a saturating effect on the absorption process. This 
finding is consistent with previously observed data in the perfused 
rat gut following 0.5 and 1.0 mg/ml ABZ dissolved in DMSO (Prieto et 
al., 1988).
The metabolism of ABZSO to ABZSO2 has been exclusively attributed to 
cytochrome P-450c in perfused rat liver (Souhaili-El Amri et al., 
1988) and this conversion is dependent upon the ABZSO concentrations 
in the medium. The rat studies demonstrated that the conversion of 
ABZSO to ABZSO2 is consistent with the AUC ratios which were almost 
identical irrespect of ABZ (5 and 10 mg/kg) or ABZSO (10 mg/kg) 
administered.
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It has been previously suggested that conversion of ABZ to ABZSO is 
reversible in the liver (Gyurik et al., 1981). Studies in rats 
receiving 10 mg/kg ABZSO demonstrated that rats were able to reduce 
ABZSO to ABZ. AUC for ABZ was 8 % of the AUC for ABZSO. There was no 
evidence of reduction of ABZSO in vitro in sheep and cattle 
microsomes (Lanusse et al., 1992). ABZ was formed however when ABZSO 
was incubated in sheep and cattle ruminal and ileal fluids (Lanusse 
et al., 1992). Studies on sulphoxide-containing drugs have shown that 
the gastrointestinal tract is the principal site for reduction of 
these drugs (Renwick et al., 1986). It has been suggested that this 
metabolic reduction may act as a source of ABZ (Lanusse et al., 1992) 
and therefore be of importance for the efficacy of ABZ against 
parasites as ABZ has greater affinity for parasite tubulin than ABZSO 
(Lubega and Prichard, 1991).
Oxidation of ABZ may also take place in the gastrointestinal tract as 
ABZSO was found in higher concentrations than ABZ in the stomach and 
intestine after oral doses of ABZ in rats. ABZSO2 was also present in 
small amounts. ABZSO2 was not detectable in any of the samples after 
incubation of ABZ in the stomach. ABZ and ABZSO were found in the 
stomach wash and content. Galtier et al. (1991) have postulated the 
occurence of extrahepatic sulphoxidation of ABZ in other body tissues 
or fluids may explain the 2 to 3 times greater total body clearance 
of ABZ than that previously determined in hepatic blood flow in 
sheep. Consistently, there was evidence that ABZ was converted to 
ABZSO and ABZSO2 in sheep and cattle ruminal and ileal fluids 
following anaerobic incubation (Lanusse et al., 1992).
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ABZ and ABZSO were found in the mucosal layers of the stomach after 
ABZ was incubated in the stomach for 6 hours with an ABZ/ABZSO ratio 
of 1.28. Upon incubation of the mucosal layer of the stomach and 
intestine, ABZ was progressingly oxidised to ABZSO in the samples 
with mucosal layers. In stability study of ABZ in DMSO in Chapter 4, 
it was found that ABZ degraded in DMSO. Therefore conversion of ABZ 
to ABZSO in the stomach and intestine preparations may be due to 
degradation of ABZ by DMSO and/or enzymatic degradation.
ABZ has low bioavailability which may be due to its limited 
dissolution in the gastrointestinal fluids. The enhanced absorption 
of ABZ when taken after fatty food/oil (Lange et al., 1988; Marriner 
et al., 1986) may be rationalised in term of delayed gastric
emptying and prolonged gastrointestinal transit which allows more 
complete dissolution of the drug and longer residence at the sites 
favouring the passage of the drug into the systemic circulation.
Rat studies looking at the kinetics of ABZ standard in Mig:Twn and 
PEG 400 showed there were no significant differences in the AUC 
between the formulations. As the rat models were established, a study 
in higher animal (monkey) was initiated to assess the plasma levels 
of ABZ and metabolites before going onto human studies. Four 
formulations of ABZ (standard or tablet in Mig:Twn; standard or 
tablet in PEG 400) were administered to monkeys at a dose of 6 mg/kg. 
There were no significant differences between the formulations. 
Plasma levels of ABZ, ABZSO and ABZSO2  were comparable to those found 
in rats. Interestingly, plasma levels of ABZ on a comparable mg/kg 
dosing are approximately one order of magnitude higher in rats and 
monkeys than man. The C^x is approximately 7 times higher in rats
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and 6 times in monkeys than in man. The AUC are also higher in rats 
and monkeys by 10- and 14-fold/ respectively. The enhanced absorption 
observed in animals may be due to (i) a consequence of the 
formulations used or the powdered form of ABZ used or (ii) a 
difference in absorption due to differences in animal and human 
gastrointestinal tract. In monkeys it may be due to the high pH of 
the stomach (pH 4-9) . As ABZ is a basic drug, in accordance to the 
pH-partition hypothesis, its absorption will be favoured in the high 
pH stomach since a larger fraction of ABZ in solution will be in the 
unionised form.
For potential human studies we needed to err on the safety side and 
therefore assumed that the new formulation would improve absorption, 
requiring a decrease in dose. 0.6 mg/kg ABZ was given to rats as 
ground-up tablet or standard, both prepared in Mig:Twn. The ground-up 
tablet was given to animals to compare the absorption with the 
standard since standard ABZ for human use was not available. The 
results showed no significant difference in the kinetic profiles 
between the 2 sources of ABZ and dose proportionality was maintained. 
To resolve the question as to whether powdering up the ABZ tablet or 
the new formulation was responsible for improved absorption, a study 
in man to compare ABZ tablet and/or 10% ground-up tablet in capsule, 
and 0 . 6  mg/kg new formulation in capsule would be necessary.
Plasma levels of ABZ and its two major metabolites were measured in a 
single volunteer who received a 400 mg ABZ tablet. The AUC for ABZSO 
found was comparable to previous findings (Penicaut et al., 1983; 
Marriner et al., 1986; Lange et al., 1988). Concentrations of ABZ and 
ABZSO2 found were <100 ng/ml. ABZ levels were measured for the first
2 0 0
time following an oral dose of ABZ in a healthy man. This may due to 
the sensitive and selective analytical method used as discussed in 
Chapter 3.
ABZ was also found in loa loa patients. Steady-state concentrations 
of ABZ and both metabolites were not achieved after administration of 
200 mg ABZ twice a day over 21 days in the three patients since the 
concentrations were highly variable. The variation of ABZSO 
concentrations were difficult to explain. It may be attributed to 
extensive hepatic metabolism (Marriner et al., 1986) and rapid 
gastrointestinal metabolism of ABZ to ABZSO (Lanusse et al., 1992). A 
recent study in onchocerciasis patients following multiple doses of 
800 or 1200 mg ABZ for 3 days, a steady-state level of ABZSO was not 
observed as the concentration continued to decrease over the 72 hours 
sampling time period (Hoaksey, 1990). It was suggested that it may be 
due to ABZ autoinduction, since in rats ABZ is known to induce 
cytochrome P-450c, an isoenzyme which is responsible for the 
conversion of ABZSO to ABZSO2 (Souhaili-El Amri et al., 1988) and 
therefore, it is possible that ABZ to undergo autoinduction in man. 
The measured concentrations of ABZSO2 however did not indicate this 
but it may be undergoing some other reactions. According to Gyurik 
et al. (1981), ABZSO2  is not reduced to ABZSO, but in turn may 
metabolised to three metabolites as identified in the urine of rats 
(Gyurik et al., 1981) and man (Penicaut et al., 1983) which were not 
looked for in this study as they were only present in trace amount 
(Gyurik et al., 1981; Penicaut et al., 1983).
2 0 1
In conclusion, there was no significant difference in the 
bioavailability between the "oily" (MigiTwn) and PEG 400 ABZ 
formulations in animals (rats and monkeys). However, the ABZ 
concentrations were an order of magnitude higher in rats and monkeys 
than in man receiving 400 mg ABZ tablet. The absorption of ABZ was 
improved (C^x = 6-7 times higher) and AUC was also higher (10-14 
times) in animals which necessitate a study in man to evaluate the 
bioavailability following administration of the "oily" formulation.
Concentrations of ABZ, ABZSO and ABZSO2 were highly variable in both 
animals and human, and there is evidence of reversible conversion of 
ABZ to ABZSO in in-vitro studies. ABZ was also detected for the first 
time in a healthy volunteer receiving 400 mg ABZ tablet. No tendency 
of attainment of the steady-state concentrations of ABZ, ABZSO and 
ABZSO2 were observed in loa loa patients after receiving 200 mg ABZ 





Benzimidazole carbamates have been shown to be active against both 
larvae and adult filarial nematodes (Van den Bossche et al., 1982; 
Cook, 1990). However due to low bioavailability and side-effects, 
mebendazole and flubendazole were not recommended for the treatment 
of filarial infections (Tropical Disease Research, 1984). Although 
albendazole has low bioavailability, it has better absorption in the 
gastrointestinal tract following oral administration (Morris et al., 
1983) and greater potency (Awadzi et al., 1990) compared to 
mebendazole. Currently, albendazole is being used in the treatment of 
systemic infections such as hydatid disease and cysticercosis 
(Todorov et al., 1992a, b; Jung et al., 1992). However due to its low 
bioavailability, large doses of albendazole are required. An improved 
bioavailability requiring a smaller dose is desirable since this 
would decrease any side-effects associated with the drug as well as 
the cost.
The primary aim of this study was to produce a formulation of 
albendazole which would improve the bioavailability when administered 
orally. The literature suggests that when albendazole is given with 
a fatty meal or co-administered with "oil", its bioavailability is 
improved (Marriner et al., 1986; Lange et al., 1988). The analysis 
was however based on the appearance of the sulphoxide metabolite in 
the blood, as albendazole was apparently undetected in human plasma.
The initial aim of the study was consequently to improved the 
methodology so that bioavailability could be assessed on albendazole 
and not a metabolite. This was achieved by development a sensitive 
and selective gradient elution reversed-phase HPLC method for 
quantitation of albendazole and its two major metabolites, the
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sulphoxide and sulphone in plasma. The method was sufficiently 
sensitive to measure 2 0  ng/ml albendazole and the sulphone, and 1 0  
ng/ml sulphoxide metabolite in 1 ml plasma sample with acceptable 
precision (<10% RSD). Using this method for the first time, 
albendazole was detected in volunteer/patients plasma who received a 
single clinical dose (400 mg) of albendazole. This demonstrates the 
capability of this methodology as the working tool for the 
determination of albendazole and therefore the investigation on 
albendazole could proceed further.
There were no significant differences in bioavailability of 
albendazole in both rat and monkey when "oily” formulation and when 
PEG 400 formulation were administered. However the Cmax and AUC of 
albendazole were 6-7 times and 10-14 times higher in animals, 
respectively when compared to that of a healthy volunteer who 
received an albendazole tablet (on comparing mg/kg dosing, 6 mg/kg) . 
The AUC of albendazole sulphoxide were 5 times higher in rats and, 8 - 
20 times in monkeys, which are higher than that reported by Lange et 
al. (1988) in man after given albendazole with a fatty meal (4.5 
times) .
The improved absorption of albendazole may be due to the consequence 
of the its formulation. It has been established that the mechanism of 
drug absorption in vivo from lipid-based dosage form involves the 
drug partitioning into the aqueous phase before absorption through 
the gastrointestinal wall (Armstrong and James, 1980) . Since 
dissolution process is not involved, albendazole is readily available 
and absorption is more rapid. However if the transfer across the 
mucosa is the rate limiting step, the absorption rate will dependent
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on the concentration gradient across the mucosa. In this situation, 
as the aqueous and oily phase are in equilibrium, the partition 
coefficient of albendazole would determine the rate of absorption 
(Kakemi et al., 1972). On the other hand if the rate of drug release 
is the rate determining step, the equilibrium concentration in the 
aqueous phase would not be achieved as a lipophilic drug has a 
greater affinity for oil. However this is not the case in this 
situation since the microscopic examination of albendazole in Mig:Twn 
solution when added to simulated gastric fluid showed some of 
albendazole present in aqueous phase which indicates that albendazole 
was present in excess.
The large oil/water interfacial area of the Mig:Twn system would 
promote the diffusion of albendazole from the oil phase into the 
luminal contents. Digestion of the oil would be expected to modify 
the interfacial area. Miglyol in self-emulsifying system has been 
shown to inhibit lipolysis rate (Challis, 1991). The presence of 
surfactant layer around the oil droplet will also hindered the action 
of the lipase. However Tween 80 was found to be rapidly hydrolysed 
(Challis, 1991). Therefore lipolysis of Miglyol in the system 
probably be slow. The composition of oil and aqueous phases would 
also change as lipolysis of the Miglyol would decrease the volume of 
the oil phase (Playoust and Isselbacher, 1964; Greenberger et al., 
1966) . The fatty acid and monoglyceride produced by hydrolysis of 
triglyceride of Miglyol are more polar and will associate with the 
bile salt before being absorbed by the intestinal mucosa. It has been 
suggested that in the presence of the fatty acids in the intestinal 
epithelium cell membrane, they may cause an increase in membrane 
fluidity and thereby increase the diffusion rate of the drug across
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the membrane (Grisafe and Hayton, 1978).
The excess albendazole has to be dissolved before absorption. In this 
situation the solid albendazole may dissolve in the aqueous phase as 
the drug is being absorbed and the presence of Tween 80 may increase 
the dissolution rate of albendazole into the aqueous phase. It is 
also possible that the drug in the aqueous phase partitions into the 
oil droplets, although it is generally accepted that only non-ionised 
species partitions from the aqueous phase into the non-aqueous phase 
(Florence and Attwood, 1988b).
In the presence of the bile salt, the dissolution rate of albendazole 
may also be increased and therefore may increase the absorption 
across the membrane. Del Estal et al. (1991) demonstrated that the 
intestinal absorption of albendazole was increased when it was 
administered in sodium taurocholate solution. The enhanced absorption 
of albendazole observed in rats may be due to the effect of bile 
salt. Since the rat has no gall bladder, the bile is continuously 
flowing into the duodenum and immediately available whereas in 
humans, a neural or hormonal stimuli induced by feeding is necessary 
to empty the gall bladder into the duodenum (Poelma et al., 1990). 
However the composition of bile and the concentration of bile salts 
in human and rat bile are similar, taurocholate being the major bile 
salt. The effect of bile salts in the dissolution rates of a drug is 
by micellar solubilization and/or by wetting effect (Miyazaki et al., 
1979; Poelma et al., 1990). This probably caused the large variation 
in absorption between animals.
The enhanced absorption of albendazole is not due to the gastric
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emptying rate as medium-chain triglycerides did not cause any gastric 
retention (Yamahira et al., 1979). On the other hand, Miglyol when 
formulated as self-emulsifying system improved the reproducibility of 
the gastric emptying (Challis, 1991). The results from the solubility 
study of albendazole in Miglyol (Chapter 4) showed that albendazole 
was stable at least for 5 days and therefore it is possible that 
Miglyol promotes albendazole absorption by protecting the molecule 
from the degradation in the stomach environment because at high 
concentration in acidic solution albendazole may degraded as observed 
in the stability and solubility studies of albendazole in 0.1M HC1 
(Chapter 4) .
Charman et al. (1992) observed an improvement of plasma levels of a 
lipophilic drug following oral administration of lipid-based 
preparation (self-emulsifying system: Neobee M5 a medium-chaim
triglyceride oil, Tagat TO a nonionic surfactant and a lipophilic
drug, 40:25:35%, w/w) in two separate studies. However the levels
were inconsistent and erratic, and proposed that the formulation is 
most likely to be a function of solubilisation and dispersion of the 
drug and not the function of lipid component in the formulation. The 
concentrations of albendazole following administration of this "oily" 
formulation were highly variable. It may be that Mig:Twn behaves 
similar to the Neobee M5:Tagat TO system (Charman et al., 1992).
The powdered form of albendazole used as opposed to a compressed
tablet/standard albendazole may also affect the absorption. According 
to the Noyes-Whitney equation (Eqn. 4.4 in section 4.1.2) an increase 
the surface area of the drug will increase the dissolution rate of 
the drug. This was demonstrated by the results from the comparison
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study of the standard albendazole and ground-up tablet, both in
MigrTwn in rats. There was no difference statistically in the kinetic 
profiles from the two sources.
A study in man is necessary to evaluate the bioavailability of
albendazole following the administration of the "oily" formulation 
since improved absorption was observed in animals. This study would 
also address the question raised as to whether the absorption was 
improved due to the formulation, or to the powdered form of
albendazole used or simply due to the difference in absorption. 
However there is a solubility problem in the new formulation. The 
concentration of albendazole in MigrTwn is 2 mg/g. In order to dose a 
healthy volunteer of 65 kg with 0.6 mg/kg albendazole, approximately 
19 ml of the MigrTwn solution (2 mg/g) is required which is 
approximately two tablespoon of the formulation. However due to the 
palatability and patient compliance, this may not be possible. 
Therefore for oral dosage form in man the formulation may have to be 
filled in soft gelatine capsules. Unfortunately, a gelatine capsule 
can only be filled with a dose volume of 0 . 1 0  ml to 0.80 ml (range 
from the round to oblong shape capsule). Therefore it is not possible 
to dose a man with this formulation.
The work resulting from this investigation that should be considered 
for further study is to reformulate albendazole as a suspension in 
MigrTwn for assessment of bioavailability of albendazole in humans. 
Various investigations have been undertaken to increase drug aqueous 
solubility by using cyclodextrin. Therefore another possibility is to 
increase aqueous solubility of albendazole and therefore its 
bioavailability by formulating albendazole as cyclodextrin complexes.
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The Bartlett Test is calculated using the following equations
(x - x) 2
X2




where x *= slope value 
X * mean slope 
s^ “ standard error of slope 
n^ * number of points on curve
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APPENDIX 2
Fig. 2A.1 NMR spectrum of ABZ
ABZ.SULPHOXIOE
Fig. 2A.2 NMR spectrum of ABZSO
222
BH10.
Fig 2A.3 NMR spectrum of Unknown 2 (ABZ 2-amine)
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Fig.3A.l Chromatograms of (a) ABZ and (b) ABZSO standards in DMSO.
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Table 3A.1 Concent rations of ABZ, ABZSO and ABZSO2 following oral
dose of 5 mg/kg ABZ in DMSO in rats. (ND:not detectable)
Sampling ABZ concentration (ng/ml)
time (hr) 1 2 3 Mean±SD
0.5 174 357 209 247± 97
1 . 0 347 233 163 248± 93
1.5 439 183 215 279±140
2 . 0 594 544 300 479±157
2.5 543 340 130 3371206
3.0 1 0 0 332 171 2011119
4.0 263 403 705 3291214
5.0 389 319 331 3461 38
6 . 0 228 1 2 1 166 1721 54
7.0 367 273 153 2641107
ABZSO concentration (ng/ml)
1 2 3 MeanlSD
0.5 530 641 915 696±198
1 . 0 857 1104 2228 13971731
1.5 1053 721 2534 14361965
2 . 0 1142 2962 1791 19651922
2.5 1595 2311 2233 20461393
3.0 929 1547 944 11401352
4.0 1420 1136 2179 15781539
5.0 976 1228 1363 11891197
6 . 0 528 1923 1844 14311784
7.0 649 2219 1842 15701819
ABZSOo concentration (ng/ml)
1 2 3 MeanlSD
0.5 155 ND ND 521 89
1 . 0 1 2 0 ND ND 401 69
1.5 188 103 163 1511 44
2 . 0 233 168 148 1831 44
2.5 267 150 195 2041 59
3.0 189 146 98 1451 46
4.0 306 193 302 2671 64
5.0 325 161 224 2371 83
6 . 0 291 316 451 3531 8 6
7.0 623 313 289 4081187
226
Table 3A.2 Concentrations of ABZ, ABZSO and ABZSO2 following oral
dose of 10 mg/kg ABZ in DMSO in rats. (ND:not detectable, NS:no
sample)
Sampling ABZ concentration (ng/ml)
time (hr) 1 2 3 Mean±SD
0.5 314 155 233 234± 80
1 . 0 232 481 522 4121157
1.5 474 198 781 4841291
2 . 0 590 283 1 1 2 1 6651424
2.5 205 171 187 1871 17
3.0 383 272 263 3061 67
4.0 351 238 NS 2951 80
5.0 351 242 711 4351245
6 . 0 126 215 234 1921 58
7.0 2 1 1 196 231 2131 18
ABZSO concentration (ng/ml)
1 2 3 MeanlSD
0.5 1167 696 1172 10121 274
1 . 0 2413 1801 3332 25161 771
1.5 4216 1019 4365 320011890
2 . 0 4163 2579 5192 397811317
2.5 2466 2696 1505 22221 631
3.0 2865 3493 2709 30221 415
4.0 4756 2873 NS 381511331
5.0 6057 2223 3372 388411967
6 . 0 1716 3761 3297 292511072
7.0 2545 2576 2125 26701 750
ABZSO2 concentration (ng/ml)
1 2 3 MeanlSD
0.5 44 ND ND 151 25
1 . 0 77 ND 67 481 42
1.5 150 57 247 1511 95
2 . 0 284 170 236 2301 57
2.5 189 233 78 1671 80
3.0 2 1 0 224 243 2261 16
4.0 557 255 NS 4061213
5.0 691 513 635 6131 91
6 . 0 303 500 585 4631145
7.0 370 366 426 3871 34
227
Table 3A.3 Concentrations of ABZ/ ABZSO and ABZSO2 following oral







0.5 383 2255 119
362 4853 266
1 . 0 492 4847 282
520 5485 588
1.5 584 7029 526
1123 4603 427
2 . 0 551 6017 548
647 5938 590
2.5 217 7172 661
577 7332 850
3.0 1 0 0 1985 2 2 1
2 2 0 6455 1066
4.0 161 4053 582
242 3889 534
5.0 414 5777 1074
257 4244 662
6 . 0 218 4718 993
431 4226 8 8 8
7.0 245 2 2 0 1 415
319 5170 1242
228
Table 3A.4 Concentrations of ABZ, ABZSO and ABZSO2 following oral








0.5 1128 1256 ND
771 1333 ND
1 . 0 238 786 129
2802 3122 155
1.5 428 1495 166
518 1416 2 0 0
2 . 0 910 1907 266
510 2405 350
2.5 234 1268 313
NS NS NS
3.5 359 2244 251
229 1615 506
4.0 126 865 247
ND 488 250
5.0 336 1968 413
95 2314 611
6 . 0 ND 603 312
96 1 1 1 0 304
8 . 0 ND 731 413
ND ND 193
1 2 . 0 ND 775 976
ND 194 248
24.0 ND 244 247
ND ND ND
229
Table 3A.5 Concentrations of ABZ, ABZSO and ABZSO2 following oral








0.5 303 938 1 0 0
623 983 84
1 . 0 596 .1934 225
855 1464 119
1.5 711 1722 164
636 1 0 0 1 182
2 . 0 357 1979 292
419 1283 151
2.5 535 1083 295
359 1585 272
3.5 339 132 299
816 1530 269
4.0 832 2420 416
591 2288 336
5.0 462 1024 397
1698 89 559
6 . 0 532 840 634
311 1326 534
0CO NS NS NS
388 985 479
1 2 . 0 ND 362 1379
ND ND 445
24.0 ND ND ND
ND ND ND
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Table 3A. 6 Concentrations of ABZ, ABZSO and ABZSO2 following oral








0.5 154 417 ND
1106 464 ND
NS NS NS
1 . 0 347 1 1 0 1 ND
242 843 ND
157 6 6 6 55
1.5 264 1092 140
445 1003 94
332 1283 79
2 . 0 530 1986 104
956 974 143
176 1290 1 0 2
2.5 371 1586 116
289 2072 214
282 2 0 1 0 236
3.0 579 2 2 2 2 141
156 2038 2 2 2
262 1814 315
4.0 644 2605 265
424 2480 229
425 2316 467
5.0 443 2162 304
425 2432 389
161 1773 158
6 . 0 367 1279 270
215 2330 478
NS NS NS
7.5 358 1172 414
219 2181 556
NS NS NS
1 2 . 0 ND ND ND
ND ND 116
ND 135 399




Table 3A.7 Concentrations of ABZ, ABZSO and ABZSO2 following oral








0.5 294 454 ND
51 162 ND
8 8 8 837 ND
1 . 0 599 967 36
459 757 ND
NS NS NS
1.5 333 1723 89
549 1711 99
675 1732 108




1 1 2 0 2332 209
421 2248 263
3.0 650 1850 238
670 2606 278
800 2127 185
4.0 606 1612 213
218 2404 363
508 3034 412
5.0 549 1785 272
379 2501 537
428 2803 643
6 . 0 223 1755 336
303 2396 734
NS NS NS
7.5 452 1393 472
188 1408 467
192 1483 590
1 2 . 0 ND ND ND
ND ND 1 2 0
ND 41 225




Table 3A.8 Concentrations of ABZ, ABZSO and ABZSO2 following oral








0.5 90 64 ND
30 158 ND
1 . 0 53 128 ND
1 0 2 2 2 1 ND
2 . 0 44 290 58
1 2 0 578 ND
3.0 96 533 130
81 597 162
4.0 2 0 1 2 2 63
131 864 230
5.0 38 193 150
47 310 254
6 . 0 ND ND 48
60 185 130
7.0 ND 32 ND
ND 6 8 ND
Table 3A.9 Concentrations 
dose of 0.6 mg/kg ABZ
detectable, NS:no sample)
of ABZ, ABZSO and 
standard in Mig: 1
ABZSO2  following oral 
Twn in rats. (ND:not
Sampling Concentration (ng/ml)
time (hr) ABZ ABZSO abzso2
0.5 109 337 ND
98 206 ND
1 . 0 133 354 ND
85 218 67
2 . 0 89 540 130
50 297 63
3.0 47 373 150
87 478 97
4.0 36 125 132
36 207 140
5.0 51 172 117
6 8 395 239
6 . 0 ND 135 2 1
58 49 141
7.0 ND ND ND
ND ND ND
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Table 3A.10 Concentrations of ABZ, ABZSO and ABZSO2 following oral








513 1.0 334 938 87
0CM 490 2739 432
3.0 712 1376 347
4.0 391 1572 436
5.0 986 2708 743
533 1.0 139 854 31
2 . 0 557 2555 332
3.0 333 2985 459
4.0 649 4634 1024
5.0 855 3510 999
8 . 0 408 3606 1191
1 2 . 0 313 1454 562
24.0 199 1380 534
48.0 ND 2 2 55
535 1.0 34 1147 79
2 . 0 379 1847 190
3.0 326 1986 2 1 0
4.0 280 2657 437
5.0 215 2928 581
8 . 0 2 0 0 1954 506
1 2 . 0 26 1596 575
24.0 39 248 181
48.0 ND ND ND
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Table 3A.11 Concentrations of ABZ, ABZSO and ABZSO2 following oral








486 1.0 69 36 ND
2 . 0 76 140 ND
3.0 106 350 ND
4.0 140 260 ND
5.0 97 280 60
8 . 0 258 1 0 0 6 6
1 2 . 0 123 145 59
24.0 648 2864 483
48.0 194 250 148
434 1.0 69 314 ND
2 . 0 388 1040 91
3.0 429 1923 148
4.0 561 3014 277
5.0 355 2208 246
8 . 0 175 1136 1 0 0
1 2 . 0 NS NS NS
24.0 198 2843 487
48.0 76 447 2 1 1
435 1.0 46 90 ND
2 . 0 235 46 ND
3.0 164 416 ND
4.0 92 346 78
5.0 139 480 119
8 . 0 109 701 146
1 2 . 0 89 1975 392
24.0 237 4698 1251
48.0 105 ND 175
235
Table 3A.12 Concentrations of ABZ, ABZSO and ABZSO2 following oral








533 1.0 NS NS NS
2 . 0 308 921 155
3.0 NS NS NS
4.0 99 1789 419
5.0 231 1429 500
8 . 0 310 1032 667
1 2 . 0 165 810 481
24.0 6 8 347 329
48.0 ND ND 33
535 1 . 0 70 465 51
2 . 0 306 1626 150
3.0 551 1957 270
4.0 422 2463 400
5.0 690 2063 500
8 . 0 150 2673 824
1 2 . 0 61 1612 788
24.0 35 188 153
48.0 ND ND 19
252 1.0 ND 1 0 0 18
2 . 0 48 283 51
3.0 1 0 0 635 103
4.0 298 519 150
5.0 246 587 189
8 . 0 233 413 292
1 2 . 0 109 736 243
24.0 ND 119 230
48.0 ND ND ND
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Table 3A.13 Concentrations of ABZ, ABZSO and ABZSO2 following oral








486 1.0 0 31 ND
2 . 0 1 2 1 586 45
3.0 1 2 1 897 1 1 0
4.0 162 1171 141
5.0 478 1397 176
0
0
0 708 2390 420
1 2 . 0 825 2323 620
24.0 390 1327 533
48.0 ND ND ND
434 1 . 0 0 387 ND
2 . 0 185 1384 1 1 2
3.0 190 1256 150
4.0 213 1573 199
5.0 625 1266 281
8 . 0 174 2395 629
1 2 . 0 ND 1231 433
24.0 ND 64 37
48.0 ND ND 39
316 1.0 0 160 18
2 . 0 35 196 25
3.0 429 541 150
4.0 339 821 188
5.0 250 1 0 1 0 241
0
0
0 273 1415 343
1 2 . 0 NS NS NS
24.0 157 900 518
48.0 ND 27 104
237
Table 3A.14 Concentrations of ABZ, ABZSO and ABZSO2 following oral
dose of 400 mg ABZ in healthy volunteer. (ND:not detectable)
Sampling Concentration (ng/ml)
time (hr) ABZ ABZSO ABZSO2
0.5 ND
1 . 0 38
1.5 35






6 . 0 42
7.0 ND
8 . 0 28


















Table 3A.15 Concentrations of ABZ, ABZSO and ABZSO2 following 200 mg 
ABZ twice a day over 21 days in loa loa patients. (ND:not detectable)
Sampling Concentration (ng/ml)
time (day) ABZ ABZSO ABZSO2
0 ND ND ND
1 ND ND ND
3 44 207 ND
6 93 515 33
9 2 2 199 ND
14 ND 55 ND
2 0 ND 40 ND
0 ND ND ND
1 ND 114 ND
3 ND 81 ND
6 78 522 35
9 ND 195 34
14 40 300 8 6
2 0 79 587 35
0 ND ND ND
1 ND 89 ND
3 ND 116 ND
6 182 ND ND
9 ND 116 28
14 ND 159 29
2 0 126 557 65
238
Table 3A.16 Concentrations of ABZ and ABZSO following incubation of 





1 . 0 124 117 1687
2 . 0 178 168 1758
4.0 150 142 2099
5.0 149 140 2069
6 . 0 129 1 2 1 1806
Control2
1 . 0 175 165 1746
2 . 0 204 192 1858
4.0 187 176 1988
5.0 196 185 1899
6 . 0 144 136 1789
Stomachi
1 . 0 232 219 1791
2 . 0 239 225 1429
4.0 251 237 1829
5.0 270 255 1937
6 . 0 262 247 1528
Stoma ch2
1 . 0 290 273 1576
2 . 0 308 291 1509
4.0 291 274 1369
5.0 368 347 1600
6 . 0 NS NS NS
Intestinel
1 . 0 208 196 1715
2 . 0 314 296 1587
4.0 700 660 1611
5.0 1009 951 1775
6 . 0 1420 1340 1620
Intestine2
1 . 0 2 1 2 2 0 0 1681
2 . 0 293 277 1806
4.0 238 224 1569
5.0 290 274 1318
6 . 0 334 316 1293
a: actual concentration 
b: ABZ equivalent 
NS: no sample
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